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‘First you will come to the Sirens who enchant all 
who come near them. If any one unwarily draws 
in too close and hears the singing of the Sirens, 
his wife and children will never welcome him 
home again, for they sit in a green ﬁeld and 
warble him to death with the sweetness of their 
song. There is a great heap of dead men's bones 
lying all around, with the ﬂesh still rotting off 
them.’ 
‘Therefore pass these Sirens by, and stop your 
men's ears with wax that none of them may hear; 
but if you like you can listen yourself, for you may 
get the men to bind you as you stand upright on a 
cross-piece half way up the mast, and they must 
lash the rope's ends to the mast itself, that you 
may have the pleasure of listening. If you beg and 
pray the men to unloose you, then they must bind 
you faster.’
Homer, The Odyssey
book 12, line 1
Translation:  Samuel Butler (1898) / 
  The Perseus Project
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Summary
Dependence on heroin or other opioids is a serious disorder that increases the risk of 
physical disease, mental disease and death. Heroin dependent patients completing inpatient 
treatment have a high risk of relapsing to opioid use once they leave controlled 
environments and return to their community. Naltrexone is a drug with the ability to block 
heroin and other opioids, but clinical studies of the treatment have generally shown that 
patients are not able to take naltrexone tablets with sufficient regularity for the medication 
to have the intended effect. Sustained release formulations of naltrexone may address this 
problem, but little is known about its effectiveness, safety, and clinical feasibility in the 
treatment of opioid dependence. 
This thesis investigated the above topics by: 
1) Conducting a systematic review of the literature on sustained release naltrexone.
2) Comparing patients randomly allocated to either naltrexone implants or no implants in 
addition to their ‘treatment as usual’ aftercare. 
3) Describing the prevalence of opioid use among naltrexone implant patients and the drug 
‘high’ experienced following such use. 
4) Observing and describing the proportion of first-time naltrexone implant patients retained 
in naltrexone implant treatment.
The literature review found that an insufficient amount of research had been published on 
sustained release naltrexone to conclude on its safety or efficacy in the treatment of opioid 
dependence. The treatment RCT found that naltrexone implants greatly reduced opioid use 
and craving, was well accepted by patients and was generally well tolerated. Just over half 
of naltrexone implant patients tried opioids, most of whom felt no effect of use. About half 
of patients who started treatment with naltrexone implants were retained in naltrexone 
implant treatment when re-implantation was due. 
These findings suggest that sustained release naltrexone is an effective treatment for opioid 
dependent patients who seek abstinence from opioids. Naltrexone implants seem to have an 
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acceptable level of safety for this patient group, and is clinically feasible in terms of 
retaining patients in the treatment and blocking opioid ‘high.’ 
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Sammendrag (Norwegian summary)
Avhengighet av heroin og andre opioidstoffer er en alvorlig lidelse som øker risikoen for 
fysisk- og psykisk sykdom og død. Når heroinavhengige fullfører institusjonsbehandling, er 
det stor risiko for at de helt eller delvis faller tilbake til heroinbruk kort tid etter utskriving. 
Naltrekson er et legemiddel som kan blokkere for heroin og andre opioidstoffer. Behandling 
med naltrekson i tablettform har imidlertid vært preget av at få heroinavhengige klarer å ta 
tablettene regelmessig, og de fleste faller derfor raskt tilbake til heroinbruk igjen. 
Langtidsvirkende preparater med naltrekson representerer en mulig løsning på dette 
problemet, men det er uvisst hvor effektiv, sikker, og praktisk gjennomførbar denne typen 
behandling vil være. 
Denne doktorgraden tok sikte på å undersøke ovenstående ved å:
1) Foreta en systematisk gjennomgang av litteraturen på langtidsvirkende naltrekson 
2) Sammenligne resultatene til heroinavhengige som ble randomisert til å motta eller ikke 
motta naltreksonkapsler i tillegg til sin vanlige oppfølging etter institusjonsopphold. 
3) Beskrive forekomsten - og rusopplevelsen av opioidbruk blant pasienter med 
naltreksonimplantat.
4) Observere og beskrive andelen av opioidavhengige med førstegangs naltreksonimplantat 
som ble videreført til en andre behandlingsperiode med naltreksonimplantat.
Resultatene av litteraturgjennomgangen viste at det var utført for lite forskning av god 
kvalitet til å kunne konkludere noe sikkert om denne typen behandling. Den randomiserte 
sammenligningen av naltreksonimplantat etter døgnbehandling fant at denne 
behandlingsformen ga betydelig reduksjon i opioidbruk og hadde et akseptabelt nivå av 
bivirkninger og hendelser for denne pasientgruppen. 
Litt over halvparten av pasientene med naltreksonimplantat prøvde opioider i løpet av 
behandlingsperioden, men kun et fåtall oppga at de fikk noen rusvirkning av det. 
Omtrent halvparten av pasientene med naltreksonimplantat klarte å fortsette med en 
implantatperiode nummer to. 
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Funnene i avhandlingen tyder på at langtidsvirkende naltrekson er en effektiv 
behandlingsmåte for opioidavhengige som ønsker avhold fra opioidstoffer. 
Behandlingsmåten ser ut til å ha et akseptabelt nivå av bivirkninger for denne 
pasientgruppen og er praktisk gjennomførbar i forhold til potensiale for gjentatte 
behandlinger og virkningen av opioidbruk. 
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2. Aims
Recovery from opioid dependence is complicated by patients’ tendency to relapse shortly 
after achieving abstinence in a detoxification clinic or similar inpatient settings. Maintaining 
abstinence from opioids could be facilitated by use of naltrexone, an opioid antagonist that 
blocks the action of heroin and other opioids. Oral naltrexone has shown limited 
effectiveness in clinical settings due to problems with feasibility; more precisely, it is 
difficult for patients to maintain daily intake of the medication. Sustained release naltrexone 
formulations represent a potential solution to this problem. 
The purpose of this thesis is to increase the scientific knowledge on clinical treatment with 
sustained release naltrexone by addressing the following research aims:
• Investigate the effectiveness of sustained release naltrexone in preventing relapse among 
opioid dependent patients who complete inpatient treatment. 
• Assess the safety of naltrexone implant treatment for opioid dependence.
• Evaluate the feasibility of using naltrexone implant as a treatment for opioid dependence 
in clinical settings. 
                                                                                                                                                        Aims
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3. Background
Opioid dependence is a debilitating disorder on an individual, family, and societal level. An 
estimated 15,6 million people worldwide experience the considerable reduction in quality of 
life and the increased risk of death associated with regular heroin use (United Nations, 
2007; Stein et al. 1998; Zanis & Woody, 1998; Darke et al. 2006; Ravndal & Amundsen, 
2009). Families of heroin users struggle with the immediate emotional and economical 
consequences of use. Communities must cope with the wider consequences of use like 
criminal activity, loss of productivity, and high consumption of health and social services 
(Mark et al. 2001).
On a neurobiological level, opioid dependence is caused by the repeated intake of opioid 
drugs which includes heroin, morphine, codeine, methadone, and many more. Opioid 
receptors exist as a separate class of receptors within the nervous system, with different 
subtypes (e.g. mu, kappa, delta) and endogenous opioid molecules that bind to them, acting 
as neurotransmitters. The opioid receptor system is involved in a wide range of CNS 
functions, many of which are related to motivation, sedation, and pain relief (Simon, 2005). 
Opioid drugs (or ‘agonists’) activate opioid receptors causing sedation and drug ‘high’ 
amongst other effects. The ‘high’ experience is thought to originate from a subsequent 
release of dopamine in an area of the midbrain called the nucleus accumbens (NAcc). 
Dopamine release in NAcc is implied in most addictive states (Wise, 1980). With regular 
intake of opioids, the sensitivity of the opioid receptor system decreases and equivalent 
dosages slowly cease to have their original effect (Yoburn et al. 1989; 1990). This is known 
as ‘tolerance’ and is a main symptom of opioid dependence (APA, 2000). 
3.1. Relapse in opioid dependence
Another main symptom of opioid dependence is the loss of control over opioid use, e.g. by 
failing to reduce intake despite genuinely trying or failing to stay abstinent following 
detoxification. The latter is the case with the majority of users who achieve abstinence in 
inpatient settings. Repeated studies have shown that most patients in this situation relapse to 
regular heroin use within the first year following discharge - the majority doing so within 
the first 1-3 months following discharge (Gossop et al. 2002; Darke et al. 2005). Such a 
                                                                                                                                            Background 
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return to heroin use represents a setback in each patient’s recovery, but more importantly 
greatly increases the risk of dying from overdose (Darke et al. 2006; Ravndal & Amundsen, 
2009). Terminating maintenance treatment is also associated with return to pre-treatment 
mortality levels (Zanis & Woody, 1998; Clausen et al. 2008). Understanding the 
mechanisms behind relapse to opioid use is thus central to further prevent deaths among 
patients with opioid dependence.  
3.1.1. Biological mechanisms of relapse
When regular use of opioids has commenced, the reward experienced through DA release in 
the NAcc are counteracted by homeostatic processes in the brain (Koob & Le Moal, 2008). 
Once intake of opioids ceases, patients experience withdrawal symptoms. The precise 
mechanisms behind withdrawal are not understood, but avoiding withdrawal may 
nonetheless become an incentive for the patient to continue using opioids. The unbalancing 
of the reward system caused by opioid intake is also thought to precipitate a more 
widespread CNS stress reaction that may continue for some time following the achievement 
of abstinence (Koob & LeMoal, 2008). 
Regular opioid use may prime frontal regions of the brain towards focusing on opioids- and 
opioid-related behaviours (Kalivas & Volkow, 2005; Robinson & Berridge, 2008). 
Stimulation of the reward/punishment system with other means - other drugs, substances, 
stressful events, sensation-seeking - may reinvoke the craving for opioids (Koob & Le 
Moal, 2008). Individuals suffering from post-traumatic stress may be especially at risk for 
drug use and relapse, as one of their core symptoms include problems with emotional 
regulation. On a cellular level, the use of opioids and other drugs increases the expression of 
a protein from CNS cells, ΔFosB, which gradually accumulates over the course of several 
weeks. Studies suggest ΔFosB increases sensitivity to opioids, thereby increasing the risk of 
relapse even after detoxification (Chao & Nestler, 2004). 
Background                              
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3.1.2. Behavioral mechanisms of relapse
Morphine and heroin can act as reinforcers of behaviour in an operant sense of the term 
(Wikler, 1948). Operant conditioning is based on the ‘law of effect’: the reward or 
‘reinforcement’ of an action will greatly increase the likelihood that the individual repeats 
the action (Thorndike, 1911; Skinner, 1938). In addition to pleasant experiences, a reward 
can also come in the form of relief of pain or stress, known as ‘negative reinforcement.’ 
Should tolerance or other mechanisms prevent drug intake from resulting in ‘high’ on 
intake, the addictive behaviour is likely to take even longer to eliminate by removal of 
reward (Ferster & Skinner, 1957). Once other objects or actions are perceived as associated 
with the primary reward, these will themselves be perceived as rewarding - a phenomenon 
called secondary conditioning. Objects present during drug-taking can also become 
associated with the drug reward through classical conditioning (Pavlov, 1927), something 
which has been shown to be strong enough to elicit withdrawal symptoms in former opioid 
dependent persons (O’Brien, 1991). 
3.1.3. Cognitive and motivational relapse mechanisms
Coping skills are central to the cognitive psychology understanding of addiction. These 
theories emphasize the patient’s agency and possibilities despite external and internal 
pressures to continue drug use. There are numerous cognitive theories on motivation and 
relapse, but one of the more widely referenced the Relapse Prevention approach has been 
chosen here as an example of such approaches. The Relapse Prevention approach sees 
relapse to drug use as occurring as a result of high-risk situations and inadequate coping 
(Witkiewitz & Marlatt, 2004). For patients dependent on drugs, situations with a high risk of 
relapse often appear suddenly and unexpectedly (Hawkins & Hawkins, 1998). In order to 
maintain abstinence in these situations, the patient can relate to the situation in a number of 
ways: focusing on the short-lived nature of drug urges and cravings (Gossop et al. 2002), 
focusing on the negative outcomes of relapse, using relaxation techniques, etc. Motivation is 
seen as a result of the person’s perception of self-efficacy and the value she or he currently 
assigns to drug use. 
The concept of mindfulness has become increasingly important in cognitive psychotherapy 
for a range of disorders. Mindfulness emphasizes the importance of attention to oneself and 
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one’s surroundings in uncovering individual mechanisms behind drug use and relapse 
(Witkiewitz et al. 2005). Awareness and reflection is seen as key to break automatic cycles 
of thought and action related to drug use, and this approach is beginning to show promising 
results in the treatment of substance abuse (Bowen et al. 2009).
3.1.4. Social mechanisms of relapse
A common identity as opioid users is established through opioid users’ shared interest in - 
and experience with opioid use, in the numerous ways of obtaining drugs or money, in 
sharing traumatic experiences and sometimes in the shared resentment for the ‘non-using 
society’ in general and public servants in particular (Becker, 1963; Cohen, 1990; Bourgois et 
al, 1997; Smith-Solbakken & Tungland, 1997; Johansen, 2002; Best et al. 2003). Interacting 
with the non-using majority often involves the activation of awareness and embarrassment 
of the contrast between the opioid-users’ life and that of others, as well as lack of trust and 
outright discrimination from family and other non-using members of society (Cohen, 1990). 
Using more drugs is a common strategy for coping with such experiences, as is re-narrating 
one’s history towards that of a conflicted hero in constant struggle with a cruel and 
inhumane society of non-users (Becker, 1963; Flynn, 2005). Although overdose is always a 
risk for opioid users, a number of users despair and overdose with suicidal intent (Biong, 
2008). Other drugs or alcohol can also be used to (temporarily) influence emotional states or 
sleep/hunger patterns; thus poly-drug use is the norm among treatment-seeking heroin users 
(Ross et al. 2005). This tends to further deteriorate mental and physical health (Regier et al. 
1990). Opioid users’ attribution of withdrawal symptoms to opioid use is an important 
element in patients’ experience of themselves as dependent; some users will then quit, while 
others will continue using and increasingly construct themselves as dependent (Lindesmith, 
1968; DeGrandpre, 2006). Thus, according to social theory, maintaining abstinence from 
opioids following detoxification or residential treatment is thus made difficult by having 
previously adapted to life as a drug user in social cognition and - networks. This position 
has gradually diminished the skills and resources necessary to lead a comfortable life 
without having drugs as an important ingredient in one’s personal and social life. 
Background                              
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3.2. Naltrexone and its role in the prevention of relapse
Naltrexone is a medication with a potential to assist opioid users in maintaining abstinence 
from opioids. This potential derives from the pharmacological effects of naltrexone as well 
as the secondary effects. 
As an opioid antagonist, naltrexone has the ability to block (or ‘antagonize’) opioid agonists 
like heroin and morphine from activating opioid receptors (Blumberg et al. 1967). Its lack of 
agonist properties makes it seem like an ideal pharmacotherapy for opioid dependence: it 
produces no discernible drug ‘high‘ or no sedative effect and therefore has little to no 
potential for overdose or abuse (Martin et al. 1973; Resnick et al. 1974; Verebey et al. 1976; 
Tai & Blaine, 1997). The dosage of naltrexone necessary to block regular dosages of opioids 
is thought to lie at plasma concentrations of 1-2 ng/ml or above (Verebey et al. 1976; 
Sullivan et al. 2006a). 
The blockade of opioid receptors by naltrexone must be assumed to prevent and sometimes 
reverse the biological changes associated with active opioid use; e.g. the reward system in 
the midbrain would not have to adjust to the dopamine release in the NAcc caused by 
relapse; levels of ΔFosB proteins should gradually stop accumulating and eventually 
decrease. Sensitivity of opioid receptors would return to normal levels (or perhaps higher) 
(Zukin et al. 1982; Yoburn et al. 1989, 1990). 
On a behavioral level, the lack of ‘high’ following opioid use in a naltrexone patient should 
lead to a decrease or even complete ‘extinguishing’ of the association between intake 
behaviour and ‘high’ (Wikler, 1965; 1976). 
On a cognitive and motivational level, knowledge about the presence of naltrexone 
blockade can mean less intrusive and distractive thoughts about relapse, and free mental 
resources to focus on recovery-related tasks. The fear (or anticipation) of relapsing is gone 
or postponed. The presence of naltrexone means opioid-related social interactions should be 
reduced and eventually stop. 
                                                                                                                                            Background 
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In addition to its ability to block opioids, naltrexone intake has also been known to reduce 
craving for heroin, alcohol, and other drugs (Sideroff et al. 1978; Ooteman et al. 2007; 
Jayaram-Lindström et al. 2008). The precise mechanism for this has not been determined, 
and its significance in the treatment of opioid dependent persons may be hard to distinguish 
from effects resulting from the awareness of opioid blockade. 
Although the 1-2 ng/ml level is thought to block opioids in most circumstances, difficulties 
in ascertaining the exact blocking level arise from the competitive nature of receptor 
activation. This means the naltrexone blockade could be overcome in special circumstances: 
e.g. if the opioid agonist used had a high affinity for opioid receptors, like fentanyl; or if 
extreme dosages of normal opioids are used in combination with the plasma level of 
naltrexone approaching sub-therapeutic levels (Toll et al. 1998; Nestler et al. 2008). Another 
limitation also comes from its opioid-specific nature: Naltrexone does not block the effects 
of non-opioid drugs or alcohol. As most heroin users are combination drug users (Ross et al. 
2005), it is conceivable that a former heroin user could undergo naltrexone treatment but 
still continue combination drug use. 
3.3. Naltrexone formulations for clinical treatment
The minimum target of administration of naltrexone in clinical settings, then, is to achieve a 
reliable plasma concentration of naltrexone above 1 ng/ml until the person no longer has a 
need for the pharmacological assistance naltrexone provides. Two main methods of 
administration have been developed for this purpose. 
3.3.1. Oral naltrexone treatment
Oral formulations of naltrexone hydrochloride were the first types of naltrexone treatment 
for opioid dependence. Studies have found that 50 mg per day or 100 mg every other day of 
oral naltrexone is sufficient to block street quantities of heroin (Resnick et al. 1974; Judson 
et al. 1981). However, the effectiveness of oral naltrexone in treating opioid dependent 
patients is usually limited by compliance problems (O’Brien et al. 1975; Greenstein et al. 
1981; Minozzi et al. 2006). The proportion of the originally recruited sample of patients that 
remain in oral naltrexone treatment at six months is usually small - from 5% to about 30% 
(e.g. San et al. 1991; Nunes et al. 2006). Retention can be increased when family, 
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supervisors, or parole officers administer the tablets (Krupitsky et al. 2004; Washton et al. 
1984; Cornish et al. 1997) or comprehensive approaches like Contingency Management or 
Behavioral Naltrexone Therapy are used (Carroll et al. 2001; Rothenberg et al. 2002; 
Sullivan et al. 2007). However, some are skeptical that these approaches will be able to 
retain more than 20-40% of patients in clinical settings (Nunes et al. 2006). In addition, one 
study using urine verification of naltrexone intake found that fewer than 50% of oral 
naltrexone tablets were actually ingested by opioid dependent patients (Sullivan et al. 
2006b).
3.3.2. Sustained release naltrexone
As some investigators had anticipated the problems with compliance in oral naltrexone 
treatment (Resnick et al. 1974), research on the development of sustained release naltrexone 
formulations was started only a few years after the discovery of naltrexone itself (Leafe et 
al. 1973; Martin & Sandquist, 1974; Yolles et al. 1975). The National Institute on Drug 
Abuse (NIDA) devoted several research monographs exclusively to sustained release 
naltrexone (NIDA, 1978; 1981) and gave them mention in many other monographs. None of 
these efforts resulted in a product that was suitable for use in clinical treatment. One 
naltrexone implant prototype was tested by Chiang and colleagues in pilot studies on 
healthy volunteers (Chiang, 1984; Chiang, 1985). The implant released naltrexone, but only 
at an estimated half of blocking levels (0.4-0.5 ng/ml). Although this was sometimes 
sufficient to block the administered opioid challenges, the implants also caused tissue 
reactions in three out of the five patients, and were not reliable in their release of naltrexone 
(range: 2-4 weeks). 
In the early 1990’s, innovations in polylactide polymers were utilized in the development of 
depot injectables for antipsychotics. Pilot studies found it was also feasible to administer 
naltrexone in this manner (Heishman et al 1994; Alim et al 1995). With NIDA support, the 
technology for depot injectables was further refined to enable the release of naltrexone at 1 
ng/ml or more for 4 weeks. One such formulation was recently approved for use in the 
treatment of alcohol dependence (Kranzler, 1998; Garbutt et al. 2005) and depot injectables 
seem promising in the treatment of opioid dependence (Comer et al. 2002). 
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The 1990’s also saw developments in capsules that could release naltrexone after surgical 
insertion. Several small-scale entrepreneurs began development of such naltrexone implants 
without regulatory supervision or - approval, and they were soon marketed for use in private 
addiction clinics. The insertion of naltrexone implants was often done during the sedation of 
patients when combined with a rapid detoxification (ROD) or ultra-rapid detoxification 
(UROD). 
In Norway, a group of addiction professionals at the University of Oslo and the Norwegian 
Institute of Public Health took interest in naltrexone after being contacted by patients who 
had received naltrexone implants in countries like Spain, Portugal, and the UK. The 
initiative was taken to summarize existing knowledge about naltrexone in Norwegian 
(Bachs & Waal, 2002) and to conduct pilot studies on the safety and kinetics of the available 
implant formulations. 
The first Norwegian study of a sustained release naltrexone formulation took place in 
2002/2003, and investigated a Wedgwood (‘compound pharmacy’) type implant. The 
investigation showed that the naltrexone release of this implant was unreliable and ranged 
from three weeks to three months. The implants caused several tissue reactions and needed 
to be surgically removed in three of 12 patients (Waal et al. 2003; Olsen et al. 2004). 
Another type of naltrexone implant was developed in Western Australia by George O’Neil 
(Hulse & O’Neil, 2002). Twenty pellets were said to release naltrexone at therapeutic levels 
for five to six months. The Norwegian naltrexone group conducted a pilot study in which 12 
patients received either 10 or 20-pellet implants. These implants were found to have a 
satisfactory naltrexone release, high patient satisfaction, and produced considerable 
reductions in self-reported opioid use 12 months post implant (Waal et al. 2006). 
The latter pilot study and the publication of other promising findings in Australia (Arnold-
Reed et al. 2003; Hulse et al. 2004; Hulse et al. 2004b) supported the potential of using this 
type of implant in larger clinical studies. Two trials were planned: One would compare 
opioid use among patients who completed inpatient treatment for opioid dependence and 
then received their usual abstinence-oriented aftercare with or without naltrexone implants. 
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The other would recruit opioid dependent inmates to be randomised to either methadone 
maintenance or naltrexone implants shortly before release from prison (Lobmaier et al. 
2010; in press). 
Material from both of these trials and a literature review were used in this thesis to 
investigate research questions on the aims (chapter 2) related to the effectiveness, adverse 
events, and clinical feasibility of sustained release naltrexone treatment for opioid 
dependence.
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4. Research questions
The effectiveness and safety of using sustained release naltrexone to treat opioid 
dependence were investigated in two studies that addressed three main questions: 
1) What is the evidence base on the safety of sustained release naltrexone and its 
effectiveness in the treatment of opioid dependence? (Paper 1)
2) How effective are naltrexone implants in reducing relapse to opioid use following 
completion of inpatient treatment? (Papers 1 & 2)
3) What kind of adverse events are associated with clinical use of naltrexone implants, and 
how frequently do they occur? (Papers 1 & 2)
Two aspects of the feasibility of treating opioid dependence with sustained release 
naltrexone in clinical settings were investigated: 
4) How many opioid dependent patients engage in the use of opioid agonists during 
naltrexone implant treatment? To what extent do they experience a drug ‘high’ following 
such use? Which factors are associated with opioid use during naltrexone implant 
treatment? (Paper 3)
5) How many naltrexone implant patients are retained beyond the first course of treatment? 
Which pre- and in-treatment factors are associated with being retained in naltrexone 
implant treatment for opioid dependence? (Paper 4)
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5. Methods and materials
Two different methodologies were used to address the above research questions: 
• A systematic review of the existing knowledge in the field of sustained release naltrexone.
• Clinical studies of naltrexone implants.
5.1. Systematic review of the literature
Systematic searches of the literature were conducted in 20 databases in accordance with the 
Cochrane Collaboration and Systematic Review guidelines before the quality of studies 
were assessed and those satisfying evaluation criteria were included in analyses. In the 
review of efficacy, only randomised controlled trials with opioid dependent patients were 
accepted for inclusion. For adverse events, non-randomised studies were included and 
descriptive analyses were conducted. A complete list of outcomes, search databases, and 
search terms can be found in the paper (Paper 1). The number of screened and included 
studies can be seen in Figure 1 (below). 
Meta-analyses were performed where appropriate for all outcomes. Individual and pooled 
relative risks (RR) with 95% conﬁdence intervals (CI) were calculated for dichotomous 
outcomes using the ﬁxed-effects model unless studies were heterogeneous, in which case 
the random-effects model was used. Statistical heterogeneity was assessed by the Chi-
squared test, with P < 0.05 indicating heterogeneity. Additionally, I-squared (values from 0 
to 100 %, with 0 % indicating no observed heterogeneity) were calculated to assess 
inconsistency. Weighted mean differences (WMD) with 95% CI were calculated for 
continuous outcomes.
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Figure 1. Overview of articles included or excluded in the literature review. 
520 potentially relevant references screened title and abstract 
444 references excluded on 
basis of title and abstract 
57 reports excluded after 
reading 
2 secondary reports excluded 
1 RCT included in the 
effectiveness analyses 
17 reports included in 
the safety analyses 
6 RCTs 11 non-RCTs 
17 reports included in the review 
 
76 reports obtained in full text 
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5.2. Clinical studies
The data in papers 2-4 came from samples recruited for three different studies, as shown in 
figure 2. The treatment RCT addressed questions on effectiveness and adverse events, while 
two studies of larger samples of naltrexone implant patients each addressed separate aspects 
of clinical feasibility: the extent to which patients used - and experienced ‘high’ from 
opioids (paper 3) and the extent to which patients were retained in naltrexone implant 
treatment (paper 4). The Design section (below) provides more information on the trials to 
which the patients in these studies were recruited. 
Figure 2. Overview of naltrexone implant patients in three recent Norwegian trials and 
the criteria and number of such patients admitted to studies across trials (papers 3 & 
4). 
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Treatment pilot: n = 12
- Naltrexone implant: n = 6
- Matched control: n = 6
Treatment RCT: n = 56
(Paper 2)
- Received implant: n = 26
- Later removed: n = 3
- Control patients implanted at 
follow-up: n = 13
Prison study: n = 46
- Received implant: n = 16
- Control patients implanted 
at follow-up: n = 2
Opioid challenge study 
(Paper 3)
Completing 6 months of 
treatment: n = 60
Retention study 
(Paper 4)
First-time implant 
patients: n = 61
Naltrexone 
implant patients: n = 63
5.2.1. Demographics
The inpatient RCT patients had the following characteristics in mean years (sd): 
Age: 34 (9); heroin use: 7 (5); morphine/codeine use: 2 (4); benzodiazepine use: 5 (6); 
Heavy alcohol use: 3 (6); Amphetamine use: 4 (5); Polydrug use: 10 (7); years in prison: 1 
(2). Twenty patients (33%) were women, 47 (84%) were injecting users, and the mean (s.d.) 
lifetime number of overdoses was 5 (7). 
Naltrexone implant patients participating in clinical studies of opioid use and retention 
(n=63) had the following characteristics in mean (s.d.) years: 
Age: 34 (8); heroin use: 7 (4); morphine/codeine use: 2 (5); benzodiazepine use: 5 (5); 
Heavy alcohol use: 4 (6); Amphetamine use: 5 (6); Polydrug use: 10 (7); years in prison: 2 
(3). Sixteen (25%) were women, 55 (87%) were injecting users, and the mean (s.d.) lifetime 
number of overdoses was 5 (7). 
Three patients included in the paper 3 study did not satisfy criteria for inclusion in the paper 
4 study and vice versa. Slight variations may therefore occur in the demographic data 
reported in the two papers. 
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5.2.2. Instruments and outcomes
All three clinical studies of naltrexone implants used identical instruments and outcomes as 
listed below. The exceptions to this were the use of visual analogue scales (VAS) and MINI 
dependence symptoms, which were only used in the treatment RCT. 
The European Addiction Severity Index (Europ-ASI) 5th edition
The European version of the Addiction Severity Index (McLellan et al. 1992; Kotkevi & 
Hargers, 1995) is a 40-minute structured interview focusing on assessing the patients’ 
lifetime experiences and current situation in seven domains: physiological health; education 
and employment; substance use, overdose history and treatment; criminal activity and legal 
history; family history of substance use; family relationships and history; mental health. 
The Addiction Severity Index has satisfactory levels of reliability and validity (McLellan et 
al. 1980; Kosten et al. 1985; McLellan et al. 1985; McLellan et al. 1992). These properties 
have largely been characteristic of the ASI in other languages (e.g. Hendricks et al. 1989; 
Liang et al. 2008) as well as in automated phone - or internet versions (Brodey et al. 2004). 
The Europ-ASI is designed for both clinical and research use. Patients’ progress can be 
monitored by calculating severity ratings and composite scores from key items in each 
domain, an these can be combined for an overall score. 
The reliability of the instrument in the hands of non-professionals has sometimes been 
questioned (e.g. Grissom & Bragg, 1991), especially the composite scores for their potential 
for bias and lack of reliability (Mäkelä, 2004). Severity ratings and composite scores were, 
however, not used as outcomes in this thesis. All interviewers used in our naltrexone 
implant studies were trained during a 3-day course and licensed to use the Europ-ASI by the 
Norwegian Europ-ASI secretariat.
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The Europ-ASI measures substance use in two ways: 
• Days used of the last 30 days (range: 0-30). 
• 6-month self-estimate of use on a 0-3 scale. ‘0’ designated ‘no use’, ‘1’ use at a frequency 
of 1-3 times per month; ‘2’ use at 1-3 times per week; ‘3’ daily or almost daily.
Both of these measures were preserved from earlier versions of the ASI (McLellan et al. 
1980) as they were shown to have acceptable levels of reliability and validity (McLellan et 
al. 1985; McLellan et al. 1992; Alterman et al. 1998). Nonetheless, some aspects of 
substance use are not measured by the Europ-ASI outcome measures, including daily 
substance dosage and frequency of use. In addition, potential confounders can be introduced 
during this period - e.g. spending time in a controlled environment where drugs are not 
easily accessible, or in maintenance treatment, where opioids are given to stabilise the 
opioid dependence. This would be recorded in the Europ-ASI as non-using days or as days 
using maintenance opioids, respectively (McLellan et al. 1992).
Timeline follow-back
Timeline follow-back (TLFB) was used to assess opioid use during each six month study 
period. TLFB is an interviewing technique based on cueing the patient’s memory for drug 
use one week at a time during a given period (Sobell & Sobell, 1992; 1995). Although the 
0-3 estimation of frequency of use is used in the Europ-ASI due to doubts about the 
accuracy of patients’ memory beyond 30 days (McLellan et al. 1992), these doubts have not 
been verified in samples of sustained release naltrexone patients who use opioids. TLFB 
also has the advantage of providing an approximation of when in a given time period use of 
a substance occurred, started, or subsided. This was of special interest to us, as we could 
relate such data on opioid use to the five-six month release period of the naltrexone 
implants. Opioid-reported TLFB has previously shown 81% concordance with 
immunoassay urine analyses of opioid use in a 365-day time window (Fals-Stewart et al. 
2000).
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Mini Neuropsychiatric Interview - drug abuse and dependence sections
The Mini Neuropsychiatric Interview (MINI) was developed as a short screening instrument 
for current psychiatric diagnoses incorporating most major symptomatic (axis I) disorders 
from the DSM-IIIR and ICD-10 diagnostic classification system (Sheehan et al. 1997). The 
substance use sections consist of simple yes/no items on the DSM criteria for drug 
dependence and - abuse. If the patient has qualified for three or more of the seven 
dependence criteria or one or more of the four abuse criteria during the last 12 months, the 
patient fulfills criteria for these diagnoses. These two parts of the MINI were used in the 
paper 2 study to measure whether patients fulfilled diagnostic criteria for opioid dependence 
and/or abuse at follow-up. In order to enable the monitoring of symptoms during the six-
month study period, the original 12-month criterion for diagnosis was replaced with a 
‘within the study period’ criterion in the follow-up interview. This means that patients who 
were abstinent for 6 months and not designated as ‘fulfilling criteria for opioid dependence’ 
would nonetheless have fulfilled these criteria if the original 12-month criterion had been 
used. 
Hair analysis
Hair samples were collected and analyzed at inclusion and at each six-month follow-up. 
Samples were analyzed using liquid chromatograph gas spectrometry (LC-MS-MS) for the 
most commonly used drugs and their metabolites, with the exception of cannabis and 
alcohol/glucoronides. An exact description of the measurement technique and the complete 
list of drugs screened for can be found in a previous paper (Hegstad et al. 2008).  Although 
our chromatographic method of analysis was likely to be more precise than previous 
techniques based on immunoassay, a number of practical problems such as varying hair 
length (Shearer et al. 2006) were deemed likely to influence hair results. Hair results were 
therefore only used for confirmation of self-reported drug use, rather than as a stand-alone 
result. 
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Visual analogue scales
Visual analogue scales (VAS) consist of a question and two extremes (e.g. ‘good’ - ‘bad’) at 
the opposite ends of a drawn line. The patient rates his or her subjective opinion of the topic 
or question by placing a mark on the line; e.g. placing it exactly between the two extremes 
signifies indifference or an unremarkable rating. The literature has found the wording of the 
VAS question and design of lines to be crucial for a reliable and valid response: This 
includes the design of instructions for responding, the placement and wording of questions 
and of descriptive anchor phrases, the line design, and the importance of unidirectional 
formulation of lines (see Wewers & Lowe, 1990). The VAS used in the investigations 
included in this thesis complied with these guidelines. 
The Beck Depression Inventory
The Beck Depression Inventory (BDI; Beck et al. 1961) was used in our studies as a 
measure of depressive symptoms. This self-response inventory consists of 21 items with 
four different statements that constitute a 0-3 rating (total range: 0-63). A more recent 
version brought questions more up to date with DSM-III criteria for depression (Beck et al. 
1988). Nonetheless, the validity and reliability of the BDI-1a we used is high, with 
Cronbach’s Alpha (internal consistency) of 0.85 (Beck et al. 1988; Ambrosini et al. 1991; 
Richter et al. 1998). In samples of drug dependent patients, concurrent validity has been 
satisfactory with an r of 0.60 - 0.70 (Rounsaville et al. 1979; Reynolds and Gould, 1981; 
Schaefer et al. 1985). 
The Hopkins Symptom Checklist 25
The Hopkins Symptom Checklist 25 (SCL-25) consists of ten anxiety items and 15 
depression items taken from the longer, 90-item SCL-90R (Derogatis, 1974). The 25 items 
are scored on a 1-4 likert scale (range: 25-100), and then divided by 25. Clinical cutoff has 
been found to be between 1.5 and 1.8 in most investigations (Winokur et al. 1984; 
Nettelbladt et al. 1993; Sandanger et al. 1998). Although the SCL-25 lacks the diagnostic 
precision of larger diagnostic interviews like the CIDI (e.g. Sandanger et al. 1998) it can 
nonetheless be used as a screening instrument for general psychiatric distress (Nettelbladt et  
al. 1993). 
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The Satisfaction With Life Scale
The Satisfaction With Life Scale (SWLS) is a five-item instrument designed to measure 
subjective well-being (Diener et al. 1985; Pavot et al. 1998). The patient responds on a 1-7 
likert scale (range: 5-35). Although its three-factor structure has not always been 
substantiated (Hultell & Gustavsson, 2008), this will have few consequences when used as a 
general, one-factor measure. The SWLS has been translated to a wide variety of languages 
and displays satisfactory internal consistency (Cronbach’s alpha >.80) and construct validity 
versus positive and negative affect (Pavot et al. 1991; Pavot & Diener, 1993; Lucas et al. 
1996; Pavot et al. 1998; Vittersø & Nilsen, 2002; Pavot & Diener, 2008; Hultell & 
Gustavsson, 2008). 
Scoring of opioid ʻhighʼ
Naltrexone implant patients who used opioids were asked about the resultant euphoric 
experience or ‘high’ from such use. These were noted in the Europ-ASI’s ‘notes’ field in the 
substance use section. These statements were then listed on a sheet and rated by Dr. 
Lobmaier and myself on a 0-3 scale; a score of ‘0’ was given to statements signifying no 
‘high’ was felt; a score of ‘1’ was given to statements that expressed uncertainty regarding 
the experience of ‘high’; a score of ‘2’ was given to statements telling of partial ‘high’ 
experiences (e.g. ‘not like before naltrexone but definitely something’); while a score of ‘3’ 
was reserved for statements that described ‘full high’. To avoid bias supporting the blocking 
effect of naltrexone, disagreements between raters were resolved by choosing the higher 
rating. 
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5.2.3. Design
a) Inpatient aftercare study
Matched pilot study
This study was designed a case-control study, matching volunteer implant patients to 
voluntary control patients on type of opioid used, age +/- 5 years, and gender before 
commencing treatment. After 9 months of recruitment with these criteria in 2005, only 12 
patients (or 6 matched pairs) had been recruited, as the interest for naltrexone implant 
treatment was far greater than the number of patients volunteering to be non-implant 
controls. In addition, no female pairs could be recruited. Due to these problems, no further 
patients were admitted to the study after nine months of recruitment. The 12 patients 
recruited in this design continued as a pilot study with follow-up and cross-over opportunity 
every 6 months for 18 months.
Treatment RCT
The new inpatient treatment trial compared the rate of relapse to opioid use among opioid 
dependent patients who were randomly allocated to receive or not receive a naltrexone 
implant in addition to their usual follow-up after completion of inpatient treatment. Inpatient 
treatment included detoxification and long-term residential services. Patients were recruited 
by staff at their in- or outpatient clinic, and sometimes following direct contact between the 
patient and the principal investigator (NK) before they entered inpatient treatment. A 
stratified permuted block protocol made by an independent statistician was used by study-
independent staff to make two equally sized sets of sealed envelopes. Following the signing 
of the informed consent and completion of study instruments, the envelope was opened in 
the presence of the patient. No placebo, concealment or masking was used. Target 
recruitment was 50 patients for each group in 12 months of recruitment. However, upon 
recruiting only 30 patients after 12 months, the recruitment period was increased to 18 
months (from January 2006 to June 2007). 
This randomized investigation was a two-centre study, with the Addiction Unit, Sørlandet 
Hospital Kristiansand recruiting, allocating, implanting, and conducting follow-up in the 
Agder municipalities; the remainder of South-Eastern Norway was covered by the 
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Norwegian Centre for Addiction Research. The Addiction Unit in Kristiansand was alloted 
20 of the 100 sealed randomisation envelopes.
b) Prison study
This study was designed to compare relapse to opioid use among former inmates receiving 
either methadone maintenance or naltrexone implants every 6 months until 18 months 
following release (Lobmaier et al. 2010; in press).  Of the 46 inmates recruited in this study, 
half were randomly allocated to naltrexone implants, of which n=16 received a naltrexone 
implant before release. Cross-over was offered from 6-months follow-up, and two inmates 
from the control group were successfully implanted. The total number of implanted patients 
in the prison study was thus n=18. 
5.2.4. Ethical and regulatory aspects
The three clinical trials were approved by the Regional Ethical Committee for Medicine and 
Health Research, and registered in the public database http://www.clinicaltrials.gov under 
the designators NCT00269607, NCT00521157, and NCT00204243. Written informed 
consents were used and informed patients of the right to withdraw from the study and have 
implants removed without questions asked. Information about the naltrexone implants and 
their status as an experimental treatment was given in a separate product folder. Naltrexone 
implants were given as supplements to standard aftercare, meaning patients’ GP or other 
regular treatment staff remained responsible for the participants’ healthcare. Implant ‘carrier 
cards’ were given to implanted patients in order to inform health personnel about the 
implant, study staff contact details, and options in case of serious injury and medical pain 
relief was needed. None of the authors had any conflicts of interest in any of the trials. 
5.2.5. Statistical analyses and power analyses
Power analyses in treatment RCT
Opioid use among non-implant patients was pre-estimated to occur on a mean of 6 (s.d.: 10) 
of the last 30 days of the study, whereas naltrexone implant patients were estimated to use 
on a mean of 1 (s.d.: 3) day of the last 30. Adopting a significance level of .05 in an ordinary  
student’s t-test, results were calculated to reach significance with a minimum group size of 
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n=25 in the control group and n=8 in the implant group. The reliability of the outcome 
measure (found in the Europ-ASI) was estimated at 0.70. As attrition from recruitment to 
six-month follow-up was a regarded as a potential threat to statistical power, target 
recruitment was set at n=50 in each group, or n=100 total.
Power analyses in other clinical studies
These exploratory studies adhered to the principles of exploratory data analysis (EDA - 
Tukey, 1977), which does not condone power estimates at an early stage of investigation - 
e.g. before the number of groups, their sizes, the variance of outcome measures and strength 
of associations are known (Behrens, 1997). Thus, no power analyses were conducted in 
these studies.  
Statistical analyses
Analysis of variance (ANOVA) was used for analyses of any difference in opioid use in the 
treatment RCT between the naltrexone implant group and the non-implant group. The 
analyses controlled for gender, study centre, and any significant pre-study differences 
between implant and non-implant groups.
To assess the effectiveness of naltrexone implants in preventing a return to opioid 
dependence, the 'Number Needed to Treat' (NTT) statistic was used. NNT quantifies the 
effectiveness of an intervention in terms of the number of patients one needs to treat in order 
to prevent a bad outcome - in this case, fulfilling MINI criteria for opioid dependence. The 
ideal outcome in an NNT statistic is 1, which signifies that everyone improves in the 
intervention group and no-one in the control group shows any improvement. A high NNT 
(e.g. ‘13’) translates to little detectable benefit of implementing the treatment. 
For analyses of efficacy, an intention-to-treat approach (ITT) was used. In order to provide a 
conservative estimate of the effect of the intervention, data on all patients who are allocated 
to treatment or control at study start are also included in the analysis of follow-up data - 
including patients who were diseased or otherwise missing at follow-up. Data on missing 
patients can be substituted for in various ways, the most common of which is 'last response 
carried forward' (LRCF). In LRCF, the patients’ relevant data are assumed to have remained 
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unchanged since the last observation before the patient went missing; these data are 
therefore included in the ITT analysis. As our study collected data only at inclusion and 
follow-up, adopting the ITT approach with LRCF meant presuming that patients who were 
missing from follow-up had returned to pre-study levels of substance use. In order to also 
provide results on the performance of groups without imputed data, separate analyses were 
conducted that included data only from patients who remained in treatment and attended 
follow-up, called ‘completer analyses’. 
Further group comparisons were conducted as t-tests with independent groups. If visual 
inspection of the scatterplot indicated failure of the normality assumption or Levene’s test 
indicated differences in distribution, results were double-checked using a non-parametric 
test. These included the Mann-Whitney U-test for continuous variables and Chi Square for 
dichotomous variables. 
For predictor variables, t-tests of the factors significantly different between outcome groups 
(e.g. ‘retained’/’not retained’) were used for an initial selection of potential outcome 
predictors. The factors who were significantly (<.05) related to outcomes were entered into 
a non-parametric intercorrelation matrix with the outcome variable using Spearman’s Rho. 
If variables showed an R of 0.7 or above, the variable that correlated highest with the 
outcome variable was selected for inclusion in regression analysis. For the final analyses of 
predictors, binomial analysis of regression was used with backwards inclusion of variables 
at a .05 significance level. 
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6. Main findings
6.1. Efﬁcacy and adverse events in the literature
The literature review of efficacy studies found only one randomized controlled trial (Comer 
et al. 2006) that satisfied criteria for inclusion. As Cochrane guidelines do not permit 
conducting a meta-analysis with less than four studies, the results of the review on this point 
was inconclusive due to a lack of research. 
In the review of adverse events, seventeen studies satisfied inclusion criteria. Ten of these 
studies were on opioid users, one on healthy volunteers, five on alcohol dependent patients, 
and one compared healthy volunteers to alcohol dependent patients. Adverse events differed 
with diagnosis and the type of sustained release technology. Alcohol dependent patients 
tended to report nausea, fatigue, vomiting, decreased appetite and upper abdominal pain. 
Opioid dependent patients reported fatigue, headache and other general complaints. 
Injection-site reactions were frequently reported with depot naltrexone, but were generally 
short-lived. Implantation of naltrexone caused infection and allergic reactions that 
sometimes resulted in surgical removal. Other adverse events seemed dose-related, and were 
more frequent in naltrexone than placebo groups; however, a statistically significant effect 
could only be detected in data on alcohol dependent patients. 
6.2. Effectiveness and adverse events in a randomized comparison
Fifty-six patients were included in the randomized controlled trial of naltrexone implants, of 
which 52 (93%) attended six-month follow-up. Of the 29 patients allocated to naltrexone 
implants, three discharged themselves from the clinic before receiving the implant, one of 
whom died of an overdose after a few days. Three implant patients had the implant 
removed, one due to site infection. Two patients reported implantation site rupturing that 
required antibiotics. Although patients reported their implant sites to have spontaneously 
opened, a pathologist alerted us to the possibility that these were attempted self-removals. 
One patient in the control group died of an overdose. 
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In addition, adverse events occurred after the six-month study period of this trial that are 
outside the scope of the current investigations but should nonetheless be mentioned here: 
Three weeks after declining the offer of implantation at follow-up, one control patient died 
of an overdose. A patient who started in the implant group declined further implantations 
due to his high level of recovery but died of unknown causes about 18 months after 
receiving the first implant. A naltrexone implant patient on his second implant required 
hospital treatment after an accident and suffered a non-lethal stroke during his stay. One 
control patient in the pilot treatment study relapsed about ten months into the study and died 
of an overdose around month 13. These cases will be reported as part of an upcoming paper 
on the 6-12 month outcomes of naltrexone implant treatment. 
Intention-to-treat analyses showed opioid use was significantly reduced in the naltrexone 
implant group, who reported using any opioid on an average of 37 (s.d.: 64) of the 180 days 
compared to 64 days (s.d.: 71) for the control group. When only completer data was 
considered, mean use for the implant group was 20 days (s.d.: 43) and 94 days (s.d.: 81) for 
control participants, respectively. During the 30-days preceding follow-up as measured with 
the Europ-ASI, implant patients had used opioids on a mean (s.d.) of 6.3 (1.5) days 
compared to control patients’ 11.4 (13.9) days. Completer data on the same variable found 
that implant patients had used opioids on 6.3 (11.5) days compared to control patients’ 17.5 
(14.3) days. 
The differences between implant patients and control patients on opioid use outcomes are 
listed in Table 1. 
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Table 1. Opioid outcomes for implant- and control participants in the treatment RCT.
Intent
samp
ion-
le (
to-treat 
n=56)
Treatm
sam
ent co
ple (n
mpleter 
=49)
Mean 
diff
F 95% C.I. Mean 
diff
F 95% C.I.
Heroin timeline 
follow-back; 
Days used of last 180 
days
45.6* 7.0
14.1 – 
77.3
57.8** 13.3
28.2 – 
87.4
Heroin (Europ-ASI); 
Days used of last 30 
days 
8* 5.8 1.8 – 14 9* 6.9
2.8 – 
15.3
All opioids timeline 
follow-back;
Days used of last 180 
days
60.2** 8.1
20.9 – 
99.5
73.5** 14.8
37.3 – 
109.8
All opioids (Europ-
ASI); 
Days used of last 30 
days
9* 5.4 1.6 - 16.4 11.2** 9.2 4 – 18.5
Note: Range was 0-180 days for timeline followback variables and 0-30 days for Europ-
ASI. 
Other opioid-related variables, like the 0-3 six-month frequency of use, 30-day injecting 
drug use, and 30-day poly-drug use, showed similar improvement as shown in table 2. The 
naltrexone group also experienced significantly higher quality of life and lower heroin 
craving compared to control patients. Satisfaction with the naltrexone implant was a mean 
of 78 (s.d.: 22) on a 0-100 scale among all implant patients, including those who had 
implants removed. 
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Table 2. Other significant differences between implant- and control patients in the 
treatment RCT.
Intent
samp
ion-
le (
to-treat 
n=56)
Treatm
sam
ent co
ple (n
mpleter 
=49)
Outcome (range)
Mean 
diff
F 95% C.I.
Mean 
diff
F 95% C.I.
Poly-drug use last 30 
days (0-30)
6.4* 4.2
0.6 – 
12.3
6.5* 4.5
.89 – 
13.2
Heroin craving 
(0-100)
27** 7.2
9.4 – 
44.2
38.5** 18.9
21.6 – 
55.5
Life Satisfaction 
(5-35)
5.4* 5.3
0.68 – 
10.1
6* 6.5
1.2 – 
10.7
Recommend implant 
to friend (0-100)
28.5* 9.1
10.8 – 
46.2
22.5* 7.1
12.6 – 
47.6
Satisfaction 
(allocation) 
(0-100)
42** 25
25.9 – 
58.5
44.7** 11.6 24.8 – 58
Note: Visual analogue scales (VAS) were used to assess craving, allocation satisfaction, and strength 
of recommendation, while the Satisfaction with Life Scale was used for life satisfaction. The Europ-
ASI was used in the measuring of poly-drug use. 
There were no significant differences between the treatment RCT groups on other variables 
of interest; e.g. non-opioid substance use, criminal activity, or mental health. 
The Number Needed to Treat (NNT) for every patient that would no longer fulfill criteria 
for opioid dependence was found to be 2.8 in intention to treat analyses and 2.4 in completer 
analyses.
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6.3. Feasibility in clinical settings - opioid use and retention
Plasma analyses showed the naltrexone implants released naltrexone above the therapeutic 
limit of 1 ng/ml for at least 5 months, and above 2 ng/ml for about 4 months. 
Opioid use was reported by a slight majority of the sixty naltrexone implant patients, with 
(n=34) of the 60 naltrexone implant patients reporting having used opioids at some point 
during the six-month study period. Mean days of opioid use was 24 days (s.d.: 49) in the 
180-day time period. Sixteen patients (27% of the total) used opioids on six or more 
occasions, of which nine patients (15% of the sample) used on 90 days or more (see Figure 
2). 
Figure 1. Number of days on which illicit opioids were used by sustained-release 
naltrexone patients in the 180-day study period (abstainers excluded).
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Exploratory analyses showed high-frequency users (6+ days of opioid use or more) had a 
steady increase in use during the six-month period on naltrexone, while low-frequency users 
(1-5 days of opioid use) mostly engaged in occasional experimentation (see Figure 3). A 
number of cases were included in the paper to better illustrate clinical diversity behind these 
descriptions. 
Figure 3. Opioid use development among high- and low-frequency opioid-using 
naltrexone implant patients. 
                                  
Note: ‘Low use’ = 1-5 days of use; ‘high’ use = 6-180 days of use. All differences from month 2 
onwards were significant.
Opioid use among naltrexone implant patients was significantly correlated with more use of 
all non-opioid drugs. 
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Nine patients reported feeling 'high' following the use of opioids, of which three were 'full 
high' and six were reduced experiences of 'high.' Patients who reported a greater extent of 
'high' following opioid use had significantly higher intake of benzodiazepines, opioids, and 
buprenorphine than patients who used opioids without feeling any 'high.' 
Of the 61 implant patients who were offered a second implant, 17 declined and 44 accepted. 
Of these 44 patients, 31 (51% of the original sample of n=61) were eventually re-implanted. 
Five of those who declined reimplantation did so on reasons of feeling recovered from 
opioid dependence. Of those who were not reimplanted, only three started maintenance 
treatment with buprenorphine and three entered long-term residential treatment. Nineteen 
patients discontinued or dropped out from naltrexone implant treatment without plans for 
entering other treatments and without considering themselves recovered from opioid 
dependence.
Retention was predicted by having a history of longer employments, as well as less needle 
use and more family engagement in the month preceding inclusion (Table 3).
Table 3. Regression coefﬁcients of pre-treatment factors predictive of 
receiving a second naltrexone implant.
Independent variable B S.E. sig.
Longest employment, years 0.57 0.23 .014
Needle use, days of last 30 
days
- 0.12 0.04 .003
Family problems days of last 
30 days
0.75 .64 .019
Note: Result of binary logistic regression with backward conditional (.05) inclusion of 
variables. 
Patients who later received a second implant had used significantly less opioids and 
amphetamines and had been less criminally involved during the first treatment period than 
non-retained naltrexone patients. 
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7. Discussion
7.1. Summary of ﬁndings
Aim 1:  Investigate the effectiveness of sustained release naltrexone in preventing 
relapse among opioid dependent patients who complete inpatient 
treatment. 
The review of the sustained release naltrexone literature confirmed our impression that there 
was a lack of prospective, controlled studies of the effect of sustained release naltrexone on 
relapse to opioid use. Only one study satisfied criteria for inclusion in the review of efficacy, 
which was insufficient for conducting a meta-analysis and for drawing conclusions about 
efficacy in the systematic review. 
Our randomised clinical trial showed that naltrexone implants significantly reduced opioid 
use after completion of inpatient treatment compared to similarly motivated control patients 
receiving usual-treatment aftercare. 
Aim 2:  Assess the safety of naltrexone implant treatment for opioid dependence.
The literature did not allow for quantified analyses of the safety of naltrexone implant 
treatment for opioid dependence. Descriptive analyses nonetheless suggested more side-
effects or site-related events in active naltrexone groups compared to placebo.
In the treatment RCT, one site-related infection occurred and two patients requested removal 
before completing a medical examination. One of these complaints, diarrhea, re-appeared 
when the patient on a later date requested to try implantation again and was put on 25 mg of 
oral naltrexone following detoxification. Most patients also experienced some site pain a 
few days following insertion of the implant. In addition, many patients experienced less 
severe symptoms associated with naltrexone like headache, gastrointestinal complaints, 
restlessness, and muscle aches. These resolved once naltrexone levels stabilised - usually 
1-3 weeks following implantation. 
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The three cases of pre-naltrexone discharges and the two possible attempts at implant self-
removal shows that patients’ fluctuations in motivation for long-term abstinence from heroin 
and other opioids is a potentially important source of adverse events in this type of 
treatment - leading to the tragic death of one patient overdosing following discharge. The 
consequences of ambivalence towards abstinence was apparent from the results despite our 
best efforts to explain the consequences of entering sustained release naltrexone treatment to 
every potential study participant. Still, the beneficial effects of sustained release naltrexone 
treatment on opioid use in the remaining patients means the overall level of safety 
nonetheless seems acceptable. 
Aim 3: Evaluate the feasibility of using naltrexone implants as a treatment for 
opioid dependence in clinical settings.
Two important aspects of feasibility were evaluated as part of this thesis in separate 
explorative studies on naltrexone implant patients: Opioid use among patients was 
investigated in order to ascertain whether the levels of naltrexone released by the implant 
seemed sufficient to block the effects of heroin. Had a majority used opioids with a reported 
‘high’, it would have been appropriate to question the feasibility of using these naltrexone 
implants in clinical treatment. Results showed that naltrexone blocked opioids in most 
cases, but that a minority of patients experienced a drug ‘high’ and used opioids and other 
drugs frequently. The size of this group (about 15% of naltrexone implant patients) was not 
large enough to threaten the overall clinical feasibility of the treatment. 
Retention among patients has severely limited the clinical feasibility of oral naltrexone 
treatment, and our study therefore investigated how large a proportion of naltrexone implant 
patients would discontinue treatment once presented with the first (non-surgical) 
opportunity to do so. 
We found that about half of patients were retained from the first six months of treatment to 
the second six months of treatment. The low number of implant removals during treatment 
means that most of this group can be assumed to achieve 10-12 months of continuous 
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antagonist protection. Retention thus seems much less of a problem to the clinical feasibility 
of naltrexone implant treatment than it is in oral naltrexone treatment. 
7.2. Contribution
The papers included in this thesis have made several contributions to research on sustained 
release naltrexone for opioid dependence. As usable sustained release formulations have 
only recently been developed, this thesis is among the first to investigate clinical topics 
related to this type of treatment in opioid dependent patients. 
• The review of the literature was the first article to systematically collect, categorize and 
evaluate the literature on the safety and efficacy of sustained release naltrexone in the 
treatment of opioid dependence.
• The randomised controlled trial was the first prospective, controlled comparison published 
on naltrexone implants for opioid dependence. It was also the first RCT of sustained 
release naltrexone with 5-6 months’ naltrexone release, and is as of January 2010 the 
second of only three controlled studies of sustained release naltrexone for opioid 
dependence that have reached publication. Our RCT is the only of these trials to have used 
treatment-as-usual controls, thus providing data on the prognosis of patients with a high 
level of abstinence motivation within the existing treatment system. 
• The opioid use study was the first explorative group-based study of opioid use among 
sustained release naltrexone patients. It is therefore the first study to address questions of 
how many users engage in how much opioid use with what consequences. As previous 
studies on this topic have been predominantly based on case material (e.g. Gibson et al. 
2007), this group-based study advanced the level of knowledge on this behaviour that 
should inform future debate on the safety of naltrexone treatment. 
• The retention study was the first prospective study of retention in naltrexone implant 
treatment. It is the second study of retention in sustained release naltrexone treatment and 
has three times as many patients as the first study to bring data on this topic. It is also the 
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first study to bring data on pre- and in-treatment factors associated with retention in 
sustained release naltrexone treatment for opioid dependence. 
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7.3. Strengths
The above section highlights many of the strengths of this research relative to other studies 
and general developments in the field (e.g. preceding and having a larger sample size than 
many previous studies). Further advantages of the specific studies are outlined below. 
7.3.1. Strengths of the systematic literature review
• The systematic and detailed procedures of the Cochrane guidelines for systematic 
reviews were adhered to in this review. This decreases the risk of overestimating the 
significance of the literature on this topic on the basis of a few studies or of studies not 
designed to address the research questions. 
7.3.2. Strengths of clinical studies
• The use of a randomised controlled design rather than a cohort design in the treatment 
RCT enabled a valid comparison with similarly motivated patients. 
• The open (or ‘non-masked’) design of the treatment RCT may have increased 
recruitment relative to a masked design. 
• The external validity of the clinical studies was strengthened by them being designed to 
interfere as little as possible with ordinary aftercare following discharge from controlled 
settings: patients knew whether they were in the naltrexone implant or the usual 
treatment group, and were only required to attend follow-up six months after the first 
interview. 
• Sample demographics indicate that the studies succeeded in recruiting opioid users with 
a reasonably long experience with injecting use of opioids and other drugs. This 
increases the likelihood that the findings can be generalized to clinical settings. 
• Basing participation upon the continuation of existing aftercare also meant that study 
participation was unlikely to be experienced as an interruption of existing treatment 
services. 
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• The high six-month retention rate for research follow-up in the treatment RCT (93%) 
meant fewer data had to be imputed in a ‘last response carried forward’ procedure, and 
fewer uncertainties regarding the extent to which data reflects patient performance. 
• The opportunity for control patients in the treatment RCT to cross over to naltrexone 
implants at six months likely prevented dropout in this group. The offer of two 
naltrexone implant periods to all participants regardless of their initial, randomly 
assigned condition is also likely to have allowed control patients to feel they too gained 
something from participating - even if they did not receive an implant during the first 
period. This also allowed us to discard other schemes for compensating patients for 
participation, e.g. money or vouchers, which could have complicated the ability to 
generalize of findings to clinical settings. 
• The use of timeline followback for the 180-day study period produced data on the 
timing of opioid use for comparison with naltrexone levels. Such temporal continuity of 
data proved of high interest to the investigation on opioid use among naltrexone implant 
patients (paper 3). 
• The retention study collected and provided data on on the alternative treatments sought 
by patients who discontinued naltrexone implant treatment. This provides more 
information on the treatment preferences of former naltrexone implant patients and the 
risks associated with discontinuation of treatment. 
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7.4. Limitations
7.4.1. Limitations of the systematic literature review
The Cochrane guidelines for systematic reviews have been criticized for putting too much 
emphasis on internal validity, focusing on short-term interventions of limited relevance or 
interest to the addiction field (e.g. Tucker & Roth, 2006; Pearson & Coomber, 2009). 
Widening the criteria to include non-randomised or cohort studies of sustained release 
naltrexone in the evaluation of effectiveness could thus have yielded a broader basis of 
articles from which to evaluate its safety and effectiveness in the treatment of opioid 
dependence. 
7.4.2. Limitations of clinical studies
Material
• The samples’ representativeness of opioid users in Norway or elsewhere is not 
determined, even though knowledge about this is one of the main purposes of clinical 
research standards for reporting of recruitment and attrition (e.g. CONSORT).
Estimation of representativeness in our clinical studies is made difficult by several aspects 
of study design and current scientific reporting standards, as well as aspects of opioid 
dependence disorder and the treatment offered for this disorder. For example, the 
recruitment process was prolonged and involved a large number of clinics or prisons, of 
which only some contributed patients to the studies. Instances of patient-to-patient (or 
‘snowball’) recruitment occurred as the treatment RCT progressed. It is estimated that many  
opioid dependent patients do not seek treatment (WHO, 2009). Outside hospital settings, it 
has been shown that information on new products or treatments take time to reach all 
potential members of a relevant community (Rogers, 1964). This contrasts with medical 
problems for which the CONSORT was designed - e.g. the vast majority of patients 
suffering complicated fractures of the tibia will seek treatment in well-organised clinics that 
are often clearly defined within a geographical area and are generally positively inclined 
towards research participation. 
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Despite these limitations it is plausible that the majority of opioid users at any given time 
will not feel ready for a long-term pharmacologically induced abstinence from opioids. The 
clinically relevant population thus consists of the subset of patients who would be willing to 
undergo this kind of treatment, rather than all patients with opioid dependence. In a clinical 
setting, this criterion is likely to be of greater significance to sample composition than many 
of the factors normally thought to affect representativeness. 
The main concern with representativeness in clinical trials is usually that patients enter the 
trial who are much better functioning than those who will eventually be offered the 
treatment in the community. Such a sample could benefit more from treatment than would 
be the case in ordinary clinical settings. Patient demographics in our studies showed that 
patients on average were experienced opioid users with a history of poly-drug use, were 
approaching their mid-thirties, and consisted of 1/4 to 1/3 females. Most had tried and failed 
existing treatments (inpatient - and/or maintenance treatment) at least once. These 
characteristics are similar to other opioid dependent patients in clinical settings. 
• The number of patients recruited for all clinical studies was insufficient for several 
research purposes, including subsample analysis / analyses of outcome-related factors, 
estimation of mortality, and decreasing the risk of type I and type II errors. 
A larger sample could have reduced uncertainties in all of the above areas, and we would 
have liked to see larger number of patients recruited, especially to reduce the risk of type I 
and type II errors. While it would have been of great interest to estimate mortality in our 
investigations, this was not our main objective. 
The additional importance of increased accuracy in the analyses of factors / subgroups is 
uncertain; e.g. it is likely that the precise kind and number of outcome-related factors will 
show some variation across cultural and clinical settings. Most such factors would 
nonetheless have a high probability of being related to a return to opioid-dominated poly-
drug use. Although it is possible that larger studies will bring data on isolated but important 
factors influencing effectiveness and / or retention, our sample size has been sufficient to 
support the more general tendency in the findings. 
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• Reliance on self-report measures left the opioid outcomes vulnerable to the under-
reporting of drug use.  Analyses of drug compounds and metabolites in urine would 
have reduced this risk and provided a better biological basis for outcome analysis than 
did hair analyses. 
Self-reported data on drug use have repeatedly been found to have satisfactory reliability 
and validity compared to biomarkers (Darke, 1998; Fals-Stewart et al. 2000). Although 
there is always potential for some underestimation in self-reporting of data, our findings and 
experiences indicate that drug use was generally reported. Collection of urine or other 
frequent biomarkers would have significantly increased the amount of effort required to 
participate in the study, and could potentially have deterred some users from volunteering. 
Methods
• The absence of a placebo control group in the treatment RCT leaves the findings 
vulnerable to placebo effects. 
The possible influence of the placebo effect is a threat to internal validity in all clinical trials 
of naltrexone. The difficulties of controlling for placebo effects in naltrexone treatment were 
experienced by Keegan and colleagues (1976):
1) “The patients tested their medication and, hence, were often the only ones to know what 
they received.” 
2) “Patients who found they were not receiving naltrexone saw no point in continuing the 
program." 
(Keegan et al. 1976; pp. 76).
These experiences, and the ethical problems of implementing a design that might lead 
patients to engage in self-testing, discouraged us from doing a double-blind placebo study. 
Placebo effects nonetheless remain a potential threat to internal validity in both open and 
masked studies of treatment with opioid antagonists. The significance of this 
                                                                                                                                              Discussion
59
methodological threat to the adoption of a new treatment should be weighed against other 
important aspects of a study in the context of clinical treatment; e.g. external validity and its 
potential for saving lives (Tucker & Roth, 2006; Pearson & Coomber, 2010). 
• The risk of bias in the treatment RCT is increased by the lack of independence / masking 
in e.g. data analyses, using the same persons for data collection at recruitment and 
follow-up, and by the lack of independent monitoring.   
Although minimizing risk of bias is important in any research study, it is uncertain that such 
design elements would have influenced conclusions of this RCT. The risk of bias was 
reduced by our lack of interests in the producer of the naltrexone implant and the policy of 
emphasizing the importance of negative results to science when talking to patients about the 
study. Some of the proposed precautions could also weaken other aspects of the study; e.g. a 
good relationship with one member of study staff throughout the study can increase 
patients’ confidence in the research and prevent dropout. 
• The use of treatment-as-usual as the control intervention in the treatment RCT risked 
helping fewer patients than e.g. the use of manualized relapse prevention therapy or 
medical interventions like oral naltrexone or buprenorphine. Little is known about what 
treatment the control group actually received in a treatment-as-usual design. 
Additional intervention to implants/no implants could have had a positive influence on 
general outcomes, but could also have reduced the clinically interesting results produced by 
the treatment-as-usual design. A comparison with methadone or buprenorphine was caused 
many patients to withdraw from our prison study when the group assignment did not match 
their initial treatment preference (Lobmaier et al. 2010). The use of treatment-as-usual also 
had the advantage of involving each participant’s existing treatment network in the study; 
structured psychotherapy could have risked less involvement from these professionals both 
during and after the study. In addition, the treatment RCT measured treatment variables like 
utilization of counseling, psychotherapy, maintenance treatment, and inpatient treatment and 
reported all statistically significant outcomes in the paper. 
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• Results may have been affected by the non-parametric distribution of outcomes on 
opioid use (e.g. Chapter 6, Fig 1), as the most common statistical procedures usually 
suppose a normal distribution in calculations of significance. The lack of a parametric 
distribution also affects the value of the mean, which could have been replaced by a 
different measure of central tendency (median/mode). 
The statistical analyses most familiar to a scientific readership (e.g. ANOVA, t-tests) 
generally presuppose normal distribution in their calculation of statistical significance. We 
used such tests in the reporting of results mainly for presentational purposes. All findings 
were checked using non-parametric tests (e.g. rank tests; Mann-Whitney U-test; Spearman’s 
Rho; binomial logistic regression). Although these sometimes have limitations of their own 
(e.g. ‘ties’ for rank tests; not providing means-based outcomes), we believe this left the 
overall integrity of the findings intact. A common approach to this type of problem - 
converting continuous data to dichotomous outcomes - was not adopted as we found the 
continuos data on opioid use to be of too great interest to split them in this manner. Other 
measures of central tendency imply simplifications of their own and are not as readily 
understood by readers as the mean. 
                                                                                                                                              Discussion
61
Discussion
62
7.5. Comparison with similar research
Two other groups have conducted prospective studies on the effectiveness of sustained 
release naltrexone in reducing opioid use since the start of the naltrexone research projects 
in 2005: The Columbia group (Comer, Sullivan et al. 2006) and the University of Western 
Australia (UWA) group (Hulse et al. 2009). Despite the differences in study design and 
cultural setting, all studies find that the level of adverse events resulting from treatment is 
acceptable, and that there is a considerable reduction in opioid use following detoxification 
on a magnitude of 45% (Hulse et al 2009) to 62% (our study) over the different control 
groups. Our data and those of the Columbia study both show that sustained release 
naltrexone produces reduced craving for heroin and has satisfactory levels of retention from 
first to second naltrexone administration. 
The findings of the three controlled studies on sustained release naltrexone occasionally 
display slight discrepancies in findings. The Columbia study found an improvement in 
opioid-positive urines of 51% in the naltrexone group relative to placebo controls. This is 
slightly lower than our study (about 62% improvement), but comparable to the UWA study’s 
45% advantage of naltrexone implants over oral naltrexone in the proportion of patients 
returning to daily use. The retention rate in the Columbia study was also somewhat greater - 
68% compared to our 51%. On opioid use, 38% (or 6 of 16) urine samples in the Columbia 
study were positive for opioids in the naltrexone group. This is higher than the self-reported 
means of 37 of 180 days (about 20% of days) in our treatment RCT (paper 2) and the 24 of 
180 days (13%) in the opioid use study (paper 3).
The above differences may be due to methodological differences as well as differences in 
cultural setting. The UWA study encountered problems with naltrexone release that 
potentially confounds their findings and makes comparison with more reliable formulations 
difficult. The following comparisons will therefore be limited to the Columbia study and our 
own studies, which both had naltrexone release profiles that conformed to expectations.
 
The differences in material and methods between our studies and the Columbia study could 
contribute to the lower relative advantage of naltrexone and the higher retention rate in that 
study: 
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The more frequent follow-up and manualized therapy of the Columbia study could have 
benefitted control patients more than naltrexone patients, thereby reducing the relative 
advantage of the naltrexone group. It could also provide increased support for patients who 
were considering discontinuing naltrexone treatment. 
The Columbia study’s use of placebo and masking could have lead patients to unmask their 
condition by self-testing with opioids (Keegan et al. 1976). In a single-dosage comparison 
(one naltrexone dosage or placebo), such self-testing might be confined to an initial phase 
following administration. The Columbia study nonetheless employed a two-dosage (192 
mg/384 mg) active medication vs. placebo design, in which some patients might continue 
testing occasionally in order to ascertain whether they were in the low-dosage group and the 
antagonist effect was wearing off. If we assume that the placebo design worked and was not 
unblinded, this too might explain a slightly lower advantage of naltrexone: a placebo effect 
could increase the performance of the control group, thus reducing the gap to the naltrexone 
group. A mixed scenario of some patients engaging in self-testing and others not is also 
possible. 
As the Columbia study lasted 60 days, a few number of days spent self-testing would 
constitute a larger proportion of the total study length than it would in our 180-day study 
period. The use of twice weekly urines as outcomes also meant that a single episode of use 
could cause a 1/16 (6%) increase in outcomes for that user, whereas it would lead to an 
increase of only 1/180 (0,006%) in our timeline follow-back measurements. This difference 
in outcome sensitivity means patients in the two studies could have had highly similar 
patterns of use despite the small differences in results. 
The Columbia study’s exclusion of patients with recent regular poly-drug use could also 
increase the performance of the sample as a whole, including the control group. Such 
patients would be less at risk of relapsing to poly-drug use during treatment, and could be 
more likely to be retained in a second course of sustained release naltrexone treatment. 
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Ambivalent patients could also be less reluctant to remain in the Columbia study’s 4-week 
injectable naltrexone treatment than in our 24-28 week surgically implanted naltrexone 
treatment. 
Our results on effectiveness have a higher risk of being influenced by bias among 
investigators and patients, as the Columbia study used only biomarker outcome, was 
monitored by an independent monitoring agency, and had analyses and data collection done 
by investigator-independent staff. 
Finally, the sample sizes of the groups range from small (n=20 in the 384 mg Columbia 
naltrexone group) to medium (n=61 in our retention study). This puts outcomes in both 
studies more at risk of measurement and statistical errors than with larger sample sizes. 
This comparison of studies has confirmed the results of the systematic review that there are 
few controlled studies currently published on the efficacy and safety of sustained release 
naltrexone in opioid dependent patients. In the few studies that have been conducted, there 
is nonetheless a high degree of consistency in findings: sustained release naltrexone seems 
effective, sufficiently safe, and feasible for continued clinical study. 
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7.6. Implications
Implications for research
Theories on relapse and naltrexone effects
Contrary to Abraham Wikler’s (1965) hypotheses, use of opioids did not seem to benefit 
naltrexone patients’ prognoses in our studies. On the contrary, such use seemed to 
precipitate more rather than less opioid use, and increase the risk of patients’ exit from 
treatment. Similar results have been found in oral naltrexone patients (Sullivan et al. 2006b; 
2007). This suggests that naltrexone research based on laboratory studies of animals 
oversimplifies the situation relative to opioid dependent, poly-drug using human outpatients. 
Wikler seems to have been open for this possibility in the 1970’s (Wikler, 1976), and 
suggested the lack of therapeutic effect of blocked self-injection in humans was due to the 
influence of other conditioned responses - e.g. classical conditioning to heroin-related cues 
(O’Brien et al. 1991). We should also be open to the possibility that factors like the sense of 
identity as a drug user or insufficient coping skills could exert an influence on relapse in 
these patients. Continued non-opioid drug use would maintain many of the same biological 
and social factors related to relapse as opioid use would.  
Basic research
The finding that a minority of naltrexone patients relapse to pre-treatment levels of opioid 
use should be further explored by investigating the biological foundations of naltrexone’s 
effects: the antagonism of the opioid receptor. Data on the extent of opioid receptor 
blockade given different blood levels of naltrexone could inform us on whether the 1 ng/ml 
concentration is too low for producing antagonism of normal heroin dosages. This would be 
an advance over previous PET studies of naltrexone blockade (e.g. Lee et al. 1988). It would 
also be important to gain knowledge about the consequences of individual differences 
related to receptor numbers or types, metabolism of naltrexone, and receptor adaptation to 
the effectiveness of long-term naltrexone treatment. 
Another meaningful area of basic research would be the continued development of sustained 
release formulations. The ideal sustained release formulation would be minimally invasive 
to administer, release naltrexone at 2 ng/ml or more for several months at a time, and could 
be removed in the event of an accident or injury requiring anesthesia. While the current 
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formulations are satisfactory given the benefits of treatment, there is still room for 
improvement in all of these areas. 
Clinical studies
Our early findings justify the implementation of more and larger studies. This would 
address uncertainties pertaining to low statistical power. In addition, longitudinal studies 
should be undertaken in order to get more data on the potential role of sustained release 
naltrexone in recovery from opioid dependence - which usually takes several years (Woody 
et al. 1978). More research is also needed to determine the chances of dropout given 
different treatment conditions and patient populations: e.g. comparing shorter-acting 
formulations and more invasive, longer-acting ones on recruitment figures and long-term 
retention. Qualitative research could identify the specific issues related to recovery with 
sustained release naltrexone, and the findings could be incorporated into a psychosocial 
treatment tailored to support these patients. 
It will be important for a safe implementation of the treatment that various approaches to 
avoiding pre-naltrexone dropout and overdose are investigated. For example, instruments on 
abstinence motivation or ambivalence might be able to indicate which patients should not be 
allowed to enter sustained release naltrexone treatment for safety reasons. Another approach 
is the adoption of rapid detoxification techniques (ROD). The advantages and disadvantages 
of adopting this procedure (see Collins et al. 2005) with sustained release naltrexone 
treatment should be compared to traditional detoxification techniques; although more 
ambivalent patients might be more easily inducted onto naltrexone using ROD, our findings 
suggest they could later be at increased risk of attempting self-removal and/or discontinuing 
treatment. 
A perhaps unsurprising finding in this thesis was the replication of something often seen in 
addiction treatment: worse patients do worse in treatment, those better off do better. This 
suggests sustained release naltrexone treatment can be delivered as part of two treatment 
philosophies: as a part of recovery and as harm reduction among patients who e.g. may wish 
to continue non-opioid drug use. Both of these options should be explored further in clinical 
investigations. Although most will favor a recovery-oriented approach to sustained release 
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naltrexone treatment, its potential for protecting against overdose means its harm-reduction 
potential should not be dismissed. 
Implications for clinical practice
The main implication for clinical treatment of opioid use comes from the finding that 
sustained release naltrexone continues to show promise as an effective and clinically 
feasible treatment for opioid dependence with high patient satisfaction and an acceptable 
rate of adverse events. With more such evidence, opioid dependent patients entering 
treatment may soon have sustained release naltrexone as an option in addition to opioid 
maintenance treatment and medication-free methods. Pre-treatment screening of patients for 
sufficient abstinence motivation and in-treatment monitoring of drug use should be 
considered in order to minimize the adverse events associated with ambivalence.
The findings in this thesis also support the use of supplemental approaches that see opioid 
dependence as a comprehensive disorder with multiple problems of conduct and substance 
abuse. The findings of the clinical studies of this thesis are open to the interpretation that 
most patients had sufficient naltrexone release to block heroin, but that some still sought 
opioids for social and psychological reasons. These patients had a greater chance of 
discontinuing treatment. Following this line of thought, more comprehensive treatment 
approaches like contingency management (Carroll et al. 2001) would seem to have greater 
chances of succeeding than approaches focusing on single issues (e.g. opioid dependence). 
In addition, sustained release naltrexone is a potential treatment of choice for better-
functioning patients dependent on opioids; e.g. those dependent on prescription opioids. 
Sustained release naltrexone would be more compatible with normal vocational and family 
functioning, as it does not involve continued dependence on opioids and the daily pick-ups 
inherent in maintenance treatment with opioid agonists. These patients might benefit from 
less comprehensive supplemental treatments, e.g. psychotherapy (Woody et al. 1983). 
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Implications for policy
The effects of naltrexone implants on relapse to heroin use provides further impetus for 
considering the approval of sustained release naltrexone in the treatment of opioid 
dependence. The effectiveness of sustained release naltrexone on opioid use means the 
introduction of sustained release naltrexone treatment would likely reduce the amount of 
funds currently assigned to coping with the consequences of heroin dependence (McLellan 
et al 1996; Mark et al. 2001; Darke et al. 2007). Naltrexone’s lack of abuse potential and its 
ability to support abstinence means it may be more popular among parts of the electorate 
than e.g. maintenance treatment. However, such a priority currently lacks a scientific basis 
and may be unfortunate for patients who are not ready for abstinence (Hall et al. 2008). Our 
findings suggest that these patients have an elevated risk for pre-naltrexone overdose and in-
treatment self-harm. Several decades of research indicates that these more ambivalent 
patients would greatly benefit from receiving maintenance treatment with methadone or 
buprenorphine. 
Rather than replacing existing treatments, sustained release naltrexone seems well suited to 
ease the transition between today’s main treatment options for opioid dependence: 
maintenance treatment and non-pharmacological approaches. The first maintains patients in 
opioid dependence, and is the logical step up from illicit heroin use. Ending maintenance 
treatment, however, is currently associated with relapse and return to pre-maintenance levels 
of overdose risk (Clausen et al. 2008). This overdose risk seems likely to decrease if 
sustained release naltrexone is commenced during discharge (Tait et al. 2008; Reece, 2009). 
Non-pharmacological treatments currently involve outpatient phases that offer more 
freedom to relapse than the majority of former opioid users can manage; however, the odds 
of remaining abstinent will improve if sustained release naltrexone is used. The true 
potential of sustained release naltrexone on a policy level may thus lie in helping to realize 
the potential of existing treatments - rather than signaling their demise. 
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7.7. Conclusions
The research in this thesis investigated the effectiveness, safety, and feasibility of sustained 
release naltrexone for opioid dependence. 
A systematic review of the literature published until 2007 found that too little research had 
been published to conclude about the the effectiveness and adverse events. 
We conducted a randomised clinical trial among opioid dependent patients who completed 
inpatient treatment in order to investigate whether naltrexone implants would be a useful, 
safe, and feasible supplement to usual aftercare after discharge. Naltrexone implants 
produced considerable reductions in opioid use in the following 180 days compared to 
controls. Adverse events were acceptable and satisfaction with the treatment was high. 
Naltrexone patients also reported reduced craving for opioid and improved quality of life 
compared to controls. 
Two aspects of feasibility were investigated: the extent to which patients engage in opioid 
use despite undergoing naltrexone treatment, and the extent to which patients discontinued 
treatment once the first implant period was at an end. About half of patients were found to 
use opioids while undergoing naltrexone treatment, most of whom only tried a few times. 
Frequent opioid users tended to use more stimulants and benzodiazepines and tended to 
report ‘high’ following use. 
Substance use and criminal activity during treatment was similarly associated with not 
continuing in naltrexone implant treatment. Nonetheless, about 50% of patients were 
retained after six months, which is sufficient for clinical implementation of the treatment.
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A B S T R A C T
Background
Naltrexone is an opioid antagonist which effectively blocks heroin effects. Since opioid dependence treatment with naltrexone tablets
suffers fromhigh dropout rates, several depot injections and implants are under investigation. Sustained-release formulations are claimed
to be effective, but a systematic review of the literature is lacking.
Objectives
To evaluate the effectiveness of sustained-release naltrexone for opioid dependence and its adverse effects in different study populations.
Search strategy
The following databases were searched from their inception to November 2007: Cochrane Central Register of Controlled Trials,
MEDLINE, EMBASE, CINAHL, LILACS, PsycINFO, ISI Web of Science, trial database at http://clinicaltrials.gov, available NIDA
monographs, CPDD and AAAP conference proceedings. The reference lists of identiﬁed studies, published reviews and relevant web
sides were searched manually. Study authors and drug companies were contacted to obtain any unpublished material or missing data.
Selection criteria
To evaluate effectiveness only RCTs were included. To evaluate safety, any clinical trial reporting adverse effects was assessed. Treatment
condition was extended to include alcohol dependent subjects and healthy volunteers.
Data collection and analysis
Reviewers independently evaluated the reports, rated methodological quality and extracted data. Analyses were performed separately
for opioid dependent, alcohol dependent and healthy participants.
Main results
Foe effectiveness, one report met inclusion criteria. Two dosages of naltrexone depot injections (192 and 384 mg) were compared to
placebo. High-dose signiﬁcantly increased days in treatment compared to placebo (WMD 21.00, 95% CI 10.68 to 31.32, p<0.0001).
High-dose compared to low-dose signiﬁcantly increased days in treatment (WMD 12.00, 95% CI 1.69 to 22.31, p=0.02). Number of
patients retained in treatment did not show signiﬁcant differences between groups.
For adverse effects, seventeen reports met inclusion criteria analyses, six were RCTs. Side effects were signiﬁcantly more frequent in
naltrexone depot groups compared to placebo. In alcohol dependent samples only, adverse effects appeared to be signiﬁcantly more
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frequent in the low-dose naltrexone depot groups compared to placebo (RR 1.18, 95% CI 1.02 to 1.36, p=0.02). In the opioid
dependent sample, group differences were not statistically signiﬁcant. Reports on systematic assessment of side effects and adverse
events were scarce.
Authors’ conclusions
There is insufﬁcient evidence to evaluate the effectiveness of sustained-release naltrexone for treatment of opioid dependence.
For naltrexone injections, administration site-related adverse effects appear to be frequent, but of moderate intensity and time limited.
For a harm-beneﬁt evaluation of naltrexone implants, more data on side effects and adverse events are needed.
P L A I N L A N G U A G E S U M M A R Y
People with opioid dependence require substantial therapeutic effort to keep them drug free. Their use of illicit opioids can be
reduced and retention in treatment improved with supervised agonist replacement therapy with
methadone, which is a highly addictive drug. Naltrexone is a long-acting, opioid-antagonist that blocks heroin effects. It is used to
prevent relapse of both opioid and alcohol dependence. Highly motivated people do best with
naltrexone. Most opioid users are sceptical about treatment with naltrexone tablets and many drop out early on. Dropouts can be
reduced with supervised tablet taking, offering incentives and using sustained-release naltrexone
such as subcutaneous implants or depot injections.
There is insufﬁcient evidence from randomised controlled trials to evaluate the effectiveness of sustained-release naltrexone. In the
one controlled study that met inclusion criteria, 60 outpatients were randomised to one of three groups that received two sequential
depot injections of naltrexone (192 or 384 mg) or placebo injections. The mean dropout time was 48 days with high dose naltrexone
compared with 27 days on placebo; an increase in
treatment of 21 days (range 11 to 31 days). The lower depot dose gave a lesser beneﬁt. The number retained in treatment at eight weeks
did not show a clear difference and ranged from a mean of 68% to 39% of participants in
the different groups. ’Wanting heroin’ did not differ on naltrexone but ’needing heroin’ scored signiﬁcantly lower with depot naltrexone
compared to placebo. The most prominent adverse effects were general symptoms of
fatigue and pain at the injection site. Seventeen reports met inclusion criteria for assessing adverse effects. Seven looked speciﬁcally at
naltrexone implants for treatment of opioid dependence and wound infection, allergic reaction to the implant and number of implants
removed. The majority of the trials did not have a control group and systematic assessment of adverse effects was lacking.
B A C K G R O U N D
Opioid dependence is considered a chronic lifelong relapsing dis-
order, which requires substantial therapeutic efforts to keep pa-
tients drug free (McLellan 2000). The prevalence of opioid de-
pendence is rather low and varies from 0.1 to 1.0 % among adult
populations in Europe and the US, but reliable estimates are dif-
ﬁcult to obtain (EMCDDA 2006; OAS 2005).
The currently most effective and well-investigated treatment for
opioid dependence is agonist replacement therapy with metha-
done (Amato 2005; Mattick 2003; van den Brink 2006). Metha-
doneMaintenanceTreatment (MMT) implies supervised intake of
a long-acting opioid receptor agonist. MMT reduces illicit opioid
use and increases retention in treatment substantially. Despite ev-
idence of its effectiveness, clinicians as well as users may be critical
towards long-term prescription of a highly addictive drug. Hence,
non-addictive alternatives have been in the focus of research for
several decades.
Naltrexone is a long-acting, non-selective opioid-antagonist with
highest afﬁnity to mu-opioid receptors (Gonzalez 1988). A daily
ingested dose of 50 mg sufﬁciently blocks the effect of opioids to
prevent relapse. Tolerance to and dependence on naltrexone does
not develop (Navaratnam 1994; Rawson 2000). Oral naltrexone
is approved for relapse prevention of alcohol and opioid depen-
dence in several countries. Some trials showed promising results
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of oral naltrexone maintenance compared to placebo (Guo 2001),
whereas others failed to detect an effect (San 1991). A Cochrane
review did not ﬁnd enough evidence to unequivocally support the
clinical effectiveness of oral naltrexone in the treatment of opioid
dependence (Minozzi 2006).
An important factor predicting treatment outcome of opioid de-
pendence is treatment retention. Compared to agonist replace-
ment therapy, the majority of opioid users are rather sceptical
towards treatment with naltrexone tablets. Hence, maintenance
therapy with oral naltrexone suffers from high early dropout rates,
which has been counteracted by supervised ingestion of the tablets.
Systematic use of incentives in order to externally strengthen pa-
tient motivation has been evaluated (Preston 1999). Another im-
portant variable to predict treatment outcome is vocational and
social stability. Systematically selected and supposedly highly mo-
tivated patients seem to do better in oral naltrexone maintenance
therapy than unbiased samples (Ginzburg 1984; Cornish 1997).
From a pharmacological point of view, efforts have been made
to improve retention in treatment by administering naltrexone
as a subcutaneous implant or depot injection. Development of
sustained-release formulations commenced three decades ago (
Chiang 1985; Reuning 1976). Only recently has sustained-re-
lease naltrexone become available for evaluation in larger human
samples (Comer 2007). The objective of using sustained-release
naltrexone is to secure medication compliance for weeks or even
months, thus removing the onus from patients to take naltrexone
tablets daily. At least 9 different sustained-release formulations are
available. To date, none is approved for opioid dependence treat-
ment in Australia, the EU or theUS. Three depot injection formu-
lations are under investigation, providing therapeutic naltrexone
blood levels between 1 and 2 ng/ml for approximately 4 weeks:
Vivitrol by Alkermes Inc., Depotrex by Biotek Inc. and Naltrel by
Elbion. Another approach to provide therapeutic blood levels for
several months is to load a biodegradable polylactic based poly-
mer with naltrexone in implant formulations. Several implants
are available commercially or through clinical trials: Sherman,
Wedgewood, GoMedical (http://www.naltrexane.com/), Cravex (
Partecke 2007), Prodetoxone, which is approved for treatment of
opioid dependence in Russia (Krupitsky 2007) and a Chinese im-
plant formulation (Moran 2007, see also http://www.1212.hk/).
Since treatment with sustained-release naltrexone is hardly or even
not reversible for a limited period of time, carefully assessing pa-
tients’ motivation must be considered essential before treatment
start. While results from clinical trials involving several hundred
patients have been published, a systematic review of the literature
is lacking.
The aim of this review is to evaluate the effectiveness and adverse
effects of sustained-release naltrexone formulations used in hu-
mans.
O B J E C T I V E S
To evaluate the effect of sustained-release naltrexone for opioid
dependence compared to placebo or alternative treatment.
To evaluate adverse effects of sustained-release naltrexone formula-
tions currently under investigation in different study populations.
M E T H O D S
Criteria for considering studies for this review
Types of studies
For assessment of effectiveness only randomised-controlled clin-
ical trials on sustained-release naltrexone for treatment of opioid
dependence were considered. For evaluation of safety and adverse
effects prospective controlled and uncontrolled trials, case series
and record-linkage studies were considered.
Types of participants
Adults or adolescents with opioid dependence. Studies investigat-
ing naltrexone treatment for other conditions were excluded for
effectiveness evaluation.
For adverse effects evaluation only, any research on healthy par-
ticipants and any research on treatment for other conditions than
opioid dependence was included.
Types of interventions
Any use of sustained-release formulations (i.e. depot or implant) of
naltrexone compared to any other pharmacological or psychosocial
or no treatment.
• Sustained-release naltrexone versus oral naltrexone
• Sustained-release naltrexone versus placebo
• Sustained-release naltrexone versus agonist replacement
therapy
• Sustained-release naltrexone versus psychosocial inter-
ventions
• Sustained-release naltrexone versus no treatment
Retrieved from literature search, but not predeﬁned in protocol:
• Low-dose versus high-dose sustained-release naltrexone
Types of outcome measures
Predeﬁned primary outcomes:
(1) Opioid use during and after treatment: use/no use; number of
days with use, self-report; number of positive urine samples per
participant
(2) Treatment adherence:
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a) Induction: started/not started
b) Compliance with protocol: days met for scheduled visits/not
met; percentage met/not met; number of implants voluntarily re-
moved.
(3) Retention in treatment: time to drop out.
(4) Adverse effects and severe AEs: percentage with/without; time
to AE.
Predeﬁned secondary outcomes:(5) Use of illicit drugs other
than opioids during and after treatment: use/no use; number of
days with use, self-report; number of positive urine samples per
patient(6) Criminal activity and incarceration: yes/no; number
of days with criminal activity; number of offences; number of
incarcerations; time spent in prison.
(7) Quality of life: as measured by validated and self-developed
questionnaires, e.g. satisfaction with treatment on visual analogue
scale (VAS).
(8) Mental health: any appropriate questionnaires; number of di-
agnoses.
(9) Duration of achieved therapeutic naltrexone blood levels:
ng/ml as a function of time.
Outcome measures not considered in protocol but retrieved
from literature search:
(10) Heroin craving
Search methods for identiﬁcation of studies
To identify studies for this review detailed electronic searches for
each data base were performed.
Electronic searches:
Electronic searches were performed to identify any RCTs investi-
gating the effect of sustained-release naltrexone and any type of
study on side effects and adverse events. The detailed search strat-
egy was developed for MEDLINE but revised appropriately for
each database to match vocabulary and syntax rules. No language
restrictions were made.
The following databases were searched to identify reports on the
effectiveness and adverse effects of sustained-release naltrexone:
1. Cochrane Central Register of Controlled Trials (The Cochrane
Library Issue 3, 2006) which includes the Cochrane Drugs and
Alcohol Group Trials Register; 2. MEDLINE (January 1966
to November 2007); 3. EMBASE (1980 to 2007 week 45); 4.
CINAHL - Cumulative Index to Nursing & Allied Health Liter-
ature (1982 to November, week 2 2007); 5. LILACS (November
2007); 6. PsycINFO (1806 to November 2007); 7. ISI Web of
Science (1975 to November 2007). Detailed search strategies for
each databases are described inAppendix 1; Appendix 2; Appendix
3; Appendix 4; Appendix 5; Appendix 6; Appendix 7
Additional searches
Manual searches in reference lists, relevant web sites, the trial reg-
isters at http://www.clinicaltrials.gov and http://www.controlled-
trials.com, conference abstracts (Annual Meetings of the College
on Problems of Drug Dependence (CPDD), Annual Meetings of
the AmericanAcademy of Addiction Psychiatry (AAAP)) were per-
formed. Triallists and pharmaceutical companies were approached
to obtain unpublished results, but contact proved difﬁcult to es-
tablish.
Data collection and analysis
Study selection
Two authors independently assessed potentially relevant studies
for inclusion. Any disagreement between the authors was resolved
by discussion. If consensus was not achieved, the senior authorwas
consulted. Missing information was sought by contacting study
authors.
Assessment of methodological quality
Two authors independently assessed methodological quality of el-
igible studies. Any disagreement was resolved by consulting the
senior author. Methodological quality assessment of all included
studies was used to systematically describe possible bias and did
not present a threshold for inclusion of trials.
Study quality of RCTs was assessed according to the Cochrane
Handbook for Systematic Reviews of Interventions criteria (
Higgins 2006):
(1) Measures to avoid selection bias
Allocation concealment in RCTs:
A) Adequate allocation concealment: central randomisation (e.g.
allocation by a central ofﬁce unaware of participant characteris-
tics), pre-numbered or coded identical bottles or containers which
are administered serially to participants, drugprepared by the phar-
macy, serially numbered, opaque, sealed envelopes, on-site com-
puter system combined with allocations kept in a locked unread-
able computer ﬁle that can be accessed only after the characteristics
of an enrolled participant have been entered, or other description
that contained elements convincing of concealment.
B) Unclear allocation concealment: when the authors either did
not report an allocation concealment approach at all or report an
approach that did not fall in the category A or C.
C) Inadequate allocation concealment: alternation or reference to
case numbers, dates of birth, day of the week. Any procedure that
is entirely transparent before allocation, such as an open list of
random numbers or other description that contained elements
convincing of not concealment
D) no allocation concealment used
(2) Measures to avoid performance bias
Blinding of those providing and receiving the intervention in
RCTs:
A) double blind
B) single blind (blinding of participants)
C) unclear
D) no blinding
(3) Measures to avoid attrition bias
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Description of drop outs in RCTs:
A) Loss to follow up completely recorded (for each group)
B) Loss to follow up incompletely recorded (data reported only
for one group or for the overall sample)
C) Unclear or not done
(4) Measures to avoid detection bias
Blinding of the outcome assessor in RCTs:
A) Blind to treatment allocation at outcome assessment
B) Unclear
C) Not blind to treatment allocation at outcome assessment
Data collection
Two review authors independently extracted data using predeﬁned
data extraction forms. Any disagreement was resolved by consen-
sus, if necessary by discussion with a third reviewer.
Data synthesis
Meta-analyses were performed were appropriate for all pre-speci-
ﬁed outcomes. Individual and pooled relative risks (RR) with 95%
conﬁdence intervals (CI) were calculated for dichotomous out-
comes, using the ﬁxed-effects model unless studies were heteroge-
neous, in which case the random-effects model was used.
Statistical heterogeneity was assessed by the Chi-squared test, with
P < 0.05 indicating heterogeneity. Additionally, I-squared (values
from 0 to 100 %, with 0 % indicating no observed heterogeneity)
were calculated to assess inconsistency. Weighted mean differences
(WMD) with 95% CI were calculated for continuous outcomes.
From a clinical perspective, it seemed reasonable to analyse safety
outcomes from reports on opioid dependent, alcohol dependent
and healthy volunteers separately.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Sixty eight reports of potential interestwere identiﬁed and assessed,
only 1 (Comer 2006) met criteria for inclusion into effectiveness
analyses.
Seventeen of 68 identiﬁed reports were included to evaluate ad-
verse effects of sustained-release naltrexone treatment (including
Comer 2006). In 2 reports the same population was investigated
and only the primary publication (Waal 2003) was included. For
adverse effects evaluation, unpublished data from 2 reports was
retrieved and used (Gölz 2000, Waal 2003). A ﬂow chart of the
study inclusion process is provided in additional Figure 1.
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Studies excluded from effectiveness and safety analyses
Reasons for exclusion of the remaining 50 reports were: publica-
tion was no clinical trial (25 reports), adverse effect data not pro-
vided (11 reports), intervention was oral naltrexone (9 reports),
publication onpharmacokinetics of a non-recommendable formu-
lation (3 reports), abstract available only (1 report), two references
to same publication (1 report). (See Characteristics of excluded
studies)
Included studies
(a) Study of effectiveness of sustained-release naltrexone for
opioid dependence
One RCT ,conducted in the USA, met inclusion criteria (Comer
2006). A depot formulation of sustained-release naltrexone (De-
potrex) was investigated among 60 outpatients. Three parallel
groups received 2 sequential naltrexone injections of 192 mg or
384 mg, the control group received 2 placebo injections. In addi-
tion, all participants were offered manualised relapse prevention
therapy. Clinic visits were scheduled twice weekly during the 8
weeks observation period. Primary outcome measures were treat-
ment retention and opioid use assessed by urinalysis. Other illicit
drug use, heroin craving, adverse effects, depression and severity of
opioid and cocaine use were considered secondary outcomes. All
outcome analyses were conducted on the intention-to-treat (ITT)
population.
(b) Studies of adverse effects of sustained-release NTX
Seventeen reports were included in the adverse effect analyses, 6
were RCTs. (See Characteristics of included studies)
• Populations
In 10 reports participants were opioid dependent. Two of these
reports were restricted to a non-treatment seeking population (
Comer 2002; Sullivan 2006). Sample sizes ranged from 5 (Sullivan
2006) to 894 participants (Tait 2007) with a mean size of 168 par-
ticipants (median=64.5). In 1 report (Dunbar 2006) the effects of
sustained-release naltrexone on 42 healthy volunteers were inves-
tigated. Six reports on alcohol dependent subjects were included,
with sample sizes ranging from 16 (Galloway 2005) to 624 par-
ticipants (Garbutt 2005) and a mean size of 174.7 participants
(median=27.5).
• Country
2 trials were conducted in Australia, 1 in Germany, 2 in Norway,
1 in Spain, 1 in the UK and 10 in the USA.
• Interventions
The investigated drugs included 3 depot formulations (Alkermes,
Biotek, DrugAbuse Sciences) containing 150 to 400 mg of nal-
trexone and 2 implant formulations (GoMedical, Wedgewood)
containing 1000 to approximately 2200 mg of naltrexone. In 10
of 17 reports depot formulations of sustained-release naltrexone
were used. The study samples were healthy volunteers, alcohol or
opioid dependent patients in 1, 6 and 3 reports, respectively. In
the remaining 7 reports on naltrexone implants, all participants
were opioid dependent. (See additional Table 1)
Table 1. Reports according to study medication used
NTX formulation Dose (mg) Condition Report
Alkermes depot (Vivitrol) 190 alcohol dependence Turncliff 2005
190 and 380 healthy volunteers Dunbar 2006
190 and 380 alcohol dependence Garbutt 2005
400 alcohol dependence Johnson 2004
Biotek depot (Depotrex) 192 and 384 opioid dependence Comer 2002
192 and 384 opioid dependence Comer 2006
206 alcohol dependence Kranzler 1998
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Table 1. Reports according to study medication used (Continued)
384 opioid dependence Sullivan 2006
DrugAbuse Sciences depot
(Naltrel)
150 and 300 alcohol dependence Kranzler 2004
300 alcohol dependence Galloway 2005
GoMedical implant 1800 and 3600 (corrected by
Tait 2007: 1100 mg and 2200
mg)
opioid dependence Waal 2006
3600 (corrected by Tait 2007:
2200 mg)
opioid dependence Hulse 2005
2200 opioid dependence Tait 2007
Wedgewood implant 1000 opioid dependence Foster 2003
1000 opioid dependence Waal 2003
1000 opioid dependence Gölz 2000
1000 opioid dependence Carreno 2003
• Groups of comparison
Opioid dependent samples
Six of the 10 reports with opioid dependent samples were un-
controlled studies, 5 investigating naltrexone implants (Carreno
2003; Foster 2003; Hulse 2005; Waal 2003; Waal 2006) and 1
naltrexone depot (Sullivan 2006). Of the 4 reports with groups
of comparison, the only RCT was conducted by Comer 2006,
comparing naltrexone depot to placebo injections. Two studies
were designedwith 2 sequential treatment groups, comparing low-
and high-dose naltrexone depot (Comer 2002) or implants and
oral naltrexone (Gölz 2000). One report compared naltrexone im-
plants to methadone maintenance based on record-linkage data (
Tait 2007).
Alcohol dependent samples
In all 6 reports with alcohol dependent samples naltrexone de-
pot injections were investigated. Four reports were RCTs (Garbutt
2005; Johnson 2004; Kranzler 1998; Kranzler 2004). In 1 report
liver impaired patients were compared to matched, healthy con-
trols (Turncliff 2005) and in 1 report a single treatment group was
investigated (Galloway 2005).
Healthy volunteers
In 1 dose-ﬁnding, phase I RCT naltrexone depot was investigated
among healthy volunteers (Dunbar 2006).
Outcome measures
Two categories of adverse effects were assessed in 9 of the 17 re-
ports: possibly naltrexone-related AEs (e.g. headache, nausea) and
administration site-related AEs, such as itching, pain, tissue reac-
tions or surgical site revision. In the majority of studies involv-
ing opioid dependent populations only administration site-related
AEs were reported, however, in the record-linkage study by Tait
2007 mortality during course of treatment was investigated. Most
reports on alcohol dependent subjects included assessment of AEs
possibly related to both categories: the drug naltrexone and its par-
ticular formulation used. The predeﬁned outcome measure time
to AE was not assessed in any report.
Studies ongoing
We found six studies ongoing, as soon as results will be available,
we will update the results.
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Risk of bias in included studies
(See additional Table 2)
Table 2. Reports and potential sources of bias
report selection bias performance bias attrition bias detection bias
Kranzler 2004 A A A B
Garbutt 2005 B A A A
Comer 2006 B A A B
Johnson 2004 B A A B
Kranzler 1998 B A A B
Dunbar 2006 B A B B
Comer 2002 non-RCT, 2 sequential
treatment groups
not applicable (N/A) loss to follow-up completely
recorded
N/A
Turncliff 2005 non-RCT, 2 matched-con-
trolled treatment groups
N/A loss to follow-up completely
recorded
N/A
Galloway 2005 non-RCT, uncontrolled N/A loss to follow-up completely
recorded
N/A
Gölz 2000 non-RCT, 2 sequential
treatment groups
N/A loss to follow-up completely
recorded
N/A
Foster 2003 non-RCT, uncontrolled N/A loss to follow-up completely
recorded
N/A
Hulse 2005 non-RCT, record-linkage
data
N/A N/A prospectively collected data:
blind to treatment allocation
at outcome assessment
Tait 2007 non-RCT, record-linkage
data
N/A N/A prospectively collected data:
blind to treatment allocation
at outcome assessment
Sullivan 2006 non-RCT, uncontrolled N/A loss to follow-up completely
recorded
N/A
Waal 2003 non-RCT, uncontrolled N/A loss to follow-up completely
recorded
N/A
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Table 2. Reports and potential sources of bias (Continued)
Waal 2006 non-RCT, uncontrolled N/A loss to follow-up completely
recorded
N/A
Carreno 2003 non-RCT, uncontrolled N/A unclear or not done N/A
Study of effectiveness
In the 1 report included for analyses of effectiveness, the method
of allocation concealment was not clearly described (category B).
The trial was conducted in a double-blind fashion (category A)
and loss to follow up was recorded completely for each treatment
arm (category A). It remains unclear whether or not the outcome
assessors were blind to which intervention participants had re-
ceived (category B).
Studies of adverse effects
(see table characteristics of included studies)
RCTs: 6 reports
1) Comparison and allocation concealment:
In 1 of 6 RCTs an opioid dependent sample was investigated,
this report was also included for analyses of effectiveness (Comer
2006). A detailed description of an adequatemethod for allocation
concealment (category A)was provided by 1 study group (Kranzler
2004), the other 5 descriptions were rated category B: unclear
allocation concealment.
2) Blinding of participant / provider:
All 6 RCTs were considered double-blind (category A), i.e. those
receiving and providing treatment were blind to the intervention
used.
3) Drop out:
In 5 RCTs loss to follow up was completely recorded for each
treatment group (category A). The RCT by Dunbar 2006 was
rated category B: loss to follow up incompletely recorded.
4) Blinding of the outcome assessor:
One of 6 RCTs was considered triple blind: besides participants
and treatment staff, researchers assessing outcomes were blind to
treatment allocation (Garbutt 2005). The remaining 5 RCTs were
rated category B: unclear if outcome assessor was blind to treat-
ment allocation.
non-RCTs with parallel control group: 2 reports
Turncliff 2005 used amatched case-control design to compare liver
impaired alcohol dependent patients and healthy controls. This
trial was open-lable, loss to follow-up was completely recorded
for each group. Tait 2007 retrospectively compared record-linkage
data of opioid dependent patients receiving naltrexone implant
to patients entering methadone maintenance. Patient data was
recorded prospectively by health care staff who was considered
blind to treatment condition. Reporting drop-out was not feasible
due to record-linkage study design.
non-RCTs without parallel control group: 9 reports
Eight of the 9 reports were investigations on opioid dependent
samples, only Galloway 2005 investigated an alcohol dependent
sample. In 7 reports loss to follow up was completely recorded for
treatment groups. In the remaining 2 reports the description of
drop-outs was either not done (Carreno 2003) or not feasible due
to record-linkage study design (Hulse 2005).
Effects of interventions
• Effectiveness of sustained-release naltrexone for opi-
oid dependence
For the 1 report (Comer 2006) that met inclusion criteria for
effectiveness studies, the following primary treatment outcomes
allowed calculations of effect estimates:
(1) Retention in treatment (number of participants in each group
completing the 8-week study period)
(2) Time to drop out (number of days in treatment)
All conﬁdence intervals are 95%, effect estimates are based on
intention-to-treat analyses.
(1) Retention in treatment at week 8 was 68.2%, 60.0% and
38.9% of participants in the high dose, low dose and placebo
group. There was no statistically signiﬁcant difference between
either dosage of depot naltrexone and placebo with high dose, one
study, 40 participants, RR 1.75 (CI 0.92 to 3.34), seeAnalysis 1.1;
and low dose, one study, 38 participants, RR 1.54 (CI 0.78 to
3.05), see Analysis 1.2. No statistically signiﬁcant difference was
found between groups receiving naltrexone depot, one study, 42
participants, RR 1.14 (CI 0.72 to 1.80), see Analysis 1.3.
(2) Time to drop out was 48, 36 and 27 days in the high dose,
low dose and placebo group. Group comparisons were statisti-
cally signiﬁcant between high dose naltrexone depot and placebo,
one study, 40 participants, WMD 21.0 (CI 10.68 to 31.32), see
Analysis 1.4, and between high and low dose depot, one study,
42 participants, WMD 12.0 (CI 1.69 to 22.31), see Analysis 1.5.
There was no statistically signiﬁcant difference between low dose
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depot and placebo, one study, 38 participants, WMD 9.0 (CI -
3.40 to 21.40), see Analysis 1.6.
The comparisons described below were regarded secondary out-
comes by Comer 2006. Calculation of effect estimates was not
possible with the data provided.
(3) heroin craving assessed on visual analogue scales
(4) depression / severity of drug use
(5) naltrexone blood levels
(3) Heroin craving, on visual analogue scales:
“Wanting heroin” did not show signiﬁcant group differences
throughout the study. “Needing heroin” was scored signiﬁcantly
lower by the high and low dose naltrexone depot group compared
to the placebo group (p<0.001).
(4) Depression (HAM-D scale); severity of opioid and cocaine
use (CGIS):
No signiﬁcant difference between treatment groups was reported
ondepression or severity of druguse scores. In regard to depression,
all groups scored lower on HAM-D at follow-up than at baseline.
(5) Mean plasma levels of naltrexone during the 8 weeks study
period ranged from 1.3 to 3.2 ng/ml in the high dose group. In
the low dose group mean plasma levels were measured between
0.4 and 1.9 ng/ml. 4 weeks after the ﬁrst injection plasma trough
levels were reached and the naltrexone depot re-administered.
The following outcomes were predeﬁned in the review’s protocol,
but not reported in Comer 2006:
Opioid use per participant
Other drug use per participant
Treatment adherence
Criminal activity / incarceration
• Adverse effects of sustained-release naltrexone treat-
ment in RCTs
In 8 of the 17 reports included for assessment of adverse effects
parallel comparison groups were used. Six of the 8 reports were
RCTs (Comer 2006; Dunbar 2006; Garbutt 2005; Johnson 2004;
Kranzler 1998; Kranzler 2004) and 2 were non-RCTs (Turncliff
2005; Tait 2007). In 7 of the 8 reports naltrexone depot injec-
tions were investigated and possibly drug-related adverse effects
were assessed. Only Tait 2007 investigated naltrexone implants
in comparison to methadone maintenance and assessed mortality.
Effect analyses for non-RCTs were performed separately from the
RCTs. Subgroup analyses were performed separately for the dif-
ferent populations, i.e. opioid dependent, alcohol dependent and
healthy controls.
(1) RCTs
High-dose naltrexone depot compared to placebo injection:
• Opioid dependence, one RCT (Comer 2006):
No signiﬁcant differences for reporting 1 or more adverse effects,
38 participants, RR 1.36 (CI 0.79 to 2.35), see Analysis 2.1, sub-
category 01 and for number of participants discontinuing the trial
due to adverse effects, 38 participants, RR 0.28, (CI 0.01 to 6.38),
see Analysis 2.1, sub-category 02.
• Alcohol dependence, two RCTs (Garbutt 2005 and
Johnson 2004):
Group differences of reporting 1 or more adverse effects were not
signiﬁcant in Johnson 2004, 30 participants, RR 1.15 (CI 0.73
to 1.81), see Analysis 2.2, sub-category 01. In Garbutt 2005, no
signiﬁcant differences for reporting 1 or more severe adverse event
, 414 participants, RR 0.68 (CI 0.31 to 1.48 ), see Analysis 2.2,
subcategory 02 and for reporting injection site pain ,414 partici-
pants, RR 1.29 (CI 0.73 to 2.28), see Analysis 2.2, sub-category
03., while de difference was statistically signiﬁcant in favour of
control group for number of participants discontinuing the trial
due to adverse effects, 414 participants, RR2.11 (CI 1.15 to 3.88),
see Analysis 2.2, sub-category 04.
Low-dose naltrexone depot compared to placebo injection:
• Opioid dependence, 1 RCT by Comer 2006:
No signiﬁcant differences between the groups for reporting 1 or
more adverse effects, 38 participants, RR 1.30 (CI 0.74 to 2.28),
see Analysis 2.3, sub-category 01, number of participants discon-
tinuing the trial due to adverse effects, 38 participants, RR 1.80
(CI 0.18 to 18.21), seeAnalysis 2.3, sub-category 02 and reporting
injection site induration RR 0.90 (CI 0.60 to 5.60), see Analysis
2.3, sub-category 03.
• Alcohol dependence, 3 RCTs by Garbutt 2005;
Kranzler 1998; Kranzler 2004
In the trials by Kranzler 1998 and Kranzler 2004 group differences
of reporting 1 or more adverse effects were not signiﬁcant , 353
participants, RR 1.06 (CI 0.95 to 1.179, see Analysis 2.4, sub-cat-
egory 01. In the trial by Garbutt 2005 no differences for number
of participants discontinuing the trial due to adverse effects, 419
participants, RR 1.00 (CI 0.49 to 2.04), see Analysis 2.4, sub-cat-
egory 02. In all 3 trials group no statistically signiﬁcant differences
for reporting injection site pain, 772 participants, RR 1.17 (95%
CI 0.92 to 1.47), seeAnalysis 2.4, sub-category 03. No statistically
signiﬁcant difference in Kranzler 1998 and Kranzler 2004 for re-
porting injection site induration , 353 participants, RR 1.17 (CI
0.76 to 1.80), see Analysis 2.4, sub-category 04. In Kranzler 2004
no differences for reporting injection site contusion , 499 partic-
ipants, RR 1.24, 95% (CI 0.60 to 2.57), see Analysis 2.4, sub-
category 05, while the difference between groups was signiﬁcantly
in favour of control for reporting 1 or more injection site reaction,
333 participants, RR 1.19 (CI 1.02 to 1.38), see Analysis 2.4, sub-
category 06. In Garbutt 2005 severe adverse events were described
as most commonly hospital admissions for alcohol detoxiﬁcation.
Two cases of pneumonia were judged possibly naltrexone depot-
related. Group differences of reporting an severe adverse events
were not signiﬁcant, 419 participants, RR 0.73 (CI 0.34 to 1.55),
see Analysis 2.4, sub-category 07.
In all 3 trials group differences of reporting any type of injection
site related adverse effect (i.e. injection site pain, induration, con-
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tusion and one or more reaction) was signiﬁcant with pooled RR
1.18 (CI 1.02 to 1.36), see Analysis 2.4, sub-category 08.
• Healthy volunteers, 1 RCT by Dunbar 2006:
No difference between the groups for reporting 1 or more AE
were not signiﬁcant , 42 participants, RR 2.46 (CI 0.16 to 38.89),
see Analysis 2.5, sub-category 01 and for reporting one or more
injection site reaction, 42participants, RR1.32 (CI 0.08 to 22.92),
see Analysis 2.5, sub-category 02.
High-dose compared to low-dose naltrexone depot:
• Opioid dependence, 1 RCT by Comer 2006:
No difference for reporting 1 or more adverse effects , 42 partic-
ipants, RR 1.05 (CI 0.68 to 1.6), see Analysis 2.6, sub-category
01) and for number of participants discontinuing the trial due to
adverse effects, 42 participants, RR 0.18 (CI 0.01 to 3.59), see
comparison Analysis 2.6, sub-category 02.
• Alcohol dependence, 1 RCT by Garbutt 2005:
Group differences for number of participants discontinuing the
trial due to adverse effects were signiﬁcant in favour of control,
415 participants, RR 2.12 (CI 1.02 to 3.22), see Analysis 2.7, sub-
category 01. No signiﬁcant differences for reporting injection site
pain, 415 participants, RR 1.37 (CI 0.76 to 2.44), see Analysis
2.7, sub-category 02 and for reporting an severe adverse effect (as
described above), 415 participants, RR 0.93 (CI 0.40 to 2.15), see
Analysis 2.7, sub-category 03.
(2) non-RCTs with parallel control group
Liver impaired compared to healthy controls:
In the report by Turncliff 2005 the same dose of naltrexone depot
(Alkermes Inc. 190 mg) was administered in two non-random-
ized groups: cases consisting of liver impaired, currently abstinent
alcohol dependent patients matched to a control group of healthy
volunteers. The relative risk of reporting 1 or more AE was statis-
tically signiﬁcant in favour of control, 25 participants, RR 3.25
(CI 1.14 to 9.24), see Analysis 2.8.
Naltrexone implant compared to methadone maintenance:
In Tait 2007 mortality of two non-randomised cohorts of opioid
dependent patients treated with naltrexone implants (GoMedical
Inc.) or methadone maintenance is described. Of the 341 patients
in the naltrexone group, 6 died in the study period between 2001
and 2006, whereas 15 of 553 patients in MMT died during those
years. Group differences were not statistically signiﬁcant with RR
0.65, CI 0.25 to 1.66 (see Analysis 2.9).
(3) Adverse effects of sustained-release naltrexone treatment
reported in non-RCTs without control group
(a) Naltrexone implant (GoMedical Inc., Australia) for treatment
of opioid dependence
In the report by Waal 2006 a local tissue reaction was evident in 2
of 13 participants, in both cases the sites were surgically revised and
the implants removed. According to unpublished data from this
trial, possibly naltrexone-related adverse effects were decreasing
during the course of the study, for example: irritabilitywas reported
by 6 of 12 patients 1 week after treatment start; at week 8 only
2 of 6 subjects reported irritability. Headache and nausea were
experienced by 5, respectively 2 of 12 participants 1 week after
treatment start. At week 8 none of the 6 patients still in treatment
complained about headache or nausea.
In the report by Hulse 2005 3 implant removals in 361 treated pa-
tients were registered: 1 due to wound infection and 2 on patients’
request. No statement on possibly drug-related AEs or number of
treatment responsive wound infections was made.
(b) Naltrexone implant (Wedgewood pharmacy, USA) for treat-
ment of opioid dependence
Local tissue reactions occurred 7 times among 156 patients (
Carreno 2003). Furthermore 3 incidents of wound infection and
no implant removal were reported in this sample. According to
reports by Foster 2003; Gölz 2000 and Waal 2003 the numbers
of local tissue reactions were 15 of 101, 25 of 104 and 2 of 10
patients, respectively. Unpublished data fromGölz 2000 indicates
wound infection in 6 of 104 patients (Partecke 2007). In the ﬁrst
cohort of 55 patients from Foster 2003, 2 patients died during
treatment. Both deaths were deemed unrelated to implant treat-
ment. No death was reported during treatment in the second co-
hort of 46 patients. Waal 2003 reports 3 implant removals, 2 due
to adverse effects and 1 on patient’s request. 6 of 10 patients com-
plained about dysphoria during the course of the study.
(c) Naltrexone depot injection (Biotek Inc., USA) for treatment
of opioid dependence
In the report by Comer 2002, 11 out of 12 participants experi-
enced pain at the injection site, no incidence of induration, ery-
thema or irritation was observed. According to Sullivan 2006, 3
out of 5 subjects complained about pain, a burning sensation or
induration.
(d) Naltrexone depot injection (Elbion NV Belgium, formerly
DrugAbuse Sciences Inc. USA) for treatment of alcohol depen-
dence
All 16 participants in the report by Galloway 2005 experienced
1 or more possibly naltrexone-related adverse effect, 15 out of 16
reported administration site-related adverse effects. None of the
adverse effects were rated serious (i.e. having signiﬁcant medical
consequences) by research staff.
D I S C U S S I O N
The main result of this review is a negative one: evidence to eval-
uate effectiveness of sustained-release naltrexone for treatment of
opioid dependence is scarce.Only one reportmet inclusion criteria
for analyses of effectiveness (Comer 2006). The naltrexone depot
injection appeared dose-dependently beneﬁcial: more subjects in
the high-dose group spent longer time in treatment than subjects
in the low-dose or placebo group. Time to drop-out was signif-
icantly longer in the high-dose group compared to the 2 other
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groups. Craving scores also seemed to support the effectiveness of
sustained-release naltrexone, as scorings on “needing heroin”, but
not on “wanting heroin”, were signiﬁcantly lower in the groups
receiving naltrexone depot. Urinalysis ﬁndings on heroin use were
reported and indicated a considerable reduction in the high-dose
group compared to the low-dose or placebo group. Since urinalysis
ﬁndings could not be related to number of urine samples provided
per participant, these data were omitted from our analyses and cal-
culation of overall effect estimates was considered inappropriate.
Despite consistent ﬁndings, we ﬁnd it premature to conclude with
the effectiveness of sustained-release naltrexone for treatment of
opioid dependence on the basis of only one report. Any conclusion
from a systematic literature review should be based on ﬁndings
from several (at least two) clinical trials using satisfactory measures
to limit possible bias.
One of the major challenges in oral naltrexone treatment has been
high drop out rates, which are also reﬂected by the ﬁndings from
the Cochrane review on oral naltrexone (Minozzi 2006). When
comparing oral naltrexone with or without psychosocial support
to placebo, twomonths retention rates did not exceed 60% (Lerner
1992). The mean retention rate from the ﬁve included trials was as
low as 33.3%. The two months retention rate of 68.2 % achieved
in the high-dose depot group investigated by Comer 2006, in-
dicates a considerable advantage of sustained-release naltrexone,
which needs to be conﬁrmed by further investigations.
For treatment of opioid dependence, only the Russian Federa-
tion has recently approved the naltrexone implant Prodetoxone (
Krupitsky 2007). However, our literature search did not retrieve
any clinical trials on that formulation. Although to date evi-
dence on effectiveness of sustained-release naltrexone for treat-
ment of opioid dependence is clearly lacking, we would like to
point out that several thousand opioid dependent patients are
treated with naltrexone depots, and more frequently, implants. In
Australia (Hulse 2005; Tait 2007) China (Moran 2007), Egypt
(Maksoud 2006), Germany (Partecke 2007), England (Brewer
2002) and Russia (Ramenskaya 2005), naltrexone implants are
used in clinical studies and, probably more widely, in private
clinic settings. Independent of the circumstances of treatment,
randomised-controlled trials seem to be the exception rather than
the rule. Analysing reasons for the imbalance between number of
opioid dependent patients in naltrexone implant treatment and
number of good quality reports goes beyond the scope of this re-
view.
The second objective of this systematic review was to assess the
safety of sustained-release naltrexone when used in opioid and al-
cohol dependent samples and healthy volunteers. Safety outcomes
were assessed separately for the three different populations. From
a clinical perspective, qualitatively similar adverse effects would
be expected regardless of treatment condition, but frequency of
reporting may differ considerably due to different treatment goals
in opioid (blocking the effect) and alcohol (reducing craving) de-
pendence. Therefore, performing meta-analyses was regarded in-
appropriate. Nevertheless, alcohol dependent samples may con-
tribute substantially to safety evaluation by illustrating trends ap-
plicable to opioid dependent samples.
Possibly naltrexone-related adverse effects
Findings on supposedly naltrexone-related adverse effects revealed
signiﬁcant group differences for nausea, fatigue, vomiting, de-
creased appetite, dizziness andupper abdominal pain in alcohol de-
pendent patients (Garbutt 2005; Kranzler 2004, data not shown).
These adverse effects seemed to occur in a dose-related fashion and
most infrequently in the placebo group. Findings are consistent
with side effects of oral naltrexone treatment described earlier (
Martin 1973).
For an opioid dependent sample, Comer 2006 reports adverse ef-
fects with the most prominent symptoms being general disorders
such as fatigue and administration site-related conditions. The
composite outcome one or more adverse effect did not reach sta-
tistical signiﬁcance, but was less frequently reported in the placebo
group. These ﬁndings are in line with the Cochrane review on oral
naltrexone (Minozzi 2006).
Although the number of possibly naltrexone-related adverse effects
was not signiﬁcantly different between groups in any RCT, the
placebo groups reported adverse effects less frequently, indepen-
dent of the condition studied. Severe adverse events, as reported by
Garbutt 2005, were mostly hospital admissions for alcohol detox-
iﬁcation and favoured the naltrexone depot group. Six of ten opi-
oid dependent participants in Waal 2003 complained about dys-
phoria, but this trial lacks a control group. In another trial with-
out a control group (Waal 2006), complaints about adverse effects
possibly caused by naltrexone (e.g. irritability, headache, nausea)
were decreasing during the course of the study.
Administration site-related adverse effects and mortality
Findings for administration site-related adverse effects showed no
signiﬁcant group differences for injection site pain, -induration,
or -contusion. In the report by Kranzler 2004 the naltrexone de-
pot group reported more frequently than the placebo group one
or more injection site reaction. Moreover, the composite outcome
any injection site-related adverse effect showed a statistically sig-
niﬁcant advantage of the placebo group compared to low-dose
naltrexone in alcohol dependent samples (Garbutt 2005; Kranzler
1998; Kranzler 2004).
In the seven reports on naltrexone implant for treatment of opioid
dependence, adverse effect assessment consisted of wound infec-
tion, allergic reaction to foreign body and number of implants
removed. However, ﬁndings should be interpreted with caution,
as the majority of the trials did not have a control group. Besides,
systematic assessment of adverse effects was mostly lacking and
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loss to follow-up was not always reported completely.We therefore
ﬁnd it inappropriate to calculate prevalence of allergic reactions
or wound infections. Nevertheless, it should be kept in mind that
these adverse effects do occur with any of the implant formula-
tions investigated and that they may lead to surgical revision of
the implant site.
The non-randomised trial which investigatedmortality had several
limitations and causality to interpret group differences cannot be
imputed (Tait 2007).Data is based on retrospective record-linkage
and information on number and duration of treatment episodes
was unavailable for both groups.
When gathering data on adverse effects, substantial differences in
methodological quality became obvious (Table 2). Four of the six
reports on alcohol dependent patients were double-blind, placebo-
controlled, randomised trials providing complete information on
participants lost to follow-up. Only one out of ten reports on opi-
oid dependent patients met a similar standard. Systematic assess-
ment of drug- and administration site-related adverse effects was
more prevalent in research involving alcohol dependent subjects
compared to opioid dependent subjects. Regardless of the con-
dition studied, any trial on experimental treatment such as sus-
tained-release naltrexone, should be subject to the same quality re-
quirements, i.e. active assessment and log of adverse effects, events
and severe adverse events.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
To date, there is insufﬁcient evidence to evaluate effectiveness of
sustained-release naltrexone for treatment of opioid dependence.
Sustained-release naltrexone formulations should still be consid-
ered investigational drugs, however, naltrexone depot injections
available today seem promising in the treatment of opioid depen-
dence.
Findings of possibly sustained-release naltrexone-related side ef-
fects are in line with research on naltrexone tablets. For naltrexone
depot injections, administration site-related adverse effects such as
pain appear to be frequent, but usually of moderate intensity and
time limited. Data on administration site-related adverse effects
of naltrexone implants is scarce. Hence, commercial use of any
implant formulation still needs to be evaluated thoroughly.
Implications for research
Future studies of sustained-release naltrexone involving opioid de-
pendent patients should provide a complete description of drop-
out and be conducted with a control group, preferably in a
randomised-controlled fashion. RCTs evaluating effectiveness for
treatment of opioid dependence should compare sustained-release
naltrexone to oral naltrexone or agonist replacement treatment
with methadone or buprenorphine. Besides effectiveness, any re-
search on naltrexone implants should also focus on safety to make
an analysis of harm-beneﬁt possible.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Carreno 2003
Methods non-RCT: uncontrolled, prospective trial, 1 year observation period
Participants opioid dependent outpatients, n=156, treatment seeking
Interventions Wedgewood naltrexone implant 1000 mg, rapid opioid detoxiﬁcation with induction onto naltrexone:
sequential treatment periods possible
Outcomes retention in treatment, relapse to opioid use, adverse effects, Addiction Severity Index outcomes
Notes included for safety analyses only: no comparison group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Comer 2002
Methods non-RCT: dose-ﬁnding trial (phase II), 2 sequential treatment groups, 6 weeks observation period
Participants opioid dependent inpatients, n=12, non treatment seeking
Interventions Biotek naltrexone depot 192 or 384 mg, detoxiﬁcation followed by depot injections, heroin challenge
protocol
Outcomes heroin effects during blockade, opioid withdrawal symptoms, naltrexone plasma levels, adverse effects
Notes included for safety analyses only: non treatment seeking sample
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
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Comer 2006
Methods RCT: 2 centres, 3 parallel treatment groups, placebo-controlled randomised trial, 8 weeks observation
period
Participants opioid dependent outpatients, n=60, treatment seeking
Interventions Biotek naltrexone depot 192 or 384 mg, or placebo, detoxiﬁcation followed by depot injections, all 3
treatment groups with manualised relapse prevention therapy
Outcomes retention in treatment / time to drop out, illicit drug use by urinalysis, heroin craving, depression, adverse
effects
Notes only study included for analyses of effectiveness
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Dunbar 2006
Methods RCT: dose-ﬁnding trial (phase I), 2 sequential panels of 5 treatment groups, 2 (panel A) or 5 (panel B)
months observation period
Participants healthy volunteers, outpatients
- Panel A consisted of n=28 participants in 3 treatment groups: low dose, high dose, placebo
- Panel B consisted of n=14 participants in 2 treatment groups: high dose or placebo
Interventions Alkermes naltrexone depot 190 or 380 mg, or placebo, oral naltrexone lead-in followed by single (panel
A) or multiple (panel B) depot injections.
Outcomes pharmacokinetics, adverse effects
Notes included for safety analyses only: healthy volunteers
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Foster 2003
Methods non-RCT: uncontrolled, prospective trial, 12 weeks observation period
Participants opioid dependent outpatients, seeking treatment in private clinic, ﬁrst cohort n=55, second cohort n=46
Interventions Wedgewood naltrexone implant 1000 mg, sequential treatment periods possible
- ﬁrst cohort: rapid detoxiﬁcation under general anaesthesia (RODA) followed by implant
- second cohort: domiciliary (i.e. non-iv sedation) rapid detoxiﬁcation followed by implant
Outcomes opioid use, naltrexone plasma levels, adverse effects
Notes included for safety analyses only: no comparison group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Galloway 2005
Methods non-RCT: uncontrolled, prospective trial, 6 weeks observation period
Participants alcohol dependent outpatients, n=16, treatment seeking
Interventions DrugAbuse Sciences naltrexone depot (300mg), oral naltrexone lead-in followedby depot injection,weekly
individual counselling sessions
Outcomes alcohol use, alcohol craving, pharmacokinetics,
adverse effects
Notes included for safety analyses only: alcohol dependent sample
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
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Garbutt 2005
Methods RCT: 24 centres, 3 parallel treatment groups, placebo-controlled randomised trial,24 weeks observation
period
Participants alcohol dependent outpatients, n=624, treatment seeking
Interventions Alkermes naltrexone depot 190 or 380mg, or placebo, sequentially administered monthly during 6
months,
12 sessions of manual based supportive therapy
Outcomes alcohol consumption, time to drop out, changes in liver enzyme levels
adverse events, side effects
Notes included for safety analyses only: alcohol dependent sample
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Gölz 2000
Methods non-RCT: 2 sequential treatment groups, prospective trial, 2 year observation period
Participants opioid dependent outpatients, n=108, treatment seeking
Interventions Wedgewood naltrexone implant 1000 mg or thrice weekly oral naltrexone, rapid opioid detoxiﬁcation
under anaesthesia followed by induction onto naltrexone, unclear if repeated implantations possible, free
to choose groups
Outcomes relapse to opioid use, abstinence, duration of receptor blockade, additional safety data provided by Partecke
Notes included for safety analyses only: no adequate comparison group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
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Hulse 2005
Methods non-RCT: uncontrolled, retrospective record-linkage study, pre-post design, 18months observation period
Participants opioid dependent outpatients, n=361 treatment seeking
Interventions GoMedical naltrexone implant 3400mg, rapid opioid detoxiﬁcation with induction onto naltrexone
Outcomes hospital presentations due to opioid or other drug poisonings
implants removed
Notes included for safety analyses only: uncontrolled, retrospective record-linkage study
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Johnson 2004
Methods RCT: 4 centres, 2 parallel treatment groups, placebo-controlled randomised trial, 4 months observation
period
Participants alcohol dependent outpatients, n=30, treatment seeking
Interventions Alkermes naltrexone depot 400mg or placebo, psychosocial support once monthly, manual based at the
two US centres
Outcomes alcohol consumption, pharmacokinetics, changes in liver enzymes,
adverse effects
Notes included for safety analyses only: alcohol dependent sample
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Kranzler 1998
Methods RCT: 2 parallel treatment groups, placebo-controlled randomised trial, 12 weeks observation period
Participants alcohol dependent outpatients, n=20, treatment seeking
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Kranzler 1998 (Continued)
Interventions Biotek naltrexone depot 206mg or placebo, two weeks with oral naltrexone lead-in, weekly psychotherapy
sessions
Outcomes alcohol consumption, pharmacokinetics, changes in gamma GT levels,
adverse effects
Notes included for safety analyses only: alcohol dependent sample
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Kranzler 2004
Methods RCT: 30 centres, 2 parallel treatment groups, placebo-controlled randomised trial, 3 months observation
period
Participants alcohol dependent outpatients, n=333, treatment seeking
Interventions DrugAbuse Sciences naltrexone depot 300 or 150 mg, or placebo, oral naltrexone lead-in followed by
sequentially administered depot injections during 3 months, 4 manual based counselling sessions
Outcomes alcohol consumption,
adverse effects
Notes included for safety analyses only: alcohol dependent sample
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Sullivan 2006
Methods non-RCT: uncontrolled, dose-ﬁnding trial (phase II), 6 weeks observation period
Participants opioid dependent inpatients, n=5, non treatment seeking
Interventions Biotek naltrexone depot 384 mg, detox and oral naltrexone lead-in followed by depot injection, heroin
challenge protocol
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Sullivan 2006 (Continued)
Outcomes heroin dose effects, adverse events
Notes included for safety analyses only: non treatment seeking sample
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Tait 2007
Methods two parallel treatment groups, record linkage, 5 and a half years observation period
Participants opioid dependent outpatients, n=341 treatment seeking
Interventions GoMedical naltrexone implant 2200 mg, methadone maintenance treatment, possibility of sequential
treatment episodes not stated
Outcomes mortality
Notes included for safety analyses
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Turncliff 2005
Methods non-RCT: 2 parallel treatment groups, matched case-control trial, 3 months observation period
Participants alcohol dependent outpatients (currently abstinent, liver impaired) and healthy controls, n=25, treatment
seeking
Interventions Alkermes naltrexone depot 190 mg
Outcomes pharmacokinetics, adverse effects
Notes included for safety analyses only: alcohol dependent sample
Risk of bias
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Turncliff 2005 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Waal 2003
Methods non-RCT: uncontrolled, prospective trial, 2 months observation period
Participants opioid dependent outpatients, n=10, treatment seeking
Interventions Wedgewood naltrexone implant 1000 mg, sequential treatment periods possible, counselling sessions
Outcomes pharmcokinetics, drug use, adverse effects
Notes included for safety analyses only: no comparison group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Waal 2006
Methods non-RCT: uncontrolled, prospective trial, 1 year observation period (after last implant)
Participants opioid dependent outpatients, n=13, treatment seeking
Interventions GoMedical naltrexone implant 1800 or 3600 mg, sequential treatment periods possible
Outcomes pharmacokinetics, drug use, quality of life, adverse effects
Notes included for safety analyses only: no comparison group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
27Sustained-Release Naltrexone For Opioid Dependence (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
112
Characteristics of excluded studies [ordered by study ID]
Albanese 2000 oral naltrexone
Brewer 2001 no clinical trial (comment)
Brewer 2002 case study, adverse effect data not reported
Brewer 2004 case report, adverse effect data not reported
Carreno 2002 oral naltrexone
Chiang 1984 pilot study on healthy volunteers with focus on pharmacokinetics
Chiang 1985a pilot study on healthy volunteers with focus on pharmacokinetics
Chiang 1985b pilot study on healthy volunteers: concludes with recommending no further investigations on this particular
product
Collins 2005 oral naltrexone
Colquhoun 2005 non-RCT, adverse effect data not reported
Dean 2005 no clinical trial (review)
Dean 2006 oral naltrexone
Garcia-Alonso 1989 oral naltrexone
Gooberman 1998 abstract from conference presentation only
Grusser 2006 non-RCT, adverse effect data not reported
Hamilton 2002 non-RCT, adverse effect data not reported
Harrison 2006 no clinical trial (review)
Heading 2006 no clinical trial (review)
Hulse 2002a non-RCT, adverse effect data not reported
Hulse 2002b case report, adverse effect data not provided
Hulse 2003a non-RCT, adverse effect data not reported
Hulse 2003b non-RCT, adverse effect data not reported
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(Continued)
Hulse 2003c case report, adverse effect data not provided
Hulse 2004a no clinical trial
Hulse 2004b no clinical trial
Hulse 2004c non-RCT, adverse effect data not reported
Hulse 2004d non-RCT, adverse effect data not reported
Iversen 2005 no clinical trial
Jasinski 2006 no clinical trial
Jeffrey 2007 non-RCT, hepatitis C treatment-related outcomes only, adverse effect data not reported
Johnson 2006 no clinical trial
Lerner 1992 oral naltrexone
Marlowe 2006 no clinical trial
Martin 1974 no clinical trial (dogs)
Modesto-Lowe 2002 no clinical trial (review)
Ngo 2007 non-RCT, adverse effect data not reported
NRCC report 1978 oral naltrexone
O’Brien 2005 no clinical trial (comment)
O’Brien 2006 no clinical trial (comment)
O’Malley 1992 oral naltrexone
Oliver 2005 no clinical trial (letter)
Pekta 1998 abstract available only
Pitt 1981 no clinical trial (animals) and duplicate of NIDA research monograph 28
Poser 1996 no clinical trial (review)
Rabinowitz 1998 oral naltrexone
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(Continued)
Ramenskaya 2005 no clinical trial (pharmacokinetic results)
Rawson 2000 no clinical trial (review)
Reece 2007 non-RCT, adverse effect data not reported
Resnick 1977 no clinical trial (review)
Reuning 1976 no clinical trial (animals)
Riddle 2001 no clinical trial (review)
Schwope 1975 no clinical trial (mice)
Sobel 2001 abstract available only
Suhaida 2004 no clinical trial (in vitro study)
Teagle 2007 no clinical trial (press release)
Warhaft 2003 no clinical trial (letter)
Wesson 2003 abstract available only, 9 and 12 months follow-up data from same sample as included report Kranzler 2004
Willette 1978 no clinical trial
Willette 1981 no clinical trial (review and animal studies)
Wodak 2001 no clinical trial (review)
Characteristics of ongoing studies [ordered by study ID]
Hulse
Trial name or title A randomised, double-blind, placebo-controlled clinical trial of naltrexone implants for the treatment of
heroin addiction
Methods
Participants opioid dependent outpatients (DSM IV)
Interventions 2 groups: naltrexone implant + oral placebo compared to placebo implant + oral naltrexone
30Sustained-Release Naltrexone For Opioid Dependence (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
115
Hulse (Continued)
Outcomes naltrexone blood levels, retention in treatment,
opiate use, opiate overdose, opiate related morbidity and mortality, craving for heroin, other drug use, other
drug overdose, other drug-related morbidity or
mortality, social functioning, general health, implant insertion site healing
Starting date recruitment and follow-up is completed
Contact information Gary Hulse: hulseg@meddent.uwa.edu.au
Notes Country: Australia
Kunøe
Trial name or title Naltrexone Implants - a Randomised Study
http://clinicaltrials.gov reference: NCT00521157
Methods
Participants opioid dependent outpatients opting for relapse prevention with naltrexone implants compared to treatment-
as-usual controls
Interventions 12 months, observation 2 groups: treatment start with naltrexone implants before institutional discharge,
group cross over optional after 6 months
Outcomes drug use, quality of life, depression, adverse effects
Starting date recruitment started January 2006, completed in June 2007
Contact information Nikolaj Kunøe: nikolaj.kunoe@medisin.uio.no
Notes Country:
Norway
Lobmaier
Trial name or title Naltrexone Implants - a Treatment Alternative for Heroin Dependent Prisoners?
http://clinicaltrials.gov reference: NCT00520793
Methods
Participants opioid dependent inmates
31Sustained-Release Naltrexone For Opioid Dependence (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
116
Lobmaier (Continued)
Interventions 18 months observation 2 groups: treatment start with naltrexone implants or methadone maintenance before
prison release, cross over optional after 6 and 12 months
Outcomes drug use, criminal activity, quality of life, depression, adverse effects
Starting date recruitment started May 2005, completed July 2007
Contact information Philipp Lobmaier: p.p.lobmaier@medisin.uio.no
Notes Country:
Norway
Nunes 2002
Trial name or title Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence Clinicaltrial.gov reference:
NCT00332228
Methods
Participants opioid dependent outpatients
Interventions 6 months observation, 4 groups: 1) behavioral therapy plus depot naltrexone 2) behavioral therapy plus
placebo injections 3) Compliance Enhancement (CE), simulating standard treatment with oral naltrexone
plus depot naltrexone 4) CE plus placebo injections
Outcomes heroin use, retention in treatment, naltrexone blood levels,
Starting date recruitment started June 2002
Contact information Stephen Anen: anenste@pi.cpmc.columbia.edu
Notes Country:
USA
Nunes 2008
Trial name or title Behavioral NaltrexoneTherapy (BNT) for PromotingAdherence toOralNaltrexone (BNT-Oral) vs Extended
Release Injectable Depot Naltrexone (Depot-BNT); a Randomized Trial
Methods
Participants opioid dependent outpatients
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Nunes 2008 (Continued)
Interventions 6 months observation, 2 groups: behavioral naltrexone therapy for depot naltrexone (depot-BNT) compared
to BNT plus oral naltrexone
Outcomes opioid use, retention in treatment, medication compliance
Starting date Recruitment started September 2007
Contact information Yaacov Elkus: elkusya@pi.cpmc.columbia.edu and Elizabeth Martinez: martine@pi.cpmc.columbia.edu
Notes Country:
USA
Tiihonen
Trial name or title Naltrexone depot implant in the treatment of co-morbid amphetamine and opioid dependence: a double-
blind, randomised, placebo-controlled trial
Methods
Participants Amphetamine and opioid dependent outpatients
Interventions 10 weeks observation, two groups: naltrexone implant compared to placebo
implant
Outcomes amphetamine use, opioid dependence, use of benzodiazepines and cannabis
Starting date recruitment started November 2007, anticipated completed by December 2009
Contact information Jari Tiihonen:
jari.tiihonen@niuva.ﬁ
Notes Country:
Russia
Woody
Trial name or title Effectiveness of Oral and Depot Naltrexone in Treating Heroin Dependent Individuals Seeking Treatment
for Heroin Addiction
clinicaltrials.gov reference NCT00218426
Methods
Participants opioid dependent outpatients
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Woody (Continued)
Interventions 6 months observation, 3 groups: 1) oral naltrexone + placebo injection, 2) oral placebo + depot naltrexone 3)
oral placebo + placebo injection
Outcomes opioid use, time to drop out, other drug use, psychiatric symptoms, HIV risk
Starting date recruitment started July 2006
Contact information George Woody:
woody@tresearch.org and
Evgeny Krupitsky: kru@ek3506.spb.edu
Notes Country:
Russia
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D A T A A N D A N A L Y S E S
Comparison 1. effectiveness outcomes treatment vs. control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 treatment retention in high-dose
depot vs. placebo
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [0.92, 3.34]
2 treatment retention in low-dose
depot vs. placebo
1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [0.78, 3.05]
3 treatment retention in high-dose
vs. low-dose depot
1 42 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.72, 1.80]
4 time to drop out in high-dose
depot vs. placebo
1 40 Mean Difference (IV, Fixed, 95% CI) 21.0 [10.68, 31.32]
5 time to drop out in high-dose vs.
low-dose depot
1 42 Mean Difference (IV, Fixed, 95% CI) 12.0 [1.69, 22.31]
6 time to drop out in low-dose
depot vs. placebo
1 38 Mean Difference (IV, Fixed, 95% CI) 9.0 [-3.40, 21.40]
Comparison 2. safety outcomes treatment vs. control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 high-dose depot vs. placebo in
opioid dependence
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 one or more adverse effects 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.79, 2.35]
1.2 discontinued due to
adverse effects
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.01, 6.38]
2 high-dose depot vs. placebo in
alcohol dependence
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 one or more adverse effects 1 30 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.73, 1.81]
2.2 severe adverse effects 1 414 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.31, 1.48]
2.3 injection site pain 1 414 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.73, 2.28]
2.4 discontinued due to
adverse effects
1 414 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [1.15, 3.88]
3 low-dose depot vs. placebo in
opioid dependence
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 one or more adverse effects 1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.3 [0.74, 2.28]
3.2 discontinued due to
adverse effects
1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.8 [0.18, 18.21]
3.3 injection site induration 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.9 [0.06, 13.36]
4 low-dose depot vs. placebo in
alcohol dependence
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 one or more adverse effect 2 353 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.95, 1.17]
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4.2 discontinued due to
adverse effects
1 419 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.49, 2.04]
4.3 injection site pain 3 772 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.92, 1.47]
4.4 injection site induration 2 353 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.76, 1.80]
4.5 injection site contusion 1 333 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.60, 2.57]
4.6 one or more injection site
reaction
1 333 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [1.02, 1.38]
4.7 severe adverse effect 1 419 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.34, 1.55]
4.8 injection site related to
adverse effects, pooled
3 1791 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [1.02, 1.36]
5 low-dose depot vs. placebo in
healthy volunteers
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 one or more adverse effects 1 42 Risk Ratio (M-H, Fixed, 95% CI) 2.46 [0.16, 38.89]
5.2 one or more injection site
reaction
1 42 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.08, 22.92]
6 high-dose vs. low-dose depot in
opioid dependence
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 one or more adverse effects 1 42 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.68, 1.61]
6.2 discontinued due to
adverse effects
1 42 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 3.59]
7 high-dose vs. low-dose depot in
alcohol dependence
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 discontinued due to
adverse effects
1 415 Risk Ratio (M-H, Fixed, 95% CI) 2.12 [1.16, 3.90]
7.2 injection site pain 1 415 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.76, 2.44]
7.3 severe adverse effects 1 415 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.40, 2.15]
8 one or more adverse effects
in liver impaired vs. healthy
controls
1 25 Risk Ratio (M-H, Fixed, 95% CI) 3.25 [1.14, 9.24]
9 mortality in naltrexone implant
vs. methadone maintenance
1 894 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.25, 1.66]
Analysis 1.1. Comparison 1 effectiveness outcomes treatment vs. control, Outcome 1 treatment retention
in high-dose depot vs. placebo.
Review: Sustained-Release Naltrexone For Opioid Dependence
Comparison: 1 effectiveness outcomes treatment vs. control
Outcome: 1 treatment retention in high-dose depot vs. placebo
Study or subgroup high-dose naltrexone placebo injection Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Comer 2006 15/22 7/18 100.0 % 1.75 [ 0.92, 3.34 ]
Total (95% CI) 22 18 100.0 % 1.75 [ 0.92, 3.34 ]
Total events: 15 (high-dose naltrexone), 7 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.088)
0.01 0.1 1 10 100
Favours treatment Favours control
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Analysis 1.2. Comparison 1 effectiveness outcomes treatment vs. control, Outcome 2 treatment retention
in low-dose depot vs. placebo.
Review: Sustained-Release Naltrexone For Opioid Dependence
Comparison: 1 effectiveness outcomes treatment vs. control
Outcome: 2 treatment retention in low-dose depot vs. placebo
Study or subgroup low-dose naltrexone placebo injection Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Comer 2006 12/20 7/18 100.0 % 1.54 [ 0.78, 3.05 ]
Total (95% CI) 20 18 100.0 % 1.54 [ 0.78, 3.05 ]
Total events: 12 (low-dose naltrexone), 7 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
0.01 0.1 1 10 100
Favours treatment Favours control
Analysis 1.3. Comparison 1 effectiveness outcomes treatment vs. control, Outcome 3 treatment retention
in high-dose vs. low-dose depot.
Review: Sustained-Release Naltrexone For Opioid Dependence
Comparison: 1 effectiveness outcomes treatment vs. control
Outcome: 3 treatment retention in high-dose vs. low-dose depot
Study or subgroup high-dose naltrexone low-dose naltrexone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Comer 2006 15/22 12/20 100.0 % 1.14 [ 0.72, 1.80 ]
Total (95% CI) 22 20 100.0 % 1.14 [ 0.72, 1.80 ]
Total events: 15 (high-dose naltrexone), 12 (low-dose naltrexone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
0.01 0.1 1 10 100
Favours treatment Favours control
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Analysis 1.4. Comparison 1 effectiveness outcomes treatment vs. control, Outcome 4 time to drop out in
high-dose depot vs. placebo.
Review: Sustained-Release Naltrexone For Opioid Dependence
Comparison: 1 effectiveness outcomes treatment vs. control
Outcome: 4 time to drop out in high-dose depot vs. placebo
Study or subgroup high-dose naltrexone placebo injection Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Comer 2006 22 48 (13) 18 27 (19) 100.0 % 21.00 [ 10.68, 31.32 ]
Total (95% CI) 22 18 100.0 % 21.00 [ 10.68, 31.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.99 (P = 0.000067)
-100 -50 0 50 100
Favours placebo Favours naltrexone
Analysis 1.5. Comparison 1 effectiveness outcomes treatment vs. control, Outcome 5 time to drop out in
high-dose vs. low-dose depot.
Review: Sustained-Release Naltrexone For Opioid Dependence
Comparison: 1 effectiveness outcomes treatment vs. control
Outcome: 5 time to drop out in high-dose vs. low-dose depot
Study or subgroup high-dose naltrexone low-dose naltrexone Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Comer 2006 22 48 (13) 20 36 (20) 100.0 % 12.00 [ 1.69, 22.31 ]
Total (95% CI) 22 20 100.0 % 12.00 [ 1.69, 22.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.023)
-100 -50 0 50 100
Favours low dose Favours high dose
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Analysis 1.6. Comparison 1 effectiveness outcomes treatment vs. control, Outcome 6 time to drop out in
low-dose depot vs. placebo.
Review: Sustained-Release Naltrexone For Opioid Dependence
Comparison: 1 effectiveness outcomes treatment vs. control
Outcome: 6 time to drop out in low-dose depot vs. placebo
Study or subgroup low-dose naltrexone placebo injection Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Comer 2006 20 36 (20) 18 27 (19) 100.0 % 9.00 [ -3.40, 21.40 ]
Total (95% CI) 20 18 100.0 % 9.00 [ -3.40, 21.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
-100 -50 0 50 100
Favours placebo Favours naltrexone
Analysis 2.1. Comparison 2 safety outcomes treatment vs. control, Outcome 1 high-dose depot vs. placebo
in opioid dependence.
Review: Sustained-Release Naltrexone For Opioid Dependence
Comparison: 2 safety outcomes treatment vs. control
Outcome: 1 high-dose depot vs. placebo in opioid dependence
Study or subgroup high-dose naltrexone placebo injection Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 one or more adverse effects
Comer 2006 15/22 9/18 100.0 % 1.36 [ 0.79, 2.35 ]
Subtotal (95% CI) 22 18 100.0 % 1.36 [ 0.79, 2.35 ]
Total events: 15 (high-dose naltrexone), 9 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
2 discontinued due to adverse effects
Comer 2006 0/22 1/18 100.0 % 0.28 [ 0.01, 6.38 ]
Subtotal (95% CI) 22 18 100.0 % 0.28 [ 0.01, 6.38 ]
Total events: 0 (high-dose naltrexone), 1 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
0.01 0.1 1 10 100
favours naltrexone favours placebo
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Analysis 2.2. Comparison 2 safety outcomes treatment vs. control, Outcome 2 high-dose depot vs. placebo
in alcohol dependence.
Review: Sustained-Release Naltrexone For Opioid Dependence
Comparison: 2 safety outcomes treatment vs. control
Outcome: 2 high-dose depot vs. placebo in alcohol dependence
Study or subgroup high-dose naltrexone placebo injection Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 one or more adverse effects
Johnson 2004 23/25 4/5 100.0 % 1.15 [ 0.73, 1.81 ]
Subtotal (95% CI) 25 5 100.0 % 1.15 [ 0.73, 1.81 ]
Total events: 23 (high-dose naltrexone), 4 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
2 severe adverse effects
Garbutt 2005 10/205 15/209 100.0 % 0.68 [ 0.31, 1.48 ]
Subtotal (95% CI) 205 209 100.0 % 0.68 [ 0.31, 1.48 ]
Total events: 10 (high-dose naltrexone), 15 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
3 injection site pain
Garbutt 2005 24/205 19/209 100.0 % 1.29 [ 0.73, 2.28 ]
Subtotal (95% CI) 205 209 100.0 % 1.29 [ 0.73, 2.28 ]
Total events: 24 (high-dose naltrexone), 19 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
4 discontinued due to adverse effects
Garbutt 2005 29/205 14/209 100.0 % 2.11 [ 1.15, 3.88 ]
Subtotal (95% CI) 205 209 100.0 % 2.11 [ 1.15, 3.88 ]
Total events: 29 (high-dose naltrexone), 14 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
0.01 0.1 1 10 100
Favours treatment Favours control
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Analysis 2.3. Comparison 2 safety outcomes treatment vs. control, Outcome 3 low-dose depot vs. placebo
in opioid dependence.
Review: Sustained-Release Naltrexone For Opioid Dependence
Comparison: 2 safety outcomes treatment vs. control
Outcome: 3 low-dose depot vs. placebo in opioid dependence
Study or subgroup low-dose naltrexone placebo injection Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 one or more adverse effects
Comer 2006 13/20 9/18 100.0 % 1.30 [ 0.74, 2.28 ]
Subtotal (95% CI) 20 18 100.0 % 1.30 [ 0.74, 2.28 ]
Total events: 13 (low-dose naltrexone), 9 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
2 discontinued due to adverse effects
Comer 2006 2/20 1/18 100.0 % 1.80 [ 0.18, 18.21 ]
Subtotal (95% CI) 20 18 100.0 % 1.80 [ 0.18, 18.21 ]
Total events: 2 (low-dose naltrexone), 1 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
3 injection site induration
Comer 2006 1/20 1/18 100.0 % 0.90 [ 0.06, 13.36 ]
Subtotal (95% CI) 20 18 100.0 % 0.90 [ 0.06, 13.36 ]
Total events: 1 (low-dose naltrexone), 1 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
0.01 0.1 1 10 100
favours naltrexone favours placebo
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Analysis 2.4. Comparison 2 safety outcomes treatment vs. control, Outcome 4 low-dose depot vs. placebo
in alcohol dependence.
Review: Sustained-Release Naltrexone For Opioid Dependence
Comparison: 2 safety outcomes treatment vs. control
Outcome: 4 low-dose depot vs. placebo in alcohol dependence
Study or subgroup low-dose naltrexone placebo injection Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 one or more adverse effect
Kranzler 1998 7/15 2/5 2.2 % 1.17 [ 0.35, 3.88 ]
Kranzler 2004 140/167 132/166 97.8 % 1.05 [ 0.95, 1.17 ]
Subtotal (95% CI) 182 171 100.0 % 1.06 [ 0.95, 1.17 ]
Total events: 147 (low-dose naltrexone), 134 (placebo injection)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.30)
2 discontinued due to adverse effects
Garbutt 2005 14/210 14/209 100.0 % 1.00 [ 0.49, 2.04 ]
Subtotal (95% CI) 210 209 100.0 % 1.00 [ 0.49, 2.04 ]
Total events: 14 (low-dose naltrexone), 14 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
3 injection site pain
Garbutt 2005 18/210 19/209 22.6 % 0.94 [ 0.51, 1.74 ]
Kranzler 1998 5/15 2/5 3.6 % 0.83 [ 0.23, 3.03 ]
Kranzler 2004 78/167 62/166 73.8 % 1.25 [ 0.97, 1.61 ]
Subtotal (95% CI) 392 380 100.0 % 1.17 [ 0.92, 1.47 ]
Total events: 101 (low-dose naltrexone), 83 (placebo injection)
Heterogeneity: Chi2 = 1.01, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
4 injection site induration
Kranzler 1998 11/15 2/5 9.7 % 1.83 [ 0.60, 5.60 ]
Kranzler 2004 31/167 28/166 90.3 % 1.10 [ 0.69, 1.75 ]
Subtotal (95% CI) 182 171 100.0 % 1.17 [ 0.76, 1.80 ]
Total events: 42 (low-dose naltrexone), 30 (placebo injection)
Heterogeneity: Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
5 injection site contusion
Kranzler 2004 15/167 12/166 100.0 % 1.24 [ 0.60, 2.57 ]
Subtotal (95% CI) 167 166 100.0 % 1.24 [ 0.60, 2.57 ]
0.01 0.1 1 10 100
Favours treatment Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup low-dose naltrexone placebo injection Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 15 (low-dose naltrexone), 12 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
6 one or more injection site reaction
Kranzler 2004 123/167 103/166 100.0 % 1.19 [ 1.02, 1.38 ]
Subtotal (95% CI) 167 166 100.0 % 1.19 [ 1.02, 1.38 ]
Total events: 123 (low-dose naltrexone), 103 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.025)
7 severe adverse effect
Garbutt 2005 11/210 15/209 100.0 % 0.73 [ 0.34, 1.55 ]
Subtotal (95% CI) 210 209 100.0 % 0.73 [ 0.34, 1.55 ]
Total events: 11 (low-dose naltrexone), 15 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
8 injection site related to adverse effects, pooled
Garbutt 2005 18/210 19/209 8.3 % 0.94 [ 0.51, 1.74 ]
Kranzler 1998 16/30 4/10 2.6 % 1.33 [ 0.58, 3.06 ]
Kranzler 2004 247/668 205/664 89.1 % 1.20 [ 1.03, 1.39 ]
Subtotal (95% CI) 908 883 100.0 % 1.18 [ 1.02, 1.36 ]
Total events: 281 (low-dose naltrexone), 228 (placebo injection)
Heterogeneity: Chi2 = 0.63, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.24 (P = 0.025)
0.01 0.1 1 10 100
Favours treatment Favours control
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Analysis 2.5. Comparison 2 safety outcomes treatment vs. control, Outcome 5 low-dose depot vs. placebo
in healthy volunteers.
Review: Sustained-Release Naltrexone For Opioid Dependence
Comparison: 2 safety outcomes treatment vs. control
Outcome: 5 low-dose depot vs. placebo in healthy volunteers
Study or subgroup low-dose naltrexone placebo injection Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 one or more adverse effects
Dunbar 2006 6/36 0/6 100.0 % 2.46 [ 0.16, 38.89 ]
Subtotal (95% CI) 36 6 100.0 % 2.46 [ 0.16, 38.89 ]
Total events: 6 (low-dose naltrexone), 0 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 one or more injection site reaction
Dunbar 2006 3/36 0/6 100.0 % 1.32 [ 0.08, 22.92 ]
Subtotal (95% CI) 36 6 100.0 % 1.32 [ 0.08, 22.92 ]
Total events: 3 (low-dose naltrexone), 0 (placebo injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
0.01 0.1 1 10 100
Favours treatment Favours control
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Analysis 2.6. Comparison 2 safety outcomes treatment vs. control, Outcome 6 high-dose vs. low-dose
depot in opioid dependence.
Review: Sustained-Release Naltrexone For Opioid Dependence
Comparison: 2 safety outcomes treatment vs. control
Outcome: 6 high-dose vs. low-dose depot in opioid dependence
Study or subgroup high-dose naltrexone low-dose naltrexone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 one or more adverse effects
Comer 2006 15/22 13/20 100.0 % 1.05 [ 0.68, 1.61 ]
Subtotal (95% CI) 22 20 100.0 % 1.05 [ 0.68, 1.61 ]
Total events: 15 (high-dose naltrexone), 13 (low-dose naltrexone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
2 discontinued due to adverse effects
Comer 2006 0/22 2/20 100.0 % 0.18 [ 0.01, 3.59 ]
Subtotal (95% CI) 22 20 100.0 % 0.18 [ 0.01, 3.59 ]
Total events: 0 (high-dose naltrexone), 2 (low-dose naltrexone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
0.01 0.1 1 10 100
favours high-dose favours low-dose
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Background
Naltrexone is a competitive opioid 
antagonist that effectively blocks the action 
of heroin and other opioid agonists. 
Sustained-release naltrexone formulations 
are now available that provide long-acting 
opioid blockade. This study investigates the 
use of heroin and other opioids among 
opioid dependent patients receiving 
treatment with long-acting naltrexone 
implants, their subjective experience of 
drug  'high' after opioid use, and factors 
associated with opioid use.  
Methods
Participants (n=60) were opioid dependent 
patients receiving treatment with naltrexone 
implants. Outcome data were collected over 
a 6 month period on substance use, drug 
‘high’, depression, and criminal activity. 
Blood samples were taken to monitor 
naltrexone plasma levels, and hair samples 
to verify self-reported opioid use.  
Results
More than half (57%, n=34) of the patients 
challenged the blockade with illicit opioids 
during the 6 month treatment period; 43% 
(n=26) were abstinent from opioids. Mean 
opioid use was reduced from 18 (s.d.:13) 
days during the month preceding treatment 
to 6 (s.d.: 11) after 6 months. Sixteen 
patients (27%) used opioids on six or more 
days, and these accounted for 1409 (97%) 
of the total 1446 days of opioid use. Nine 
patients reported partial drug ‘high’ 
following illicit opioid use, and three 
reported full ‘high’. Opioid use was 
associated with use of non-opioid drugs 
and criminal behaviour. 
Conclusions
Challenging naltrexone blockade with 
heroin on at least one occasion is common 
among sustained-release naltrexone 
patients, but only a minority of patients use 
opioids regularly. Challenges represent a 
warning sign for poor outcomes and often 
occur in the context of poly-drug use and 
social adjustment problems. 
_______________________________
Naltrexone is a competitive opioid 
antagonist that is known to block the action 
of heroin and other opioids [1-4]. However, 
some opioid use persists [5-10], even in 
patients conﬁrmed as having taken 
naltrexone [10] and in patients on 
sustained-release formulations of 
naltrexone [9, 11]. Different models of 
addiction take different perspectives 
regarding possible harms associated with 
opioid use during naltrexone treatment. 
From a pharmacological perspective, 
naltrexone’s blockade of agonists leads to a 
substantial reduction in the risk of 
respiratory arrest resulting from opioid 
intake. Taking a behavioural perspective, 
Abraham Wikler's [12] theory on antagonist 
pharmacotherapy for opioid addiction 
proposes that blocked heroin use should be 
harmless or even therapeutic: repeated 
administrations followed by the lack of 
reinforcement provided by the heroin 'high' 
should lead to extinction and gradually 
eliminate the user’s desire for heroin. 
However, empirical data from clinical 
studies of oral naltrexone treatment suggest 
that blocked heroin use among oral 
naltrexone patients may be harmful in that 
it often leads to dropout and relapse to 
unblocked use [10, 13]. 
141
Challenges to antagonist blockade during 
sustained-release naltrexone treatment
Addiction (accepted for publication)
Despite the capacity of naltrexone to block 
the effects of heroin, studies on oral 
naltrexone have reported experiences of 
drug 'high' among naltrexone patients after 
heroin use [5-8, 14, 15]. While some such 
experiences may have occurred among 
patients who were not compliant with their 
oral naltrexone regimen [16], two single-
case reports have recently reported of 
similar experiences occurring in sustained-
release naltrexone patients [17, 18]. In 
addition, an autopsy search found two 
naltrexone implant patients who died of 
drug-related causes [19]. This has caused 
concerns about the extent to which 
sustained-release naltrexone blocks the 
effect of heroin and other opioids [18, 19]. 
The possible role of poly-drug use on the 
experience of drug ‘high’ [20, 21] or 
mortality [22] was, however, not discussed 
in these papers. The self-challenges that 
occur in clinical samples can be expected to 
include high opioid dosages as well as 
other drugs in combination with opioids.  It 
is not known to what extent this produces 
different results from laboratory-based 
challenge studies. 
Sustained-release preparations of 
naltrexone have recently shown promise in 
reducing relapse to heroin use [9, 11, 23, 
24].  It is important that better information 
be collected about the benefits and 
drawbacks of this type of treatment. In 
particular, research is required which 
investigates the extent to which patients on 
sustained-release naltrexone challenge this 
treatment by using opioids, including how 
often they use opioids, and with what sorts 
of risk. This study investigates the use of 
heroin and other opioids among opioid 
dependent patients treated with sustained-
release naltrexone implants; in addition, the 
extent to which these patients experience 
'high' from such use is investigated, as well 
as the behaviours and problems associated 
with opioid use. 
Methods 
Patients were included in clinical trials of 
20-pellet naltrexone implants from 
GoMedical Industries, Australia, previously 
shown to provide naltrexone blockade for 
ﬁve to six months [25-27]. Two of the trials 
have been described elsewhere [24, 28] 
while the third was a pilot study (n=6) 
using identical implants and materials. 
Trials included patients who were opioid 
dependent adults (18 or above), not 
psychotic or pregnant, and who volunteered 
for participation in naltrexone implant 
research. Patients or inmates who had been 
coerced into treatment were not eligible for 
participation. The trials were approved by 
the regional ethical board, funded by public 
grants from the South Eastern Norway 
Regional Health Authority and the 
Norwegian Research Council, and 
registered in clinicaltrials.gov as 
NCT00269607, NCT00521157, and 
NCT00204243. The naltrexone implants 
were imported for research purposes in 
2005-2006 with the approval of both the 
Australian and Norwegian medicinal 
agencies. The experimental nature of the 
treatment was emphasized in all 
communication with the patients, including 
the product information folder and the 
written informed consent. 
The main outcome variables were opioid 
use and subjectively reported drug ‘high’. 
The use of opioids and other substances 
were measured using the European version 
of the ﬁfth Addiction Severity Index (ASI) 
[29]. Outcome variables were days used 
during the previous 30 days, and a 
frequency scale describing the whole 6-
month period on a 0-3 scale (0 = no use; 1 
= 1-3 times per month; 2 = 1-3 times per 
week; 3= daily or almost daily). Data on 
different opioid drugs in the ASI were 
analyzed separately (including heroin, 
morphine, methadone, buprenorphine, 
codeine), and these data were also summed 
into a composite (all opioids) outcome 
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variable. Time-line follow-back was used 
to assess days' opioid use in each of the six 
study months. Based on previous ﬁndings 
that some patients would be expected to 
“test” the blockade no more than a few 
times [30], we created a dichotomous 
variable based on whether patients used 
opioids on one to ﬁve days versus six days 
or more during the six-month study period. 
All patients were asked about opioid 
dosage. Non-opioid substance use, criminal 
activity, and employment situation were 
assessed using the ASI. The Beck 
Depression Inventory [31] was used to 
assess depression. The Temporal 
Satisfaction with Life Scale’s ‘present’ 
items [32] was used to assess life 
satisfaction, and the Hamilton Symptom 
Checklist 25 (SCL-25) [33] used to assess 
general mental health.  
Heroin 'high' was assessed by means of 
patients’ verbal reports of subjective opioid 
euphoria or ‘high’ during the follow-up 
interview: these were recorded and later 
rated by the 1st and 2nd authors on a 0-3 
scale using 0 for "No high"; 1 = "Not 
certain"; 2 = "Some high"; and 3 = "Full 
high." Cases of non-agreement between 
raters or multiple narratives by the same 
patient were resolved by selecting the 
higher rating. 
Blood samples were taken at convenience 
during the study period to verify naltrexone 
plasma levels [33] released by the implants 
[25-27]. Hair samples were taken during 
follow-up and analyzed for the presence of 
opioids using liquid chromatography mass 
spectrometry (LC-MS-MS) as described 
elsewhere [35]. Additional hair- and blood 
samples were requested for patients who 
reported opioid effects. 
Analyses were done with SPSS 16 for Mac 
OS X using ANOVA controlling for gender 
and age. If Levene’s test or plots indicated 
that the normality assumption was violated, 
the rank-test procedure (e.g. Spearman’s R) 
was used instead. For all tests, a .05 
signiﬁcance level was used. Chi-square 
with Fischer’s exact test was used for 
binomial variables. 
__________________________________
Results
Sixty implant patients met inclusion criteria 
and were recruited to the study. Mean age 
was 33.7 (s.d. 8) years (range: 21-55). 
Mean years of heroin use was 6.7 (s.d. 4.5; 
range: 0-20), poly-drug use 10.4 (s.d. 7.4; 
range: 0-34), injecting drug use 9 (s.d. 8; 
range: 0-31) years, while years in prison 
was 2 (s.d. 3.1; range: 0-14) and completed 
education 11 (s.d. 2; range: 0-15) years. 
Fourteen were women. Of the sixty 
participants, 42 came from treatment 
settings and 18 from criminal justice 
settings. Five participants did not attend the 
6 month follow-up interview: for these 
patients, data were collected from 
secondary sources such as family members 
or treatment staff. 
Opioid use
More than half of the naltrexone patients 
(57%, n=34) used illicit opioids on one or 
more occasions during the 6 month 
treatment period: 43% (n=26) reported 
having been abstinent from opioids 
throughout this period. The distribution of 
opioid-use among naltrexone patients is 
shown in Figure 1 (Fig 1). Fourteen 
naltrexone patients reported using opioids 
on one or two days, 16 (27%) used opioids 
on 6 days or more, of which nine (15%) 
reported using opioids on 90 days or more. 
The mean frequency of opioid use for the 
34 opioid-using patients was 24 (s.d. 49) 
days during the 180-day study period 
(range: 0-180 days). Median was 4 days, 
while mode was 2 days.
Frequency of opioid use was reduced from 
a mean of 2.4 (s.d. 1) on the 0-3 frequency 
scale before implantation to 0.9 (s.d. 1) 
after six months (difference: 1.5; 95% C.I.: 
1.1-1.7; p<.001). Illicit opioids were used 
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on a mean of 18 
(s.d. 13) out of 30 days (range: 0-30 days) 
in the month preceding implantation: this 
fell to a mean of 6 days (s.d. 11) in the last 
treatment month (difference: 12; 95% C.I.: 
8.1-15.5; p<.001). There was a tendency for 
opioid use to increase during the 6 month 
period, with a mean of 1 (s.d. 4) day’s 
opioid use was reported for the ﬁrst 
treatment month increasing to 6 (s.d. 11) in 
the last treatment month (range: 0-30; 
difference: 5 days; 95% C.I.: 2.2-7.6; p<.
01). Using opioids in month 1 was 
associated with a moderately increased risk 
of using illicit opioids again later in the 
study (Chi square risk estimate = 2.7; 95% 
C.I.: 1.7-4.4; p=.029). 
Subgroup analysis of the 34 opioid users 
showed the low-frequency (1-5 days) group 
(n=18) used illicit opioids on a mean of 2 
(s.d. 1) days during the study period (range: 
0-180 days), while the high-frequency use 
(6 or more days) group (n=16) averaged 88 
(s.d. 60) days of opioid use (difference: 86 
days; 95% C.I.: 57-115; p<.001). The high-
frequency use group accumulated 1409 
(97%) of the total of 1446 reported days of 
illicit opioid use. The high-use group on 
average returned to pre-treatment levels of 
use, with 20 (s.d. 13) days of use in the last 
30 days of naltrexone treatment compared 
to a mean of 25 (s.d. 9) days in the month 
preceding treatment (range: 0-30 
days; difference: 4.5 days; 95% C.I.: 
-2.5-11.7; p=.19). For the low-frequency 
group, illicit opioids were used on a mean 
of 1 (s.d. 1) days in the last study month: 
this was significantly reduced from the 16 
(s.d.13) days before implantation 
(difference: 15; 95% C.I.: 8-22; p<.001). 
Development of illicit opioid use differed 
between the two groups when assessed 
using time-line follow-back (see Figure 2). 
The extent of opioid use by the low-use 
patients remained unchanged throughout 
the 6 month treatment period, while the 
high-use group steadily increased opioid 
use after an initial reduction of use at the 
start of treatment. Month-by-month 
differences between groups were 
significant (p<.01) from month 2 onwards. 
The main types of opioid used by 
naltrexone patients were heroin (n=19) in 
dosages of 0.1-0.5 grams, illicit 
buprenorphine (n=9) in doses of 2-16 mg, 
injected morphine (n=5) tablets in doses of 
150-500 mg, and one patient (n=1) who 
obtained daily methadone doses of 20-40 
mg from his partner. Two patients 
deliberately sought to challenge the 
blockade with higher than usual amounts of 
opioids at 1.5 grams of heroin and 700 mg 
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Figure 1. Number of days on which illicit opioids were used by 
sustained-release naltrexone patients in the 180-day study period 
Figure note: 
Frequency of illicit opioid use 
among naltrexone implant 
patients in the 180-day 
treatment period. Many 
naltrexone implant patients 
(n=26 of 60; not shown) 
stayed abstinent from opioids, 
but the majority engaged in 
self-challenge behaviour of 
the naltrexone blockade. 
of 
morphine, respectively (see case examples 
below and in Table 1). 
Hair analyses indicated that underreporting 
of opioid use was rare. Analyses of the 46 
collected hair samples showed 33 to be 
concordant with self-reported opioid use. 
Of the 13 discordant sets, 2 were positive 
results for patients not reporting opioid use: 
11 patients had no trace of opioids in hair 
but reported opioid use. 
Naltrexone patients who used opioids 
during treatment were more frequent poly-
drug users during the entire six-month 
implant treatment period (R=.32; p=.017), 
and during the last 30 days of treatment 
(R=.32; p=.018). They were more frequent 
users of benzodiazepines in the previous 
six-months (R=.33; p=.014) and 30 days 
(R=.27; p=.044); more frequent users of 
cocaine in the six-month period (R=.32; p=.
028); more frequent users of amphetamines 
in the previous six months (R=.29; p=.028) 
and the last study month (R=.35; p=.008); 
opioid users were also more frequent users 
of cannabis in the last study month (R=.32; 
p=.017). They reported having spent more 
money buying illicit drugs during the six 
month period (R=.36; p=.008). 
Patients who used opioids during treatment 
were more likely to have used drugs by 
injection during the six month naltrexone 
period (R=.45; p<.001); they had injected 
more frequently than those abstinent from 
opioids (R=.33; p=.013), and reported more 
frequent sharing of injecting equipment 
(R=.34; p=.011). 
Naltrexone patients who used opioids 
during treatment were more likely to have 
been charged with acquisitive crimes 
during the study period (R=.28; p=.040), 
more likely to have been convicted of a 
crime (R=.36; p=.007), spent more months 
in custody or prison (R=.36; p=.007), had 
more days of the previous month in prison 
or custody (R=.28; p=.036), and were more 
likely to be awaiting further criminal 
charges or sentences (R=.40; p=.002). 
Patients who abstained from opioids during 
treatment were more satisfied with their 
quality of life at the end of the six month 
study period (R=.38; p=.004), more 
satisfied with their housing situation (R=.
33; p=.016), more likely to be in skilled 
work (R=.27; p=.045), worked more days 
during the last study month (R=.31; p=.
029), and reported lower levels of anxiety 
in the six-month study period (R=.32; p=.
026) compared to naltrexone patients who 
had used opioids. There was also a 
tendency for opioid abstinent naltrexone 
patients to be less depressed than opioid 
users on the Beck Depression Inventory 
(p=.055). Patients who used opioids on 
only one or two occasions during the six 
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Figure 2. Days of illicit opioid use per study month.
Figure note: Monthly opioid use development among 
naltrexone implant patients by subgroup. Low-
frequency users of opioids (reporting use on 1-5 days  
of the 180 study days) engaged in sporadic 
experimentation at the beginning and end of the 
naltrexone treatment period. High-frequency users 
(reporting opioid use on 6 days or more) followed 
steadily increased their opioid use. Note: Differences 
month 2-6 are signiﬁcant at p<.01. Opioids include 
heroin, morphine, methadone, buprenorphine, 
codeine.
month naltrexone period had more 
problems with non-opioid drug use and 
crime than abstinent patients, although 
these differences rarely reached statistical 
significance. 
Opioid ‘high’
Statements on subjective experience of 
'high' following opioid use were recorded 
from 31 of the 34 opioid-using patients: 19 
reported they had felt no euphoria or 
"high", and three were not sure if they had 
felt anything. Nine patients who had used 
opioids reported having felt some degree of 
subjective drug ‘high’: of these, six 
described having an effect that was 
categorized as a "partial high", and three 
patients reported having felt a "full" 
euphoric effect or "high" on at least one 
occasion. Mean rating of patients’ 
statements on the 0-3 drug effect rating 
scale was 0.77 (s.d 1.1) for the whole study 
period. The mean scores for the subgroups 
were 0.14 (s.d 0.4) for the ‘no high’ group, 
and 2.33 (s.d. 0.5) for the ‘high’ subgroup 
(range: 0-3; p<.001). 
Those who reported more drug ‘high’ were 
more frequent users of all opioids than the 
‘no high’ group during the last 30 days of 
the study (R=.40; p=.027). Patients feeling 
more ‘high’ were more frequent users of 
buprenorphine during the six month study 
period (R=.60; p<.001) and during the 
previous 30 days (R=.44; p=.016). Patients 
who experienced drug ‘high’ were more 
frequent users of benzodiazepines during 
the previous six months (R=.41; p=.025) 
and in the previous 30 days (R=.50; p=.
005). 
No deaths occurred during the study period. 
Of the non-fatal overdoses that were 
reported, two overdoses were reported by a 
patient who had used opioids and who 
reported having experienced full opioid 
‘high’ (described below). Another patient 
reported two non-fatal overdoses following 
the use of non-opioid drugs only.
The three patients who at some point 
reported full ‘high’ were: A man in his 20’s 
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Case 1: M45 Case 2: F38 Case 3: F36
I: Persistent blocked use II: Alleviating withdrawal III: Blockade challenge
This male of forty-five injected 
heroin during the first two weeks 
following implantation. He described 
the effect as “a disappointment” but 
after a further four weeks of 
amphetamine use he began adding 
heroin to his “mix” every day. Daily 
use continued for two months until 
rearrest. At six months follow-up, he 
was encouraged to speak freely about 
any heroin 'high' but repeated that he 
had felt no discernible effect from his 
opioid use. This man had been a 
street drug user all of his adult life, 
only interrupted by periods of 
imprisonment. Although naltrexone 
seems to have been effective in 
blocking his experience of heroin 
‘high’, other factors (e.g. social and 
conditioning types) appears to have 
supported regular use.
Prior to implantation, this woman of 38 
had experienced severe withdrawal 
distress during a two-week 
detoxification. The morning after 
receiving the implant, she discharged 
herself from the clinic and soon 
proceeded to inject heroin. She felt this 
relieved her withdrawal distress, but 
never felt any opioid high and suffered 
no overdoses during the six-month 
period. As it seems unlikely that heroin 
intake would exert an isolated effect on 
some dependence symptoms but not 
others, it is possible that her 
withdrawal symptoms were not 
directly caused by the absence of 
opioids. The patients’ experience could 
instead be influenced by other 
plausible mechanisms like non-opioid 
drug use and - dependence, anxiety, 
and negative reinforcement effects. 
Daily use of amphetamines and 
benzodiazepines started within days 
of receiving the naltrexone implant. 
After about two months, she tried 
heroin and started daily use, feeling 
“a partial high.” When admitted to 
detoxification at five and a half 
months, she reported withdrawal 
symptoms. Unexpectedly, 
withdrawal was not alleviated by the 
standard tapering of up to 8 mg 
buprenorphine. As this suggests that 
the patient’s naltrexone blockade was 
still intact, her partial experience of 
‘high’, any dependence symptoms as 
well as subsequent withdrawal 
symptoms may have been related to 
the use of non-opioid drugs. 
Table 1 note: Case examples of naltrexone implant patients using opioid agonists. Benzodiazepines and/or stimulant 
use before and/or alongside the intake of opioids made it difficult for both patients and investigators to make firm 
conclusions about the influence of opioid intake on patients’ symptoms and experiences.
Table 1. Case examples of challenge behaviour during naltrexone implant treatment.
diagnosed with bipolar disorder who used 
buprenorphine twice during month 6 
together with benzodiazepines and 
amphetamines. He said this buprenorphine 
use had ‘produced similar high to before 
starting on naltrexone.’ Another man 
reported having used heroin on a daily 
basis following implantation, and reported 
a consistent and full ‘high’ before being 
lost to follow-up after three months. The 
third patient was a man in his late forties 
who injected morphine in 200 and 500 mg 
quantities two weeks after implantation 
without feeling any effect. After a 4-week 
relapse to amphetamine and 
benzodiazepine use and experiencing 
hallucinations, he started injecting again 
and now reported ‘full high.’ After a week’s 
recuperation and detoxification on a 
psychiatric ward, he injected 300 mg of 
morphine but found it now had no effect. 
After relapsing to amphetamines again, he 
once more reported “full high.” At follow-
up two months later he also said he had had 
two non-lethal overdoses (see above). Table 
1 presents three typical examples of 
patients who used opioids despite having a 
functioning naltrexone blockade. 
Antagonist plasma levels
Plasma analyses showed that all samples 
taken at the end of month 5 were above the 
therapeutic level of 1 ng/ml of naltrexone, 
indicating a reliable naltrexone release for 
about ﬁve months (see Figure 3). Of the 
samples taken during month 6, three had 
dropped below this protective level. During 
this last month of treatment, all participants 
were reminded that naltrexone levels would 
soon be depleted and encouraged to seek 
treatment in existing treatment services. 
Discussion
Opioid dependent patients who received 
sustained-release naltrexone implants 
showed a mean reduction in opioid use 
during treatment. This reduction was 
unevenly distributed. Almost half of the 
naltrexone patients did not use opioids at 
all. However, more than half of the sample 
challenged the antagonist effects of 
naltrexone at some point during the 6 
month treatment period. More interestingly, 
about a quarter of the sample challenged 
the blockade repeatedly, and 15% reported 
having used opioids on at least 90 days 
during the 180 day study period. 
This repeated use of opioids despite 
receiving naltrexone is difﬁcult to 
understand. The majority of opioid use took 
place when naltrexone levels were above 
the therapeutic limit of 1-2 ng/ml of 
naltrexone [3,4]. These levels of naltrexone 
have previously been shown to antagonize 
both the physiological, and reinforcing 
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Figure 3. Plasma levels of naltrexone and 6-beta 
naltrexol in the 180-day study period.
ng/ml
Figure 3 note: Plasma levels of naltrexone and 6-beta 
naltrexone during the 180-day treatment period with 
naltrexone implants. All samples contained naltrexone at 
therapeutic levels in plasma (>1ng/ml) until month 5, after 
which an increasing number of samples dropped below 
1ng/ml
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effects of heroin [3,4]. Even though an 
increase in subjective ratings of heroin 
intake have sometimes preceded objective 
signs of heroin action in laboratory studies 
[3,4], the increased variability of the 
implants’ naltrexone release during the 
sixth and ﬁnal month of treatment was not 
associated with a large increase in opioid 
use. This suggests factors other than 
naltrexone depletion were important to 
opioid use. 
Nor can repeated opioid use by naltrexone 
patients be readily explained in terms of the 
subjective ‘high’ experienced by users. 
Many patients conﬁrmed the blocking 
properties of naltrexone by administering 
heroin or other illicit opioids, sometimes at 
high doses, to no effect. Few of the patients 
who repeatedly challenged the antagonist 
blockade reported having experienced a full 
drug ‘high’. Although nine of the high-
frequency opioid users reported having 
experienced at least some drug ‘high’, this 
may have been due less to the effects of 
opioids than to the concurrent use 
(including injection) of other types of drugs 
such as benzodiazepines, amphetamines, 
and cocaine. The majority of drug 
dependent patients use multiple substances 
[21, 36] and naltrexone does not 
signiﬁcantly alter the 'high' produced by the 
intake of non-opioid drugs. Where an 
opioid and one or more other types of drugs 
are taken at the same time, any subjective 
‘high’ may be misattributed to the opioids 
when the effect may be due to the effects of 
the other substance(s). In addition, we 
cannot exclude the occurrence of 
conditioned effects [20] in these patients’ 
experiences of opioid ‘high’.
Whatever the reasons for using heroin or 
other opioids while on naltrexone, this was 
found to be associated with poor outcomes 
in a wide range of outcome domains. 
Patients who repeatedly challenged the 
naltrexone blockade showed no treatment 
beneﬁt at the end of the 6 month period by 
which time they had returned to pre-
treatment levels of opioid use. Patients who 
challenged the blockade showed poor 
outcomes in a range of other areas: they 
were more likely to be using non-opioid 
drugs (benzodiazepines, amphetamines, 
cocaine, and cannabis), to be injecting 
drugs and sharing injecting equipment, and 
to have social adjustment problems 
including a more serious involvement in 
crime. These ﬁndings suggest that use of 
opioids while receiving sustained-release 
antagonist treatment are likely to be 
associated with a number of serious 
problems in treatment response and as 
indicative of the need for urgent clinical 
attention. Such results do not support the 
suggestion [12] that blocked opioid use is 
insigniﬁcant or of positive therapeutic 
value. As has been found for oral 
naltrexone treatment [10], opioid use 
among sustained-release naltrexone 
patients is a risky undertaking that may 
compromise their involvement in treatment 
and increase their likelihood of 
involvement in a range of problem 
behaviours including relapse to regular 
heroin use [13, 37]. In the present study, 
even patients who used opioids only once 
or twice tended to report more problem 
behaviours relative to abstinent patients, 
although the sample size meant these 
differences did not reach statistical 
signiﬁcance. 
These findings are subject to a number of 
limitations. One limitation concerns the 
size of the sample. Our results showed that 
only a minority of naltrexone patients were 
frequent users of opioids and even fewer 
reported experiencing a drug “high” during 
treatment. Further research on these 
specific phenomena should, therefore, 
recruit larger initial samples. In addition, 
there are problems inherent in the use of 
self-report ratings or even questionnaires to 
assess the experience of ‘high’ after using 
opioids. The use of PET imaging of 
receptor availability under various levels of 
naltrexone blockade may be able to provide 
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better data on the nature and mechanisms 
involved in such experiences and on how 
much naltrexone is needed to block them.
Nonetheless, the findings are interesting 
and of clinical relevance. Despite its overall 
effectiveness, sustained-release naltrexone 
did not eliminate opioid use in all patients. 
Clinicians who provide this type of 
medication can expect that many patients 
may challenge the naltrexone blockade by 
using opioids during treatment: some 
patients will engage in frequent opioid use, 
and a minority may report opioid ‘high.’ As 
there can sometimes be individual 
variability in naltrexone release, it may be 
appropriate for patients reporting drug 
‘high’ following opioid intake to have their 
naltrexone plasma levels confirmed by 
blood [34] or urine [36] analyses. Our 
results suggest that all forms of repeated 
challenge to the naltrexone blockade (with 
or without reported ‘high’) should be 
regarded as a warning sign for treatment 
providers that the patient is at risk of 
relapsing to a lifestyle involving poly-drug 
use and crime. In order to maximise each 
patient’s recovery potential with 
naltrexone, treatment services should 
monitor patients for injecting poly-drug use 
before and during sustained release 
naltrexone treatment. Where required, 
patients should be offered supplemental 
interventions [38] that address the wider 
context of substance use for the individual 
patient. 
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N. Kunøe, P. Lobmaier, J.K. 
Vederhus, B. Hjerkinn, S. Hegstad, 
M. Gossop, Ø. Kristensen, H. Waal.
Naltrexone's usefulness in the treatment of 
opioid dependence stems from its ability to 
block the action of heroin and other 
opioids. However, many patients are 
ambivalent towards naltrexone and often 
drop out of treatment with orally 
administered naltrexone. Sustained release 
naltrexone seems promising in reducing 
opioid use, but the extent to which patients 
remain in treatment beyond the first dosage 
of naltrexone is not clear.
Methods
Patients (n=61) undergoing treatment with 
sustained release naltrexone implants were 
offered a second naltrexone implant after 
six months. Patients who remained in 
treatment were compared to those who did 
not, on drug use, mental health, and social 
problems before and during naltrexone 
implant treatment. Information was 
obtained on other treatments sought by 
patients who discontinued naltrexone. 
Blood samples were used to verify 
naltrexone release, and hair samples to 
confirm opioid intake. 
Results
Of the patients who received the first 
naltrexone implant, 51% (n=31) remained 
in naltrexone implant treatment. Among 
those who discontinued treatment, 21% 
expressed a wish to re-implant but failed to 
attend for reimplantation and 28% declined 
reimplantation: 6 non-retained patients 
initiated maintenance or residential 
treatment. Remaining in naltrexone 
treatment was related to pre-study length of 
employment, illicit drug use, and concern 
for family problems. 
Higher levels of substance misuse and 
criminal activity during naltrexone 
treatment were negatively related to 
subsequent retention. 
Conclusion
Rates of retention among opioid dependent 
patients receiving naltrexone implant 
treatment are encouraging and support this 
as a feasible long-term treatment option. 
___________________________________
Naltrexone is an opioid antagonist that 
blocks the action of heroin and other 
opioids (Martin et al. 1973; Resnick et al. 
1974), thereby providing protection against 
the reinforcing, euphoric, and sedating 
effects of heroin (Verebey et al. 1976; 
Sullivan et al. 2006) with minimal risk of 
medication diversion or abuse (Tai & 
Blaine, 1997). These characteristics also 
constitute a challenge when attempting to 
use naltrexone in clinical treatment. 
Naltrexone studies tend to have long 
recruitment times, suggesting that only a 
subgroup of the opioid-using population 
volunteer for naltrexone-assisted abstinence 
(Fram et al. 1989; Bell et al. 1999; Tucker, 
Ritter et al. 2005). More importantly, 
engagement in naltrexone treatment tends 
to falter the more often patients are 
presented with an opportunity to miss their 
naltrexone dosage and relapse to heroin 
(Greenstein et al. 1997). As oral naltrexone 
treatment presents the patient with a 
dropout opportunity every 24-48 hours, this 
mode of administering naltrexone often 
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Retention in naltrexone implant treatment 
for opioid dependence
(submitted)
sees 70-80% or more of its patients drop 
out by six months (San et al. 1991; Nunes 
et al. 2006). Retention problems can be 
seen as a reason why oral naltrexone may 
not offer an advantage over placebo in the 
treatment of opioid dependence (Carroll et 
al. 2001; Minozzi et al. 2006; Nunes et al. 
2006). 
Sustained release formulations of 
naltrexone have been developed that extend 
the time of medication release from a few 
days to one month for depot injectables 
(Comer et al. 2002; 2006) and for up to six 
months for implantable pellets (Hulse et al. 
2004; Waal et al. 2006; Ngo et al. 2008). 
This has proven beneficial compared to 
placebo (Comer et al. 2006), compared to 
oral naltrexone (Hulse et al. 2009) and 
compared to 'usual treatment' controls 
(Kunøe et al. 2009). These findings 
constitute support for the hypothesis that 
reducing the frequency of dropout 
opportunities is of importance in making 
naltrexone treatment effective in the 
treatment of opioid dependence. Such 
opportunities are not eliminated, however, 
in sustained release naltrexone, but merely 
reduced to once every 1-6 months. In a 
double-blind placebo RCT of one-month 
injectable naltrexone 68% of active 
naltrexone patients were retained from the 
first to the second injection (Comer et al. 
2006). For the longer-lasting naltrexone 
implants, only case series data are available 
(Hulse et al. 2004b). The literature is 
lacking prospective cohort data on retention 
in sustained release naltrexone treatment 
among opioid dependent patients who are 
also regular users of non-opioid drugs.  
The present study prospectively 
investigates treatment retention among 
opioid dependent patients being offered a 
second implantation with sustained release 
naltrexone. The study also investigates the 
association between retention and pre- and 
in-study factors, and tracks the alternative 
treatments sought by patients who do not 
receive a second naltrexone implant. 
__________________________________________
Methods
Participants
Participants were opioid dependent adults 
(18 or above) who had voluntarily received 
a 20-pellet naltrexone implant from 
GoMedical Industries, Australia as part of 
their participation in one of three clinical 
trials. This implant has previously been 
shown to release naltrexone at therapeutic 
levels (1 ng/ml or more) for five to six 
months (Hulse et al. 2004; Waal et al. 2006; 
Ngo et al. 2008). All participants in the 
current study were detoxified from opioids 
in a residential setting before voluntary 
inclusion in studies on treatment-as-usual 
aftercare supplemented by up to two 
consecutive naltrexone implant periods for 
a total of ten to twelve months of 
antagonist blockade. Exclusion criteria 
were pregnancy, current psychotic 
symptoms, having been coerced into 
treatment, and severe or acute liver 
dysfunction. The trials were voluntary and 
open-label and were approved by the 
regional ethical board, funded by public 
grants from the South Eastern Norway 
Regional Health Authority and the 
Norwegian Research Council, and 
registered in clinicaltrials.gov under 
NCT00269607, NCT00521157, and 
NCT00204243.
Procedure
Following detoxification, signing of 
informed consent, baseline data collection, 
and initial implantation, patients were 
discharged from the detoxification setting. 
The implantation procedure and any 
adverse events have been described 
elsewhere  (Kunøe et al. 2009; Lobmaier et 
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al. in press). Four to eight weeks before 
six-month follow-up, patients were 
contacted by telephone to offer a second 
implant and to schedule an appointment for 
the follow-up data collection. Patients who 
declined were reminded of the dangers of 
overdose and encouraged to initiate some 
other treatment for opioid dependence (e.g. 
opioid maintenance treatment or long-term 
residential treatment). Patients who 
requested a second implant but failed to 
attend the scheduled reimplantation 
appointment were contacted again to 
inquire about their wish to reimplant. Three 
contact attempts were made before 
treatment personnel or next of kin was 
contacted as indicated in the original 
informed consent. 
Assessments
The main outcome in the present study was 
continuation or discontinuation of 
naltrexone implant treatment: continuation 
was defined as the successful 
administration of a second naltrexone 
implant. Other variables investigated in the 
study were: 1) baseline (pre-study) factors 
related to remaining in naltrexone implant 
treatment. 2) follow-up (in-study) factors 
related to remaining in naltrexone implant 
treatment. 
For factors relating to outcomes, the 
European version of the Addiction Severity 
Index (McLellan et al. 1992; Kotkevi & 
Hargers 1995) (ASI) were used to assess 
self-reported drug use, health -  and 
treatment data. Substance use was recorded 
by the ASI in two ways: I) as days of the 
last 30 days and II) as a frequency scale 
describing the whole 6-month period on a 
0-3 scale where a score of '0' means “no 
use”, '1' is "1-3 times per month", '2' "1-3 
times per week", and '3' "daily or almost 
daily." Injection drug use, workdays, and 
counseling attendance was recorded as 
'days of previous month' and/or 'months of 
previous six months.' At follow-up only, 
time-line follow-back (Sobell & Sobell 
1992) was used for the whole 180-day 
period. For mental health, the Beck 
Depression Inventory (Beck 1961) was 
used to assess depressive symptoms, while 
Hopkins’ Symptom Checklist 25 (SCL-25) 
(Derogatis et al. 1974) was used to assess 
general mental health. The Temporal 
Satisfaction With Life Scale ‘present’ items 
(Pavot et al. 1998) were used to assess life 
satisfaction. 
To investigate whether variations in 
naltrexone plasma levels affected 
outcomes, blood samples were taken of 
patients at follow-up and at convenience 
(Olsen et al. 2004). To verify opioid use, 
hair samples were taken during follow-up 
and analyzed for the presence of opioids 
using liquid chromatography mass 
spectrometry (LC-MS-MS) as described 
elsewhere (Hegstad et al. 2008). 
Statistical analyses
The main results of this study are 
descriptive. T-tests were used to investigate 
associations between pre-treatment and in-
treatment factors in relation to remaining in 
treatment. If inspection of the distribution 
indicated the normality assumption was 
violated, analyses were re-done using a 
rank-test. Significant pre-study factors were 
entered into a binary multiple regression 
with backward conditional entry of 
variables. For dichotomous variables, chi-
square with Fisher's exact test was used. 
Patients who had the first implant removed 
or discontinued treatment due to lack of 
treatment need were included in descriptive 
analyses only. Scatterplots of main outcome 
variables were visually inspected to 
exclude outliers. All tests utilized a .05 
significance level and were done with 
SPSS 16 for Mac OS X.
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Results
Sixty-one patients were included: of these 
47 (67%) were men and 14 (23%) were 
women. Participants had a mean age of 
33.3 years (sd: 8), had spent a mean of 1.8 
years (sd: 3) in prison, used heroin for a 
mean of 6.6 years (sd: 4.4), injected drugs 
for a mean of 8.7 years (sd: 7.6), and had 
engaged in poly-drug use for a mean of 
10.4 years (sd: 7.4). 
Treatment retention
More than two thirds (44, 72%) of the 61 
included patients reported that they wished 
to accept the offer of a second implant (see 
Figure 1). These patients were scheduled a 
reimplantation appointment, and 31 (51%) 
received an implant. Of the 30 who did not 
continue with naltrexone implant treatment, 
17 (28% of 61) declined the offer of a 
second implant while 13 patients (21%) 
reported wanting reimplantation but failed 
to attend for the second implant. Two of the 
three patients who had the first implant 
removed declined the offer to reimplant 
(see below). Six of those who discontinued 
treatment initiated other treatments for 
opioid dependence: three entered long-term 
residential treatment, and three started 
opioid maintenance treatment with 
methadone or buprenorphine. 
Pre-treatment predictors of retention
In the six months before inclusion in the 
study, patients that would later receive a 
second implant used drugs by injection in a 
mean of 2.8 (sd: 2.5) months compared to 
non-retained patients' mean of 4.2 months 
(sd: 2.3) (mean diff: 1.4; 95%C.I.: 2.6-15.3; 
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Figure 1.Treatment engagement before, during six-month naltrexone implant treatment for 
opioid dependence.
Figure 1 note: Dropout, discontinuation, continuation, and post-naltrexone treatment alternatives 
among naltrexone implant patients. OMT = opioid maintenance treatment. 
LRT = long-term residential treatment. 
p=.007). In the 30 days prior to their 
inclusion into the study, patients that would 
later be retained had on average 9.4 (sd: 12) 
days of injection drug use compared to 19.6 
(sd: 12) days for non-retained patients 
(mean diff: 10.2; 95%C.I.: 3.5-17; p=.004). 
Retained patients also had a mean of 5 days 
(sd: 8.7) of benzodiazepine use during the 
month preceding inclusion compared to a 
mean of 14 days (sd: 13) for those not 
retained (mean diff: 9; 95%C.I.: 2.6-15.3; 
p=.007). Patients who were later retained 
worried about family problems on more 
days than non-retained patients (mean diff: 
-.9; 95%C.I.: 0.1 - 1.6; p=.034). Patients 
who remained in naltrexone implant 
treatment had remained in their longest 
employment for a mean of 3.7 (sd: 4.3) 
years compared to a mean of 1.4 (sd: 1.9) 
for non-retained patients (mean diff: 2.4; 
95%C.I.: 0.4-4.3; p=.021).
Patients who would later discontinue 
naltrexone implant treatment experienced 
more of all types of mental health problems 
(including hyperactivity and concentration 
problems) with a mean of 9.2 (sd: 12) days 
during the month preceding inclusion 
versus 3.3 days (sd: 6.5) for retained 
patients (mean diff: 5.9; 95%C.I.: 0.7 - 
11.6; p=.044). 
Injection drug use during the 6 months and 
30 days prior to study entry were found to 
be intercorrelated above .7, and the 30-day 
variable was included with the other above 
factors in a binary logistic regression 
analysis with backward conditional 
inclusion of variables. In the final model 
for predictors, regression analysis included 
duration of longest employment period as 
the only lifetime predictor. In the month 
preceding incarceration or treatment, non-
retained patients had more days of in-
jection drug use and fewer days of concern 
about family problems (see Table 1). 
In-treatment factors related to retention
Patients who received a second naltrexone 
implant reported less opioid use, 
amphetamine use, injection drug use, and 
days of criminal activity during the first 
implant period than non-retained patients. 
Factors from the last 30 days of the study 
that related to remaining in naltrexone 
implant treatment are shown in Table 2. 
Patients who relapsed to poly-drug use, 
blocked opioid use, and criminal activity 
were less likely to remain in naltrexone 
implant treatment. 
Factors related to drug use and criminal 
involvement were also significant over a 
six-month time span. The time-line follow-
back for days of opioid use in the whole 
180-day period showed that reimplanted 
patients had used opioids on a mean of 6.4 
days (sd: 27) versus a mean of 55 days (sd: 
65) for non-retained patients (mean diff: 
48; 95% C.I.: 18-78; p=.003). On the ASI 
six-month frequency scale (range: 0-3), 
retained patients' opioid use averaged 0.5 
(sd: 0.7) versus the discontinued patients' 
1.5 (sd: 1) (mean diff: 0.7; 95% C.I.: 0.5 - 
1.5; p<.001). 
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Independent variable B S.E. O.R. 95% C.I. sig.
Longest employment, years 0.34 0.14 1.4 1.1 – 1.9 .017
Injecting drug use, days of last 
30 days
-0.08 0.03 0.9 0.9 - 1 .007
Concerned about family 
problems, days of last 30 days
0.52 0.24 1.7 1 – 2.7 .034
Table 1. Regression coefficients of pre-treatment factors 
predictive of receiving a second naltrexone implant.
Table 1 note: Result of binary logistic regression with backward 
conditional (.05) inclusion of variables. The factors removed by 
the regression procedure were: frequency of benzodiazepine use 
and frequency of mental health problems in the month preceding 
inclusion. 
Six-month heavy drinking was also higher 
in the non-retained group (mean 0.7 (sd: 
0.9)) compared to in retained patients 
(mean 0.1; sd: 0.4) (mean diff: 0.6; 95% 
C.I.: 0.1-1.1; p=.018), as was 
benzodiazepine use (mean diff: 0.9; 95% 
C.I.: 0.3-1.4; p=.004) and amphetamine use 
(mean diff: 0.6; 95% C.I.: 0.01-1.3; p=.
050). Non-retained patients were also more 
likely to report receiving income from 
acquisitive crime in the least 6 months 
(Fisher's exact test; Pearson's R=-.31; p=.
049) and to have been treated by a doctor in 
the same period (Fisher's exact test; 
Pearson's R=-.34; p=.023).
Patients who remained in treatment tended 
to report better mental health than non-
retained patients, scoring a mean of 11.2 
(sd: 10) on the Beck Depression Inventory 
compared to 17.7 (sd: 11) for non-retained 
patients (mean diff: 6.5; 95% C.I.: 0.01-13; 
p=.050). Non retained patients also tended 
to answer 'yes' more often to experiencing 
anxiety both in the last 30 days (Fisher's 
exact test; Pearson's R=.31; p=.044) and in 
the time before that (Fisher's exact test; 
Pearson's R=.43; p=.005). On life 
satisfaction (range 5-35), retained patients 
scored 18 (sd: 8) and non-retained 12 (sd: 
6) (mean diff: 6; 95% C.I.: 1.3-10.4; p=.
013). 
Groups of special interest
 'Recovered' patients
Five patients who declined reimplantation 
reported they were no longer in need of any 
treatment for opioid dependence. Three had 
completed long-term residential treatment 
for a mean time of 12 months (sd: 12) prior 
to inclusion in the study. Substance use was 
reported by these patients for a mean of 1.2 
days (sd: 1.6) for alcohol use in the last 
study month, with one patient reporting one 
day each using benzodiazepines and one 
using cannabis. Two of the recovered 
patients reported having used opioids on 
two occasions each. On time-line follow-
back, this amounted to a mean of 0.8 (sd: 1) 
days of opioid use in the entire 180-day 
period. No hair samples taken from this 
group at follow-up were positive for 
opioids. This group was not criminally 
active during the study. 
 Other patients declining 
re-implantation
Twelve patients declined the offer of 
reimplantation. Among these patients, 
mean days of opioid use on the 180-
day time-line follow-back was 58 (sd: 
62). During the last 30 days of the 
follow-up period these patients 
reported having used drugs by 
injection on a mean of 15.5 (sd: 14) 
days, reported a mean of 4 (sd: 10) 
heavy drinking days, reported having 
experienced drug-related problems on 
15 days (sd: 15), and engaged in 
criminal activities on 2.6 (sd: 7) days. 
Amphetamine use was reported on 
nine (sd: 12) of the last 30 days. Nine 
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Independent 
variable
Retained
mean 
(sd)
Not 
retained
mean (sd)
Mean 
diff.
95% C.I. sig.
All opioid use 1.8 (5.6) 12.8 (14) 11 4 - 18 .003
Amphetamines 4.3 (9) 12 (13) 7.7 0.6 - 15 .034
Injection drug 
use
5.3 (9.6) 19.3 (13) 14 6.7 - 21 <.001
Illegal activity 1.8 (5.2) 7.2 (10) 5.3 0.01 - 11 .050
Table 2. Regression coefficients of pre-treatment 
factors predictive of receiving a second naltrexone 
Table 2 note: All data recorded as ‘days of last 30 days.’ Patients 
who had recovered (n=5) or had their naltrexone implant removed 
(n=3) were not included in this analysis.
patients had no treatment plan following 
their discontinuation of naltrexone 
implant treatment (Figure 1).
 Re-implantation dropout 
patients
Patients (n=13) who expressed a 
wish to reimplant but failed to do so 
constituted 21% of the total sample 
(n=61) and 30% of those expressing 
a wish to reimplant (n=44). In the 
last 30 days of the study, these 
patients used drugs by injection on a 
mean of 23 days (sd: 10), reported drug-
related problems on 19 (sd: 12) days, and 
criminal activities on a mean of 9 (sd: 10) 
days. No heavy drinking days were 
reported in this group (mean: 0.2 s.d.: 0.6), 
but mean use of amphetamines were 13 (sd: 
13) days of the last 30. 
A comparison of opioid use during 
naltrexone treatment for patients who 
dropped out, discontinued treatment, or 
were reimplanted is displayed in Figure 2. 
The figure illustrates the influence of 
opioid use on treatment retention.
 Cases of implant removal
Three patients had their naltrexone implant 
removed during the first treatment episode 
- one due to tissue infection with necrosis, 
two due to subjective complaints about 
gastrointestinal and site pain, respectively. 
At follow-up, these three had used opioids 
on a mean of 28 days (sd: 3) of the last 
study month. None of these patients 
received a second implant. Two declined 
further implant treatment. The third patient 
completed detoxification but abandoned her 
plans to have a second implant after her 
gastrointestinal symptoms reappeared 
following an initiation onto oral naltrexone. 
None of these patients continued to other 
treatments, despite staff encouragement to 
do so and despite all of them fulfilling the 
minimum criteria for agonist maintenance 
treatment in Norway.
Hair analyses
Of the 45 samples received, 30 were 
concordant for self-reported opioid use 
versus opioids in hair, and 15 were 
discordant. In 13 of these cases, patients 
reported low levels of use but no opioids or 
metabolites could be detected in hair 
analysis. 
Naltrexone blood levels
50 patients gave a total of 73 blood samples 
in the first treatment period, of which three 
were damaged during transport and ten 
were excluded due to instrument calibration 
problems. Analyses of the remaining 60 
samples showed levels of naltrexone and 6-
beta naltrexol were above therapeutic levels 
at least five and a half months for all but 
three patients, who had naltrexone levels 
below the therapeutic limit of 1ng/ml at 
157-168 days. Two of these three were 
successfully reimplanted.
___________________________________
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Reimplanted Dropped out Recovered Not recovered
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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Daily use
1-3 x/ week
1-3 times / month
No use
Figure 2.Group differences in opioid use (ASI) 
during the six-month period on naltrexone. 
Figure 2 note: Mean self-reported 6-month frequency (range: 
0-3) of opioid use on the Addiction Severity Index. Patients 
who had their naltrexone implant removed (n=3) were not 
included in this analysis. 
Discussion 
About half of the opioid dependent patients 
(51%) who completed six months of 
treatment with sustained-release naltrexone 
implants successfully received a second six 
month implant. About one in four (28%) 
turned down the offer of a second implant, 
and about one in five (21%) expressed a 
wish to receive a second implant but failed 
to attend for reimplantation despite 
repeated efforts by the clinical team to 
encourage their attendance. The retention 
of 51% of patients in this study is 
encouraging. Retention was more than 
twice as high as in six-month studies of 
oral naltrexone treatment. For example, San 
et al. (1991) found that only 17% of their 
sample were retained in treatment after 180 
days, while the study of Nunes et al. (2006) 
retained 22% of patients with Behavioral 
Naltrexone Therapy and 9% of patients 
receiving ‘compliance enhancement.’ 
The low incidence of implant removals in 
the present sample suggests that most 
patients who remain in treatment will 
achieve ten to twelve months of continuous 
naltrexone medication. Retained patients 
are likely to continue the positive changes 
previously reported in terms of reduced 
relapse to regular opioid use (Hulse et al. 
2004; Comer et al. 2006; Hulse et al. 2009), 
reduced opioid overdose (Hulse et al. 
2005), and reduced overall mortality (Tait 
et al. 2008). 
The patients who discontinued or dropped 
out of naltrexone implant treatment were in 
many ways similar to those who drop out 
of oral naltrexone treatment. Longer pre-
treatment employment history, concern 
about family problems, and pre-treatment 
injecting drug use were associated with 
later retention in treatment, echoing the 
results of several oral naltrexone studies 
(Greenstein et al. 1983; Krupitsky et al. 
2004; Sullivan et al. 2006b). During 
naltrexone implant treatment, patients who 
used illicit opioids despite naltrexone 
blockade, engaged in the use of other illicit 
drugs or in heavy drinking, and/or engaged 
in more criminal activity were less likely to 
continue to the second course of 
naltrexone. As our sample consisted of 
poly-substance users, we interpret all of 
these factors as symptoms of a return to a 
heroin-related lifestyle that is incompatible 
with a re-commitment to naltrexone-
assisted abstinence. 
The findings of this study are subject to 
several limitations. The sample size is 
relatively small, especially for the study of 
sub-groups. In addition, the novelty of 
naltrexone implant treatment and the 
clinical trial setting means the patients in 
this study may not be fully representative 
of the wider potential treatment population 
for naltrexone implants. However, other 
aspects of the present study may increase 
the ability to generalise results to day-to-
day treatment settings; e.g. the inclusion of 
patients with poly-drug use and the 
implementation within existing addiction 
treatment services. This group of patients 
constitutes the majority of street heroin 
users (Ross et al. 2005), and their inclusion 
in the present study further strengthens the 
case for the clinical feasibility of sustained 
release naltrexone treatment for opioid 
dependence.    
Possible options for improving retention 
and reducing discontinuation and dropout 
from sustained release naltrexone treatment 
might involve integrating such treatment 
with contingency management (Carroll et 
al. 2001), self-help groups (Timko and 
DeBenedetti 2008), or behavioral 
naltrexone therapy (Rothenberg et al. 
2002). Outreach services may also be 
important in supporting and aiding any 
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naltrexone patients who return to the street 
drug scene. This could be especially 
valuable to the 21% who were willing to 
receive a second naltrexone implant but did 
not manage to attend for re-implantation. 
As family support has repeatedly proven 
important to retention in naltrexone 
treatment, abstinent family members should 
be mobilized before and during treatment to 
aid and motivate the patient to recovery.  
The results of this study suggest that it is 
feasible to treat opioid dependent patients 
with several administrations of long-acting 
sustained release naltrexone. When 
implemented as a treatment service 
alongside other proven treatments for 
opioid dependence, sustained release 
naltrexone may be used both as an 
enhancement of these treatments as well as 
a stand-alone approach. 
_______________________________
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